Protein Design Labs steigt und steigt und steigt und... - 500 Beiträge pro Seite

[BADABING]

... keine Sau interessierts

Keiner investiert?

[angryhol]

Na klar

Aber beschrei` es bloß nicht, sonst fällt das Ding wieder!

Lass` es uns einfach genießen!

Ziel 25$.

angryhol

[blb]

Bin auch schon lange dabei. Mit Nachkäufen auf nen guten Kurs gekommen. Hab mit PDLI schon viel mitgemacht. Aber der Ausbruch über 20$ schaut gut aus. Nach oben hin übrigens auch noch ein schönes Gap offen!

[danii1]

hallo zusammen,
klar interessierts uns, schaut aus als ob der weg auf 40$ jetzt frei ist .....
mal schaun

[blb]

Weiter so!

[amorphis]

gibts nen grund für den starken anstieg heute?

[goldmaki]

nasdaq 22.8 $, jetzt geht es wohl wieder abwärts.....

[danii1]

24.19 $

[blb]

Kursziel aus der riesen Cup and Handle-Bodenformation sind die 35$. Hier haben wir auch noch ein offenes Gap!

[Johannesfor]

Konsoldierung:

http://www.finanznachrichten.de/goto.asp?id=3180411

[blb]

Die Party geht weiter...

[mahatma]

sieht wirklich sehr guuut aus



gruß maha

[blb]

Wie seht ihr PDLI nach der negativen Meldung vom Wochenende?

[Boersenkrieger]

pdli sinkt wieder und keine sau interessiert´s... zeit zum nachkaufen

[blb]

Nee, PDLI steigt wieder!
Wert ist ein Bio mit hohem Beta nach obe wie nach unten. Also gute Action vorprogrammiert! Bleib hier weiter dabei.

Grüße
blb

[blb]

Netter Deal mit Roche!


Roche und PDL entwickeln und vermarkten Asthma-Medikament Zenapax gemeinsam

BASEL (dpa-AFX) - Der Schweizer Pharmakonzern Roche und die amerikanische Protein Design Labs (PDL) haben eine weltweite Zusammenarbeit bei der Entwicklung und Vermarktung des Asthma-Medikaments Zenapax vereinbart. Die PDL erhalte von Roche eine Einmalzahlung von 17,5 Millionen US-Dollar sowie Meilensteinzahlungen von bis zu 187,5 Millionen Dollar für die weitere Entwicklung und Kommerzialisierung von Zenapax (daclizumab), teilte Roche am Donnerstag in Basel mit.

Roche und PDL werden das Präparat weltweit zusammen entwickeln, sich die Entwicklungskosten teilen und das Produkt in den USA zusammen bewerben. Ausserhalb der USA soll PDL Tantiemen auf die Nettoumsätze erhalten./mf/hi

[voxel]

Dieser Deal ist doch ein wahnsinniger Umsatzschub.

Hier nur 6% im Plus. Wie werden die Amis eröffnen?

[blb]

Übernahme:

PDL to Acquire ESP Pharma, Inc.
TUESDAY, JANUARY 25, 2005 8:00 AM
- PR Newswire

FREMONT, Calif. and EDISON, N.J., Jan 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Protein Design Labs, Inc. (PDL) (PDLI) , a leading developer of humanized monoclonal antibodies, and ESP Pharma, Inc. (ESP Pharma), a leading privately held, hospital-focused pharmaceutical company, today announced that they have entered into a definitive agreement under which PDL will acquire ESP Pharma for $300 million in cash and approximately $175 million in PDL common stock, or an aggregate value of approximately $475 million, plus the assumption of net debt of approximately $14 million. ESP Pharma was founded in April 2002 around the acquisition of several therapeutics from Wyeth, including ESP Pharma`s leading product, Cardene(R) IV. ESP Pharma generated total net product sales in excess of $90 million in 2004, a significant increase over 2003.

Mark McDade, Chief Executive Officer, PDL, said, "With this transaction, we have filled the void in the one major functional expertise PDL lacked, namely commercialization capabilities. Upon closing, we will have created an exciting new, fully integrated, hospital-focused biopharma company with best-in-class marketed products, a growing and diverse revenue base, and a broad, wholly-owned proprietary pipeline. In addition to significant commercial expertise, ESP Pharma will contribute several additional clinical-stage compounds. This combination will also dramatically accelerate our path to operational profitability, as we expect to become cash flow positive in 2006 with the completion of the transaction.

"Significant to our commercialization strategy," Mr. McDade said, "we add ESP Pharma`s 75-person, experienced hospital-focused sales and sales management team and New Jersey-based marketing, medical affairs, sales operations and supply chain infrastructure for the U.S. market and Canada. We believe this strategic move will permit us to maximize the potential value of Zenapax(R) and Nuvion(R), as we are building significant competence ahead of our hoped for product introductions in 2007 and beyond. Importantly, the transaction expands our therapeutic focus into the cardiovascular arena, with Cardene IV, an intravenous anti-hypertensive used extensively in cardiac- and neuro-surgery. In the hospital setting, ESP`s IV Busulfex(R) is marketed as a preconditioning chemotherapeutic agent in bone-marrow transplant, and is a natural fit in view of our right to potentially reacquire the rights to Zenapax in the transplant indication by 2007."

John T. Spitznagel, Chairman and Chief Executive Officer, ESP Pharma, said, "ESP Pharma has established a record of success in identifying, acquiring, marketing and developing innovative therapeutics. Our flagship product, Cardene IV, is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. IV Busulfex is used in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. We believe this strategic combination with PDL will enable us to successfully market PDL`s proprietary product candidates, and acquire or in-license additional products or product candidates."

PDL expects to provide additional information regarding the financial effect of the transaction as part of its news release and conference call to discuss full-year 2004 results and forward-looking guidance for 2005. This conference call is not yet scheduled, but is expected to occur not later than March 15, 2005. PDL does not require financing to complete the transaction, but may consider additional financing transactions now or in the future.

The Boards of Directors of PDL and ESP Pharma, and the shareholders of ESP Pharma have approved the acquisition. The closing of the transaction is subject to various conditions, including the receipt of antitrust and other regulatory approvals. The initial number of PDL shares to be issued is approximately 8,870,000 and the actual number of PDL shares to be issued in the transaction is subject to upward adjustment of up to approximately 985,000 shares and to downward adjustment of up to approximately 806,000 shares based on the price of PDL stock in the period prior to the closing of the transaction. ESP Pharma and PDL have also reached an agreement as to a U.S.-marketed product acquisition under negotiation between ESP Pharma and a third party. That transaction has not been finalized and the potential financial and other terms remain confidential.

Lazard acted as financial advisor to PDL in the transaction, and SG Cowen & Co., LLC acted as financial advisor to ESP Pharma. The firms of DLA Piper Rudnick Gray Cary, and Milbank, Tweed Hadley & McCloy LLP served as counsel to PDL and ESP Pharma, respectively.

Webcast scheduled for 8:30 a.m. Eastern time on January 25

PDL will host a webcast beginning at 8:30 a.m. Eastern time today, January 25, 2005, to discuss the acquisition.

The live webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. A replay will be available at www.pdl.com starting approximately one hour after completion of the webcast.

An audio replay will also be available by telephone from approximately 10:30 a.m. Eastern time on January 25, 2005 through 10:30 a.m. Eastern time on January 29, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States; enter conference ID number 21230399.

About ESP Pharma, Inc.

ESP Pharma was founded in April 2002 and began operations in May 2002 with the acquisition of four in-market therapeutics from Wyeth, including the flagship product, Cardene IV. ESP Pharma`s "Buy and Build, Search and Develop" business plan for creating asset value focuses on selectively acquiring approved and late-stage development products addressing the needs of the acute-care hospital market. ESP Pharma has concentrated its acquisition programs on products and compounds representing strong returns on investment, driven by high growth potential.

In support of its business plan to revitalize the promotion of acquired products and to fuel near- and intermediate-term growth, ESP Pharma established its own hospital sales force of experienced pharmaceutical representatives in September 2002. Through the efforts of its sales team, ESP Pharma has planned to drive revenue growth while adding to its revenue base and realizing synergistic benefits from additional acquisitions of acute-care specialty products. ESP Pharma`s key marketed products are:

-- Cardene IV (nicardipine hydrochloride injection). Indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. Cardene is a patent-protected intravenous preparation of nicardipine, a dihydropyridine calcium channel blocker.

-- IV Busulfex (busulfan) Injection. Indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. A patent-protected, potent cytotoxic drug and intraveneous formulation of the alkylating agent busulfan.

In addition to ESP Pharma`s key marketed products, ESP Pharma has several products in clinical development targeted to the acute-care hospital market.

About PDL

Protein Design Labs is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. PDL holds fundamental patents for its antibody humanization technology. Further information on PDL is available at www.pdl.com.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements contained herein include statements about the consummation of the pending acquisition and the benefits of the pending acquisition, including its potential effect upon PDL`s future financial performance. These statements are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, the possibility that regulatory or other closing conditions will not be satisfied, whether the combined company will be able to realize the anticipated benefits or synergies of the transaction in a timely manner or at all, and the future revenues from ESP Pharma products. Other factors that may cause our actual results to differ materially from those, express or implied, in the forward-looking statements in this press release are discussed in our Annual Report on Form 10-K for the year ended December 31, 2003, in our quarterly report on Form 10-Q for the period ended September 30, 2004, and in other filings with the Securities and Exchange Commission.

NOTE: Protein Design Labs, the PDL logo and Nuvion are registered U.S. trademarks of Protein Design Labs, Inc. Zenapax is a registered trademark of Hoffmann-La Roche. Cardene IV and IV Busulfex are registered trademarks of ESP Pharma, Inc.

SOURCE Protein Design Labs, Inc.

James R. Goff, Senior Director, Corporate Communications of Protein Design Labs,
[phone], or [e-mail]


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

[maxmosch]

hallo
was gibts denn schon wieder negatives zu berichten????
weil der kurs sich schon wieder so nach unten bewegt hat
weiß einer mehr ??

[blb]

Ja, die nehmen Geld an der Börse auf, um die Übernahme zu finanzieren...

Ich halte den Kursrückgang für übertrieben, die Übernahme katapultiert PDLI in andere Dimensionen. Wart mal, wenn die ihre neuen Prognosen rausbringen!

18$ sollten halten...

Grüße
blb

[blb]

Tja zur Zeit fällt und fällt und fällt sie nur. Ich vermute dass hier einfach die Unsicherheit zur Zeit belastet. Der EPS-Deal dürfte aber PDLI in eine andere Dimension katapultieren. Bin gespannt, wann die ersten Prognosen von Seiten des Unternehmens kommen.

Abstauberlimiz 15$!

Grüße
blb

[liasis]

Was ist denn jetzt los??????????

PROTEIN DESIGN EUR 11.34 12.00 -1.68 -12.9% 13.02 «

[blb]

Ich hab auch erst gerätselt. Es ist folgende Nachricht:

Der US-Pharmakonzern Biogen Idec Inc. und sein irischer Partner Elan Corp. plc teilten am Montag mit, dass sie den Verkauf ihres neuen Multiple Sklerose (MS)-Medikaments Tysabri eingestellt haben, nachdem ein Patient an einer seltenen, aber häufig tödlichen Erkrankung des Zentralen Nervensystems gestorben ist. Die Aktien beider Unternehmen brechen derzeit deutlich ein.

Das Präparat Tysabri, das im vergangenen November die Marktzulassung erhalten hat, sollte nach Meinung vieler Experten das weltweit führende MS-Medikament werden. Es sollte zudem das bereits seit längerem auf dem Markt befindliche MS-Produkt von Biogen Idec, Avonex, ersetzen.

Die Unternehmen teilten mit, dass die betreffenden Patienten sowohl Tysabri und Avonex eingenommen haben. Man hatte sich im Vorfeld erhofft, dass die Patienten durch die Einnahme beider Medikamente einen zusätzlichen Vorteil erhalten könnten.

Die Aktie von Biogen Idec verliert an der NASDAQ vorbörslich aktuell 45,20 Prozent auf 36,87 Dollar, die von Elan in London 64,90 Prozent auf 7,15 Euro.

PDLI hätt Royalties von Tysabri bekommen...
Halte die Reaktion für total übertrieben, Nachkauflimit bei 15$ wurde ausgeführt...

Grüße
blb

[liasis]

BLb
Danke! Hatte auch mit einem Zusammenhang mit der meldung gerechnet, wusste nur nicht was PDLI damit zu tun hat.(Hatte auf der Homepage von PDLI nichts gefunden!!)
Gruss

[Isabartels]

Mittlerweile setzt sich wohl die Erkenntnis durch, dass der Kurssturz übertrieben war.

[blb]

Ich kann mich nur wiederholen, die Übernahme von ESP dürfte alle Planzahlen über den Haufen werfen. Positiver Cashflow 2006 sowie Umsatzbeitrag von ESP von um die 90 Millionen $...

Warten wir mal die Guidance Mitte März ab. Kann mit meinem Nackauf aktuell ganz gut leben!

Grüße
bkb

[blb]

Den 14. März sollte man sich markieren...

Protein Design Labs Announces March 14 Webcast of Full Year and Fourth Quarter 2004 Financial Results Conference Call
MONDAY, FEBRUARY 28, 2005 8:01 AM
- PR Newswire


FREMONT, Calif., Feb 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Protein Design Labs, Inc. (PDL) (PDLI) today announced that its financial results for the fourth quarter and year ended December 31, 2004 will be released following the close of the U.S. financial markets on Monday, March 14, 2005. PDL will hold a conference call to discuss these results, the status of its clinical development programs, the status of its pending acquisition of ESP Pharma Holding Company, Inc. (ESP Pharma) and its forward-looking information and guidance with respect to future results at 4:30 p.m. Eastern time on March 14, 2005. The call will be hosted by Mr. Mark McDade, Chief Executive Officer, Mr. Glen Y. Sato, Senior Vice President and Chief Financial Officer, and Dr. Steven Benner, Senior Vice President and Chief Medical Officer.

PDL noted that the release and conference call had been tentatively scheduled for February 28, but were rescheduled following the January 25 announcement of PDL`s proposed acquisition of ESP Pharma, to allow for completion of audited financial results for both PDL and ESP Pharma, from which PDL expects to provide forward-looking guidance for the combined companies for 2005 based on the assumption that the closing of the proposed acquisition will be consummated.

The live webcast will be available through the PDL website: http://www.pdl.com. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A replay will be available at http://www.pdl.com starting approximately one hour after completion of the webcast.

An audio replay will also be available by telephone from approximately 7 p.m. Eastern time on March 14, 2005 through 7 p.m. Eastern time on March 20, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States; enter conference ID number 21233659.

Protein Design Labs is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. PDL holds fundamental patents for its antibody humanization technology. Further information on PDL is available at http://www.pdl.com or by contacting James R. Goff, Senior Director, PDL Corporate Communications, [phone] or [e-mail].

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc.

SOURCE Protein Design Labs, Inc.

James R. Goff, Senior Director, Corporate Communications of Protein Design Labs,
Inc., [phone], or [e-mail]


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

[Isabartels]

28.02.2005 - 19:59
PROTEIN DESIGN - Kurseinbruch auf Key-Support



PROTEIN Design Labs (PDLI) : 14,97$ (-13,61%)

Wochenchart (log) seit Dezember 2001 (1 Kerze = 1 Woche)

Diagnose: Mit dem schwachen Biotechsektor steht auch die Aktie von Protein Design heute unter Abgabedruck. Ausgehend vom Key-Level bei 7,38$ startet hier Anfang 2003 eine Rallye bis 27,58$, die nach dem Ausbruch aus dem mittelfristigen Aufwärtstrend korrigiert wurde. Auf dem Retracement-Support bei 14,77$ konnte der Kurs nach oben abprallen. Der neue flachere Aufwärtstrend wurde in den Vorwochen nach dem Scheitern im Bereich des Widerstands bei 20,00$ ebenfalls nach unten gebrochen, heute kippt der Kurs deutlich auf ein neues Zwischentief. Intraday kann das noch offene Gap Up von Ende 2003 jetzt nach unten geschlossen werden, die Aktie stabilisiert sich im Bereich des Key-Levels bei 14,77$.

Prognose: Nach dem Schluss des Gap Up bietet sich bei PDLI im Bereich des Key-Levels bereits die Möglichkeit einer Wideraufnahme der Aufwärtsbewegung. Wenn das aktuelle Niveau auch auf Wochenschlussbasis gehalten werden kann, könnte eine Gegenbewegung in Richtung 18,20$ anlaufen. Gibt die Aktie den Supportbereich um 14,77$ auf, drohen mittelfristig weitere Abgaben, auch das Niveau um 10,00$ kann dann nochmals erreicht

[Isabartels]

Die ändern auch wöchentlich ihre Einschätzung:


01.03.2005 10:30:46 (FIRST ALBANY) vdrucken > vor

Protein Design Labs "buy"


Rating-Update: Die Analysten von First Albany bewerten die Aktie von Protein Design Labs (ISIN US74369L1035/ WKN 883428) unverändert mit dem Rating "buy". Das Kursziel werde von 25 auf 17 USD reduziert.
Quelle: AKTIENCHECK.DE

[Isabartels]

Wie ich gelesen habe sollte Tysabri dieses jahr 500.000$ umsetzten. Wieviel davon hätte PDLI bekommen????? Deshalb das Kurziel um 8$ senken???? Lachhaft!!!!!!!

[blb]

@Isabartels: PDLI hätte laut meiner Informationen 3% vom Umsatz bekommen. Wenn man den gestrigen Rückgang anschaut, ist das jetzt mehr als eingepreist. Zudem sollte man bedenken, dass Tysabri wieder auf den Markt kommen kann, es handelte sich rein um eine Entscheidung von Biogen/Elan und nicht der FDA. Von 3000 Personen sind 2 verstorben....
Da ist das letzte Wort noch nicht gesprochen!

Grüße
blb

[Isabartels]

Ich denke auch. Wenn man bedenkt, dass MS unheilbar ist nd irgedwann zum Tod führt finde ich jetzt 2 Tote bei 3000 patienten nicht so gravierend, wenn 2998 eine gravierende Verbesserung ihrer krankheit erleben und mehr lebensqualität. Soll jetzt nicht zynisch klingen.
Gruss
Isa

[Isabartels]

Heute kommts aber wieder mal Dicke!!!

[Nostarowie]

Hallo.
Diese Aktie raubt auch mir noch den letzten Nerv !
Die Anal-lysten werden sich wahrscheinlich wieder totlachen.

[Isabartels]

Die zeigt wirklich keinerlei Erholungstendenz. Wenn #28 stimmt, sehen wir ja noch die 10$$$.

[Nostarowie]

OK, bis ca 19 Uhr hat sie ja den nasdaq so in etwa kopiert.Doch nun scheints wieder weiter runter zu rumpeln.Zum Kotzen!Allerdings verlangsahmt sich der Verfall.
"Um die 10" ts ts das sind wieder Aussagen!
Bodenbildung könnte (muß) auch jetzt stattfinden.
Tut mir einen gefallen gebt mir begründete Hoffnung.

[blb]

Lies dir doch mal meine Postings durch, der 14.3. wird die Richtung vorgeben! Ich rechne mit guten Zahlen und einem guten Ausblick!

Grüße
blb

[Nostarowie]

Ist schon ok, es schmerzte nur die letzten Tage.(extrem)
Eh ich noch in die Tastatur beiß, schalt ich den Kasten lieber aus.

Gruß & Prost

[Isabartels]

bleib locker. wird schon wieder. Heute schau ich mal nicht auf den Kurs. Schont die Nerven!!!
Gruss
Isa

[Nostarowie]

neuer Tag, neue Hoffnung.Biotechhorror

[Nostarowie]

man,man,man trotz steigendem Nasi.Nun kauft doch endlich
ihr verfetteten Amis!
Meine Damen & Herren mein neues Auto verwandelt sich langsam in ein Mofa.
naja egal,hauptsache was zum fahren.

[blb]

Biotechs allgemein schwach heute! Schade, die Unterstützungszone hat nicht gehalten...

Meine Ami-Bios liefen auch schonmal besser!

Grüße
blb

[Nostarowie]

die Eiermaler kämpfen grad mit der 14$ Marke.
Mal sehen vieleicht ist die derzeitige Seitwärtsbewegung
ja ne Unterstützung? und wieso und überhaupt,

Fragen über Fragen

[Nostarowie]

Was für ein irrer Chart.
Hoffentlich bekommt Isa keinen akuten Darmkrebs bei dem Kursverlauf.

Machts gut, gehe jetzt auf ne Party.

[Isabartels]

Nee nosta. Hatte nämlich Freitag morgen eine Eingebung und bin mit einem drittel meines Bestandes zu 11€ raus und habe mir dafür GPC zu9,97€ gekauft.

[Nostarowie]

Jawollja.
Da biste nach Adam Riese ja noch mit 66,66% dabei.
Ich möchte mal dezent hoffen das das heute nicht nur ne Technische gegendemo ist, ansonsten sehe ich die nächste U.bei ca 12,50$.
Mein Gewissen meint das soll meine Reißleine sein.

-Ein Königreich für ein Sparbuch.-

[blb]

@Isabartels: Scheinst ja ähnliche US-Bios wie ich zu haben! Was haste im Depot? Hab im Amiland PDLI, MLNM, VRTX und VLGC!

Teilweise verbilligte Altlasten aus der Boomphase, teilweise Neukäufe! Glaube aber an weiterhin an die Zukunft aller Werte, v.a. PDLI!

Grüße
blb

[Isabartels]

Nosta,
ja bin immer noch dicke dabei.
BLB habe ausser PDLI nur noch Mlnm, überlege aber noch wegen Medx.
Gruss
Isa

[Nostarowie]

Tag auch.
Stelle hier mal mein Gruseldepot an den Pranger:
PDLI 40%
Elan 10%
Nutri 10%
Mdg 20%
Biolitec 10%
10 % Cash
Wobei ich Elan zum Glück am 8.2.gekickt hab und jetzt nach dem Theater wieder rein bin.(mein Beileid an alle noch involvierten)
Gruss
Nosta

[blb]

40% in PDLI? Nicht schlecht, wär mir persönlich zu viel, muss aber nicht verkehrt sein! Die Aussichten bleiben weiterhin gut, auch wenn es bei PDLI pipelinemäßig ähnlich wie bei VRTX einige Rückschläge gab. Kommt Nuvion auf den Markt, steht aber durchaus eine Neubewertung an!

Grüße an alle und Daumen drücken für Montag!
blb

[Nostarowie]

Heute wirds spannend, ob die Eiermaler den kurs im plus halten können oder mein/unser Geld wieder weiter ins minus versemmeln!
Bis jetzt hält sich der Kurs ganz gut obwohl die Indis konsolidieren.

[Isabartels]

um die 14$ scheint sich der Kurs gefangen zu haben!

[Nostarowie]

Dachte schon ich muß hier das Licht ausmachen.

Aber was mich etwas beunruhigt ist das hier nicht grad die totale Euphorie zu erkennen ist vor Montag.

[Isabartels]

ist doch eher ein gutes zeichen.
isa

[blb]

Der Kurs hat sich vorerst stabilisiert. Ich erwarte mir von Montag einiges...

Grüße
blb

[Nostarowie]

Na ja,
ich weis vergleiche sind blöd aber bei Biolitec wars ähnlich vor den Zahlen.

Ist nurn Gefühl -vergessen wirs-

stimmt schon läuft gut.

Gruß,nosta

[Isabartels]

Na bei der schlechten Börse heute warPDLI ja richtig gut.

[Nostarowie]

Weis jemand wann heut die Zahlen bekannt gegeben werden?

Gruß,nosta

[Isabartels]

nach Börsenschluss in Amiland!!

[blb]

Bin schon etwas aufgeregt, da ich ja zu 15$ nachgekauft habe...

[KMS]

Was ist passiert?
PDLI über 10 % nach oben!

KMS

[Nostarowie]

Ohje

und ich sitze diese Woche in München und hab nur nen 56k
modemanschluß.
Grauenvoll!
Aber hauptsache es geht hoch.

[Isabartels]

Collaborations

PDL has a commercially proven technology for generating antibody therapeutics. We receive royalty payments on 7 humanized antibodies marketed for immunology, oncology and transplant indications — Synagis®, Herceptin®, Zenapax®, Mylotarg®, Xolair®, Avastin™ and Raptiva™. In addition, there are more than 40 humanized antibodies in clinical trials, with nearly half in Phase II or Phase III, making this one of the most validated platforms on the market for generating antibody therapeutics. We continue to license our humanization technology to facilitate the discovery of new antibody medicines.

We are actively engaged in partnership discussions in the US and abroad to discover and develop our own antibody therapeutics and to build our autoimmune diseases, transplantation and oncology franchis

[Isabartels]

14.03.2005 - 21:42
Genentech: Kurssprung nach Avastin-News

Das Genentech-Medikament Avastin hilft Lungenkrebspatienten, im Zusammenspiel mit einer Chemotherapiebehandlung ihre Überlebenszeit zu verlängern, so das U.S. National Cancer Institute am Montag. Die Genentech-Aktie steigt aktuell um 18% auf $52. Patienten mit einer Kombinationstherapie aus Avastin und einer Chemotherapie überlebten den Berichten zufolge durchschnittlich 12.5 Monate, während die mittlere Lebenszeit bei ausschließlich mit einer Chemotherapie behandelten Patienten bei 10.2 Monaten lag.

[Isabartels]

Press Release Back

March 14, 2005
PDL Announces Above Consensus Full-Year anf Fourth Quarter 2004 Financial Results and Provides 2005 Update and Guidance
Company projects year of rapid transformation following anticipated late-March closing of acquisitions of ESP Pharma and Retavase®

Fremont, CA

Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) today reported a net loss of $53.2 million, or $0.56 per basic and diluted share, for the year ended December 31, 2004, compared with a net loss of $129.8 million, or $1.40 per basic and diluted share, for the year ended December 31, 2003. Excluding certain non-cash charges described in more detail below, the non-GAAP net loss for 2004 would have been $49.4 million, or $0.52 per basic and diluted share, compared with a non-GAAP net loss of $35.9 million, or $0.39 per basic and diluted share in 2003.

Total revenues in 2004 were $96.0 million, an increase of 44% over total revenues of $66.7 million in 2003. The increase included a 59% increase in royalties, which totaled $83.8 million in 2004, compared with royalty revenues of $52.7 million in 2003. License and other revenues of $12.2 million in 2004 decreased from $14.0 million in the prior year.

As of December 31, 2004, PDL had cash, cash equivalents, marketable securities and restricted investments totaling approximately $397.1 million, compared with $505.0 million at December 31, 2003. The December 31, 2004 balances reflected approximately $95.7 million in capital expenditures made during 2004, primarily related to planned ongoing construction and validation of PDL’s manufacturing plant at Brooklyn Park, Minn.

Total costs and expenses were $154.4 million in 2004, compared with $196.3 million in 2003. Excluding certain non-cash charges, which consist of acquired in-process research and development charges and the amortization of intangible assets associated with the Eos acquisition and the re-acquisition of rights to manufacture and market Zenapax® (daclizumab) in 2003, restructuring charges related to the closure of PDL’s New Jersey facility in the second quarter of 2004, as well as stock-based compensation charges, non-GAAP total costs and expenses in 2004 would have been $150.5 million compared to non-GAAP expenses of $109.1 million for 2003.

Research and development expenses increased 48% to $122.6 million in 2004, compared with $82.7 million in 2003. The increase in research and development expenses reflected additional headcount and associated costs required to pursue research and clinical development programs, contract manufacturing and direct scale-up and manufacturing expense, increased facility and equipment-related costs, and in-licensing of technology. General and administrative expenses increased to $31.8 million in 2004 from $27.6 million in 2003.

Total revenues during the fourth quarter of 2004 were $22.8 million, compared with $13.6 million in the fourth quarter of 2003. Royalties in the fourth quarter of 2004 were $19.9 million, or 124% higher than the $8.9 million of royalties reported in the 2003 fourth quarter. License and other revenues were $2.9 million and $4.7 million in the 2004 and 2003 fourth quarters, respectively. Research and development expenses were $30.2 million in the fourth quarter of 2004, compared with $24.4 million in the comparable three months of 2003. General and administrative expenses were $8.6 million and $8.1 million in the fourth quarters of 2004 and 2003, respectively. PDL reported a net loss of $14.6 million, or $0.15 per basic and diluted share, for the fourth quarter of 2004, compared with a net loss of $72.9 million, or $0.78 per basic and diluted share, in the same period in 2003, which included an acquired in-process research and development expense of $48.2 million related to the re-acquisition from Roche of rights to develop and market Zenapax in indications other than transplantation as well as an option to re-acquire rights in transplantation. Excluding certain non-cash charges, the non-GAAP net loss in the fourth quarter of 2004 would have been $13.7 million, or $0.14 per basic and diluted share, compared with a non-GAAP net loss of $17.6 million, or $0.19 per basic and diluted share in the comparable period of 2003.

Reconciliations of our GAAP results to our non-GAAP results are included in the financial results accompanying this release.

Recent Corporate Developments

On January 25, 2005, PDL and ESP Pharma, a privately held, sales and marketing-focused pharmaceutical company, announced a definitive agreement under which PDL would acquire ESP Pharma and its pipeline of marketed products and clinical candidates for $300 million in cash and approximately $175 million in PDL common stock, or an aggregate value of approximately $475 million, plus the assumption of net debt anticipated to be approximately $14 million at the time of closing. In February 2005, ESP Pharma agreed to acquire from Centocor, Inc., a biopharmaceutical operating company of Johnson & Johnson, rights to manufacture, develop, market and distribute Retavase® (reteplase) in the United States and Canada for $110 million and milestone payments of up to $45 million if additional conditions relating to ongoing clinical trials and manufacturing arrangements are satisfied. As a result of ESP Pharma’s purchase of Retavase, PDL agreed to increase the purchase price paid to ESP Pharma’s shareholders by $25 million in cash payable at closing of the ESP Pharma acquisition, and agreed to assume the purchase price obligations to Centocor under the agreement.

“By adding marketed products and sales and distribution capabilities to our antibody development and humanization technology platform, the ESP Pharma acquisition is intended to establish PDL as a fully integrated, commercial biopharmaceutical company with a diverse revenue base and a broad, proprietary pipeline,” said Mark McDade, Chief Executive Officer, PDL.

“The Retavase acquisition enhances the utilization of the sales force and provides us with another point of entry into the emergency room. In addition, the acquisition of this commercial infrastructure should put us in an excellent position for the potential future launches of Nuvion and other hospital products. Moreover, these combined acquisitions should enable us to become cash-flow positive beginning in the second half of 2006,” Mr. McDade added.

PDL currently anticipates closing its pending acquisition of ESP Pharma late in the first quarter or early in the second quarter of 2005, subject to regulatory approvals and the satisfaction of closing conditions under the agreement.

2005 Forward-looking Guidance

The following statements are based on expectations as of March 14, 2005. These statements are forward-looking, and actual results may differ materially. This guidance assumes closing of the ESP Pharma and Retavase acquisitions on or about March 31, 2005. Except for those assumptions and as expressly set forth below, these statements do not include the potential impact of new collaborations, material licensing arrangements or other strategic transactions.

For 2005 PDL anticipates that, on a non-GAAP basis, our total revenues will be in the range of approximately $250 to $260 million. Royalty revenues are expected to be in the range of approximately $112 to $115 million, and license and other revenues are anticipated to be in the range of approximately $20 to $25 million. Royalty revenue estimates do not include further royalties based on sales of Tysabri® antibody product from Biogen Idec and Elan, which is licensed under PDL’s humanization patents but was withdrawn from the market on February 28, 2005. PDL currently believes that royalty revenues for each year from 2006 through 2008 should grow approximately 25% per year.

Product revenues for Cardene IV, Retavase and IV Busulfex are expected to total approximately $93 to $95 million for the anticipated nine-month period of sales following the close of the acquisition of ESP Pharma on or about March 31, 2005. Additionally, PDL anticipates compound annual growth rates of approximately 25% for net product sales of these three marketed products for each year from 2006 through 2008. For these same products, PDL currently anticipates product operating margins of at least 80% over the 2005 through 2008 period.

During 2005 we anticipate research and development expenses in the range of $184 to $186 million of which we expect to spend approximately $100 million to advance our clinical development programs for Nuvion, daclizumab and M200. We further anticipate sales and marketing expenses in the range of $42 to $44 million resulting primarily from the ESP Pharma acquisition. We anticipate general and administrative expenses for the full year 2005 in the range of $31 to $33 million.

In addition, we expect interest income of approximately $7 million and interest expense of approximately $8 million.

Overall, for the full year 2005 we anticipate a GAAP net loss in the range of approximately $1.43 to $1.64 per basic and diluted share, and a non-GAAP net loss in the range of approximately $0.18 to $0.34 per basic and diluted share.

At year-end 2005, PDL estimates that its cash balances will be approximately $200 million. This estimate takes into account anticipated capital expenditures of $38 to $42 million, approximately half of which represents final validation and completion of our new Brooklyn Park, Minn. manufacturing facility; cash payments during 2005 of $325 million and $110 million for the acquisitions of ESP Pharma and Retavase, respectively; the receipt of approximately $240 million from the recent sale of convertible notes, net of fees and expenses; and the assumption of up to $14 million in ESP-related debt. By year-end 2005, we estimate that our headcount will be in the range of 900 to 950, split approximately 70% in research and development, 15% in sales and marketing and 15% in general and administrative functions.

The 2005 non-GAAP operating expenses exclude the following: (a) stock compensation expenses of approximately $10 to $15 million (noting that this is a highly variable expense depending upon the valuation model selected and related assumptions for stock price volatility); (b) acquired in-process research and development expenses related to the purchase of ESP Pharma of approximately $88 million; and (c) amortization of intangibles related to the acquisitions of Eos, ESP Pharma and to our recent convertible offering of approximately $31 million. We note that the stock compensation expense is a preliminary estimate based on the new standard issued by the Financial Accounting Standards Board, FAS 123R, to be adopted by us in the second half of 2005. The actual expense may be materially different depending on the assumptions and methodologies used in implementing the new standard.
Clinical Development Update

Dr. Steven Benner, Senior Vice President and Chief Medical Officer, PDL, said, “PDL is committed to the development of new antibody-based treatments. We have continued to make progress on our clinical programs and look forward to exciting new antibody programs leading to future INDs coming from our research efforts. Now, with the anticipated acquisition of ESP Pharma, we expect to add additional clinical programs that we hope will expand our product portfolio over the next few years.”

Nuvion (visilizumab, anti-CD3). Nuvion remains PDL’s highest development priority. PDL expects to meet with the FDA in late March. At this end-of-Phase I meeting, PDL will discuss its plans to move Nuvion into a Phase III program. PDL hopes to move into registrational trials with Nuvion in intravenous corticosteroid-refractory ulcerative colitis late this year. If the discussions with the FDA are positive, PDL intends to use the FDA’s Special Protocol Assessment process to continue to develop the protocol and plan the analysis of the Phase III program.

PDL expects to publicly update the status of its Nuvion program and the outcome of the discussion with the FDA by early April. Additional data from the Phase I / II study of Nuvion is expected to be presented during the Digestive Disease Week meeting to be held in Chicago from May 14-19.

Daclizumab (Zenapax, anti-IL-2 receptor). PDL is on schedule to begin in this quarter a single-dose Phase I study of PDL-manufactured daclizumab administered subcutaneously for asthma. This trial will be followed by a multiple-dose study in healthy volunteers expected to be initiated this summer. A Phase II dose range-finding study of subcutaneously administered, PDL-manufactured daclizumab in asthma patients remains on schedule for the first quarter of 2006. PDL also continues to evaluate the opportunity to develop daclizumab further in the setting of solid organ transplantation.

A randomized, placebo-controlled, Phase II study of daclizumab in patients with multiple sclerosis is pending initiation. We anticipate the first patient accrual in late March or early in the second quarter. In this study, patients with active relapsing forms of MS will receive subcutaneous daclizumab at one of two dosage levels, or placebo, for six months in addition to their current beta-interferon treatment. The three-arm study is planned to enroll a total of 270 patients.

M200 (volociximab, anti-alpha5beta1 integrin antibody). Currently, M200 is being developed as an anti-angiogenic therapy for the treatment of solid tumors in open-label pilot Phase II studies. These trials, each of up to 40 patients, will further assess the tolerability of prolonged administration of M200 and look for evidence of clinical activity. Two clinical trials are now open. Two additional pilot Phase II studies will open in the first and second quarters, respectively. Data from at least two of the initial Phase II studies is expected to be available for presentation during the ASCO meeting in June 2006.

In addition, PDL is planning a pilot trial of M200 administered intravenously in patients with age-related macular degeneration (AMD). M200 administered intravenously has shown activity in animal models and this approach reflects PDL’s belief that the treatment of this disease will evolve to systemic therapies. Consequently, given the attractiveness of this approach relative to intra-vitreal injections, we intend to proceed with development of M200 in place of F200 in this indication. F200 is a fragment of the M200 antibody and was a pre-IND candidate for the intra-vitreal treatment of AMD. We are planning a Phase II trial of M200 administered intravenously in patients with AMD, expected to begin during the second half of 2005.
ESP Pharma Products and Pipeline

ESP Pharma’s two leading marketed products are Cardene IV and IV Busulfex, and it is under contract to acquire an additional marketed product, Retavase, from Centocor. The 75 sales professionals at ESP Pharma currently detail to hospital-based physicians the following products:

Cardene IV® (nicardipine hydrochloride). Cardene IV is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. Cardene IV is used in the hospital as an option for control of hypertension. Currently, it is used most often by neurologists, neurosurgeons, anesthesiologists, cardiologists and cardiothoracic surgeons. Increasingly, it also is used in emergency departments. We believe that given the known safety profile and efficacy of Cardene IV, the use of this agent will continue to increase as new prescribers gain experience with the agent. We will be evaluating additional opportunities to further develop Cardene IV.

IV Busulfex® (busulfan injection). IV Busulfex is an intravenous formulation of busulfan and is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. When used in this regimen, IV Busulfex is administered four times per day and replaces oral busulfan, for which a patient must take over 100 pills per day. Oral busulfan is associated with nausea and vomiting that may lead to lower drug levels than was intended. We believe that additional opportunities for the development of IV Busulfex exist. We may explore other potential uses of the drug, such as a once per day regimen and expanding the use of the drug into other conditioning regimens for the treatment of other malignancies. We expect that the major use of IV Busulfex will be in conditioning regimens associated with bone marrow transplantations.

Retavase® (reteplase). Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Retavase is used predominantly by cardiologists, cardiothoracic surgeons and emergency room physicians. PDL believes that the two bolus, fixed-dosing regimen of Retavase is an advantage in the acute setting of myocardial infarction. We believe that Retavase will be an excellent fit with Cardene IV, as there is significant overlap in the hospitals and physicians that could use both products. With respect to further development opportunities for Retavase, an ongoing clinical trial being conducted by Centocor and Eli Lilly and Company, called the FINESSE trial, is exploring the use of Retavase in combination with Reopro® (abciximab) in the setting of facilitated percutaneous coronary intervention (PCI).

ESP Pharma has marketing rights for three compounds in development, as well as Phase III development and marketing rights for a fourth compound. PDL has prioritized the pipeline to focus immediately on two of these opportunities: terlipressin, a potential treatment for hepato-renal syndrome (HRS); and ESP-305, a potential treatment for congestive heart failure.

Terlipressin. Terlipressin is a synthetic 12 amino acid peptide derived from the naturally occurring lysine-vasopressin. Terlipressin causes constrictive activity in vascular and extra-vascular smooth muscle. As a consequence, it reduces blood flow in the splanchnic area and thereby lowers portal blood pressure. Terlipressin is approved in many European and Asian countries for the treatment of esophageal variceal hemorrhage. These varices develop as a complication of portal hypertension in patients with liver cirrhosis.

Results from early clinical trials suggest that terlipressin may have activity in patients with hepato-renal syndrome (HRS). Patients with end-stage liver disease may develop progressive deterioration of renal function, without a primary abnormality of the kidney. Patients who have a rapid decline of renal function, characterized as HRS type I, have a median survival of less than two weeks. The treatment of choice for these patients is liver transplantation, but this option is not always available to all patients.

ESP Pharma acquired exclusive marketing rights for terlipressin in the United States and Canada from a private U.S. company, Orphan Therapeutics, which is developing the compound in HRS. Orphan Therapeutics holds the IND and is conducting a Phase III trial in patients with type I HRS in the United States and Europe.

Orphan Therapeutics has obtained Orphan Drug Status for this program. We estimate that there are 4,000 to 6,000 patients in the United States each year that could be candidates for this therapy. There are no approved medical treatments for type I HRS.

ESP-305 (ularitide). ESP-305 is an agent for the potential treatment of congestive heart failure. This compound is a natriuretic peptide, urodilatin (INN: ularitide). Ularitide is a recombinant form of this naturally occurring peptide, originally isolated from human urine. Ularitide is formed from the cleavage of the same prohormone that produces atrial natriuretic peptide. Ularitide enhanced natriuresis and diuresis and decreased central venous pressure in a previous small study of patients with CHF. The peptide was first isolated by scientists affiliated with the University of Hanover, Institute of Peptide Research and has been developed by a German company, CardioPep Pharma GmbH.

Recently, CardioPep has been conducting clinical studies of ularitide in hospitalized patients with decompensated congestive heart failure. The first of their two studies, the SIRIUS I trial, was a double-blind, placebo-controlled, ascending dose study in patients with decompensated chronic heart failure. This trial enrolled 24 patients. The study was primarily intended to assess safety, but evidence of hemodynamic activity was observed at two higher dose levels when assessed at six hours. There was no apparent difference in adverse events across the four treatment groups. The results of this study, SIRIUS I, are now in press in the American Heart Journal. Currently, CardioPep is conducting SIRIUS II, a larger, double-blind, placebo-controlled Phase II study of ularitide. A total of 221 patients have been enrolled. Results of this trial should become available in the second quarter of this year.

ESP Pharma acquired from CardioPep exclusive rights to conduct all subsequent Phase III development and exclusive marketing rights for ularitide for all indications in the United States, Canada, the European Union and Switzerland. To date, all clinical development of ularitide has taken place in Europe. PDL anticipates filing a U.S. IND for ESP-305 this year. In the United States alone, there are approximately one million hospitalizations per year for decompensated congestive heart failure.

Dr. Benner added, “We are pleased that the ESP Pharma projects will enter our pipeline at the end of Phase II or later and that the combined pipeline will maintain a focus on hospital products, while expanding PDL into cardiology. We are very excited about not only becoming a fully integrated company, but about the broader potential of our commercial portfolio with new products that are currently in developme

[blb]

Muss mich noch durch die Zahlen wühlen, der Kursanstieg in der letzten Stunde zeigt aber einiges!

Das erste Gap nach oben wurde gschlossen, bis 20$ ist auch noch eines offen!

Grüße an alle!
blb

[Isabartels]

14.03.2005 - 22:13
Protein Design Labs übertrifft die Erwartungen

Protein Design Labs erwirtschaftete im abgelaufenen vierten Fiskalquartal einen Verlust je Aktie von 14 cents. Damit konnten die Erwartungen, die noch einen cent darunter lagen, übertroffen werden. Der Umsatz lag bei $22.83 Millionen, was ebenfalls über den Erwartungen ($21.53 Millionen) liegt. Das unter dem Tickersymbol „PDLI“ an der Nasdaq gelistete Unternehmen hob zudem seinen Ausblick für das Geschäftsjahr 2005 an. Die Aktie stieg heute um 14.43% auf $16.42.

[Isabartels]

War ein schöner Doppelschlag gestern. Gute Testergebnisse für Avastin und gute Zahlen und super Ausblick. Das gibt dem Kurs jetzt hoffentlch anhaltenden auftrieb.

[Isabartels]

jede Wette, das "First Albany" jetzt wieder mit einer neuen Prognose kommt!

[Isabartels]

[/url]

[Isabartels]

kurschancen laut analyse fast 50% und dann marketperform?????


16.03.2005 - 14:21
Protein Design Labs - Rating bekräftigt

Analysten von JMP Securities haben ihr "market perform"-Rating für Protein Design Labs Inc bestätigt, senkten jedoch gleichzeitig die Gewinnerwartungen für den Konzern. Das Kursziel auf Sicht von 12 Monaten liegt bei $25.

[Nostarowie]

Mensch Leute,

endlich rumpelts im Karton !

[blb]

OUR TAKE

PDL Eyeing Up Profits
The Motley Fool Take

By Charly Travers (TMFBreakerCharly)
March 15, 2005

Making the transition from an R&D company without products to a fully integrated drug company that develops and sells drugs is a big step in the biotech industry. It often marks the turning point where a company can begin to create long-term value for its shareholders instead of just burning up investor capital. Protein Design Labs (Nasdaq: PDLI) is rapidly progressing through this metamorphosis.

Protein Design Labs owns key patents on antibody humanization technology, and because of this intellectual property estate, the company receives royalty payments on the sales of antibody drugs from companies such as Genentech (NYSE: DNA) and MedImmune (Nasdaq: MEDI). A year ago, PDL had this nice royalty stream and an interesting drug in development called Nuvion. Other than that, though, there wasn`t much to be excited about in the near term.

For a small biotech, that was pretty good, and I liked the company`s prospects enough to make it a formal recommendation for Motley Fool Rule Breakers. I`m happy to report that I like the company even more now than I did a year ago. The reason is that PDL has added commercial products to its lineup. No longer are PDL`s investors waiting for future drug sales. They are right around the corner, just awaiting the completion of PDL`s acquisition of ESP Pharma.

Taking into consideration the sales of drugs brought in through ESP Pharma, PDL announced yesterday that 2005 revenues are expected to come in at approximately $250 million, a 150% increase over last year. It is also a significant accomplishment, since there aren`t too many biotech companies that have crossed that sales threshold.

This is the beginning of an era in which PDL`s investors can focus on the financial statements as much as the drug pipeline. The company expects to become cash flow positive in the second half of next year, and I think it will hit that goal -- especially since that guidance does not include yesterday`s good news from Genentech on Avastin. Avastin should see increased use in non-small cell lung cancer in addition to sales in its current market, colorectal cancer. Since PDL receives a royalty on Avastin sales, this represents additional upside.

[blb]

Die 18$ sind ein harter Brocken, darüber lautet mein Kursziel 20$ (Gapschluss)!

[Isabartels]

17.03.2005 10:50:53 (SMITH BARNEY CITIGROUP)


Protein Design Labs "buy"
Die Analysten von Smith Barney Citigroup stufen die Aktie von Protein Design Labs (ISIN US74369L1035/ WKN 883428) von "hold" auf "buy" hoch und erhöhen das Kursziel von 20 auf 25 USD. Protein Design habe im vierten Quartal einen geringeren Verlust als befürchtet ausgewiesen. Die Royalty-Einnahmen seien besser als erwartet ausgefallen. Um die ESP-Akquisition und höhere Avastin-Umsätze im Modell zu berücksichtigen, habe man die Umsatz- und Ertragsprognosen nach oben angepasst. Den Umsatz in 2005 sehe man nun bei 253 Mio. USD (alt: 123) und den Verlust je Aktie bei 0,30 USD (-0,48). Der Markt sollte auf die zusätzlichen Einnahmen aus der ESP-Übernahme positiv reagieren, so die Analysten. Vor diesem Hintergrund empfehlen die Analysten von Smith Barney Citigroup die Aktie von Protein Design Labs nunmehr zum Kauf.
Quelle: AKTIENCHECK.DE

[Isabartels]

Warum steigt die so?????????
PROTEIN DESIGN EUR 13.30 13.70 1.07 8.75% 12.23

[blb]

@Isabartels: Schering-Reinfall hilft Genentech und Protein, da die ähnliches Krebsmittel haben!
So schnell kanns gehen. Langsam zahlt sich der Nachkauf hübsch aus!

[Isabartels]

blb
Danke!!! Ist nur fraglich ob der Anstieg Bestand hat. Glaube ich fast nicht.
Gruss
Isa

[blb]

PDLI bekommt Royalties von Avastin. Letzte Woche kamen doch gute News, daraufhin ist auch Schering gestiegen, weil deren Krebsmittel ähnlich "funktioniert". Da die Phase III-Ergebnisse aber nicht so der Hit waren, steigen jetzt DNA und PDLI, da ein Konkurrent erstmal weniger. Ist ja echt hochspannend zur Zeit!

Genentech Gains on Novartis, Schering Setback

By TSC Staff
3/21/2005 8:14 AM EST

Switzerland-based Novartis (NVS :NYSE - news - research) and its German partner Schering (SHR:NYSE - news - research)will delay plans to seek regulatory approval of their cancer drug after it produced somewhat disappointing test results.

The companies Monday said that the analysis of progression-free survival as assessed by central radiology review in their Confirm 1 clinical trial with the investigational drug PTK/ZK did not achieve statistical significance in treating metastatic colorectal cancer.

The companies, however, added that a separate preplanned analysis of progression-free survival as assessed by the investigators achieved statistical significance.

As a result, an independent data monitoring board recommended the phase III clinical trial program to continue to allow analysis of overall survival endpoints. This is expected in 2nd half of 2006.

The companies will seek both U.S. European regulatory approval sometime in early 2007, which had previously been expected sometime in 2005.

Shares of both companies fell in European trading; both trade in the U.S> as American Depositary Receipts. Novartis ADRS closed at $48.32 Friday, while Schering`s ended at $77.75.

The development boosted shares in U.S> rival Genentech (DNA :NYSE - news - research), which makes the drug Avastin. Shares rose $4.61, or 8.7%, to $57.50 in the premarket.

[Isabartels]

Komisch, genentech kann seinen Kursanstieg verteidigen, während PDLI fast wieder alles veroren hat!

[Nostarowie]

@Isa.
Ich versuche das mal mit meinem Jungbörsenverstand so zu interpretieren das es letzte Woche ja schon nen großen Anstieg gab?
Aber langfristig sind wir aufm richtigen Dampfer,- mit SL als Anker!

[Isabartels]

Nosta,
na ja, 2 schritte vor und einer zurück. ich habe keinen SL.
Gruss
Isa

[Nostarowie]

Das ist Mutig!

Ohne Angststop?!
Bei Biotechs?!
Siehe Elan?!
Und,und,und,und überhaupt und.

[Isabartels]

für ein SL sind mir die Schwankungen zu gross. du fliegst z.B. raus und anschliessend geht der Kur hoch!!

[Isabartels]

Wie ich schon sagte, die ändern fast wöchentlich ihre Einschätzung


21.03.2005 - 22:14
Protein Design Labs: Kursziel erhöht

First Albany erhöhen das Kursziel für Protein Design Labs von $19 auf $20.

[Nostarowie]

Tja.
No brian no pain.
Da wird sich doch auch nur nach dem mainstream gerichtet.

Fakt ist das es, auch durch den Aufkauf von ESP,gut aussieht.

-Was kostet die Welt? ich zahle Bar!-

[Isabartels]

ress Release Back

March 23, 2005
PDL Reports on Nuvion End of Phase I Meeting Held with the FDA
PDL plans Phase II / III clinical trial in IV steroid-refractory ulcerative colitis

Fremont, CA

Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI), today said that it has discussed with the U.S. Food and Drug Administration (FDA) the future development pathway for PDL’s Nuvion® (visilizumab) humanized anti-CD3 antibody being developed for the treatment of intravenous steroid-refractory ulcerative colitis.

Steven Benner, M.D., Senior Vice President and Chief Medical Officer, PDL, said, “At an end-of-Phase I meeting, we explored with the agency various potential development paths. As a result of these discussions, we are now considering a plan to conduct two pivotal clinical trials and a retreatment study of Nuvion in the setting of intravenous steroid-refractory ulcerative colitis. The first pivotal study will be a Phase II / III clinical trial, instead of a Phase III trial, and is expected to begin this year. Assuming certain protocol-defined criteria are met at the time of the interim analysis, the second pivotal trial would be initiated. We anticipate initiating the retreatment study at the time of the Phase II / III study. We believe that this approach of moving next to a Phase II / III clinical trial strikes an appropriate balance between time of development and development risk.

“Based on this development pathway, we will not pursue a Special Protocol Assessment; however, the proposed protocols will be reviewed in detail by the FDA,” Dr. Benner added. “Over the next weeks, we expect to more fully refine the development plan and its impact on the overall development timeline, but anticipate that the time to complete the proposed registrational studies will be longer than we have previously hoped. Nuvion continues to be our highest priority program and we are committed to making this novel therapy available to patients with intravenous steroid-refractory ulcerative colitis. We expect to provide a further development update by the end of May 2005.”

Ongoing Phase I / II Clinical Trial in IV Steroid-Refractory Ulcerative Colitis

PDL is currently conducting a Phase I / II clinical trial of visilizumab in patients with IV steroid-refractory ulcerative colitis. The Phase I portion of the trial was designed to explore four dose levels at 5, 7.5, 10 or 12.5 micrograms/kg administered intravenously on days 1 and 2 as a bolus injection. Up to 20 patients per dose cohort will be enrolled, with up to an additional 40 patients to be enrolled in the Phase II portion of the trial, for an expected total of approximately 120 patients treated. PDL is now enrolling visilizumab-naïve patients in the Phase II component of the study at the 5 micrograms/kg dose level, administered on days 1 and 2.

In a completed, 32-patient Phase I study of two dose cohorts that was reported in May 2004, a strong signal of activity was observed in the first dose cohort given at 15 micrograms/kg on days 1 and 2, in which all eight patients achieved remission. A continued strong signal of activity subsequently was observed in the second dose cohort given at 10 micrograms/kg administered on days 1 and 2. At the 10 micrograms/kg dose level, 19 of 24 patients responded to treatment and of these, 13 achieved remission. “Visilizumab has demonstrated activity at all dose levels tested to date,” Dr. Benner commented.

In each of the studies reported to date, the most common adverse events have been associated with the cytokine release syndrome, which generally consists of flu-like symptoms typically characterized by fatigue, nausea, chills and headache and a transient rise in liver enzymes. The flu-like symptoms were generally transient in nature, were seen less frequently following the second day of treatment and typically resolved within 24 hours following the second treatment. In addition, visilizumab induces a transient decline in T cells and frequently an associated transient rise in Epstein-Barr virus (EBV) titers. The decline in T cells could result in an increased incidence of infections, although this has not been observed thus far in the clinical trials in patients with IV steroid-refractory ulcerative colitis.

PDL currently expects to present additional clinical information regarding visilizumab at the Digestive Disease Week meeting to be held in Chicago, May 14-19.

In September 2004, PDL announced that the FDA had granted Fast Track status to the investigation of visilizumab in patients with IV steroid-refractory ulcerative colitis. Designation as a Fast Track product indicates that the FDA will facilitate the development and expedite the review of a new drug that is intended to treat a serious or life-threatening condition, and that demonstrates the potential to address an unmet medical need. However, Fast Track designation does not mean that the FDA will expedite approval of any application for the product or guarantee appro

[Isabartels]

Wie werden die Amis heute reagieren. Vorbörslich jedenfalls etwas gefallen!!

[Isabartels]

24.03.2005 14:07:28 (SMITH BARNEY CITIGROUP)

Protein Design Labs neues Kursziel
Die Analysten von Smith Barney Citigroup stufen die Aktie von Protein Design Labs (ISIN US74369L1035/ WKN 883428) unverändert mit "buy" ein, senken aber das Kursziel von 25 auf 22 USD. Protein Design habe Ergebnisse einer Nuvion-Studie bekannt gegeben. Das Unternehmen habe entschieden noch weitere klinische Tests durchführen zu wollen. Insofern dürfte sich der Entwicklungszeitraum verlängern. Nach Ansicht der Analysten dürfte sich die Verzögerung auf mindestens ein Jahr belaufen. Eine mögliche Zulassung könnte sich daher auf Ende 2008 verschieben. Nichtsdestotrotz glaube man, dass Nuvion nach wie vor das Potenzial habe, einen Umsatz von mehreren hundert Mio. USD zu erzielen. Die Kursschwäche sollten Investoren daher als Kaufgelegenheit nutzen. Vor diesem Hintergrund empfehlen die Analysten von Smith Barney Citigroup die Aktie von Protein Design Labs weiterhin zum Kauf.
Quelle: AKTIENCHECK.DE

[blb]

Übernahme ist durch! Wünsch euch allen schöne Feiertage!

Protein Design Labs Completes Acquisition of ESP Pharma and Retavase Product
THURSDAY, MARCH 24, 2005 8:00 AM
- PR Newswire

FREMONT, Calif., March 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Protein Design Labs, Inc. (PDL) (PDLI) , a leading developer of humanized monoclonal antibodies, today announced that it has completed its previously announced acquisition of ESP Pharma Holding Company, Inc. (ESP Pharma), a leading privately held, hospital-focused pharmaceutical company. ESP Pharma focuses on selectively acquiring approved and late-stage development products addressing the needs of the acute-care hospital market. ESP Pharma was founded in April 2002 around the acquisition of several therapeutics from Wyeth, including ESP Pharma`s leading product, Cardene(R) IV.

Under the terms of the ESP Pharma acquisition agreement, all shares of ESP Pharma common and preferred stock were exchanged for 9,853,770 shares of PDL common stock and $325,000,000 in cash.

PDL has also completed, through the purchase of ESP Pharma, the previously announced acquisition of certain product rights and assets relating to a product known as Retavase(R) from Centocor, Inc., a biopharmaceutical operating company of Johnson & Johnson (Centocor).

Under the terms of the Retavase acquisition agreement, ESP Pharma paid to Centocor $110 million for the rights to manufacture, develop, market and distribute Retavase(R) (reteplase) in the United States and Canada. Additional milestone payments of up to $45 million will be made if additional conditions relating to the ongoing clinical trials and manufacturing arrangements are satisfied.

Protein Design Labs is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. Further information on PDL is available at www.pdl.com or by contacting James R. Goff, Senior Director, PDL Corporate Communications, 510-574-1421 or [e-mail].

Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc. Cardene is a registered trademark of Roche Palo Alto LLC. Retavase is a registered trademark of ESP Pharma, Inc., a wholly-owned subsidiary of Protein Design Labs, Inc.

SOURCE Protein Design Labs, Inc.

James R. Goff, Senior Director, Corporate Communications of Protein Design Labs,
Inc., [phone], or [e-mail]


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

[Nostarowie]

Jo Leute,

meine Augen tränen erst mal nicht mehr beim Chartanblick.

Möchte mich gleich mal bedanken für die hier reingestellten Infos speziell von blb und isa.

Frohe Ostern (und immer die Ohren steif halten!)

[Isabartels]

Nosta

Ebenfalls schöne Ostern, ich denke auch, das Gröbste haben wir hinter uns.

Gruss
Isa

[Isabartels]

Ich glaube ich muss ko............

[Isabartels]

31.03. 11:09:58 12,07 EUR 12,27 EUR
Letzte Kursänderung: 09:38:34




warum wird die heute so runter getaxt? Gib es irgendeine meldung????????????

[Isabartels]

Ich kann es nicht fassen, deswegen wohl:


31.03.2005 - 09:35
Biogen u. Elan - neuer Todesfall durch Tysabri



Laut den beiden in Partnerschaft befindlichen Biotechnologieunternehmen Biogen Idec und Elan Pharmaceuticals gestanden in Zusammenhang mit dem vom Markt genommenen Multiple Sklerose-Präparat Tysabri einen zweiten Todesfall ein. Der zweite Patient sei in Zusammenhang mit klinischen Phase III-Versuchen mit Tysabri zur Behandlung der Crohn-Krankheit aufgetreten. Der Patient sei in 2003 an der extrem seltenen verlaufenden progressiven multifokalen Leukoenzephalopathie (PML), einer seltenen und häufig tödlich verlaufenden, demyelinisierenden Erkrankung des zentralen Nervensystems, gestorben. In 2003 wurde hinsichtlich des betreffenden Patienten als Todesursache fälschlicherweise die Diagnose Gehirnkrebs gefällt.

Biogen brachen im zuge der Meldung nachbörslich um 10,17% auf 34,45 USD ein

[blb]

Jo, leider ist es so. Ich hoff, die Amis checken diesmal, dass PDLIs Prognosen für 2005 allesamt OHNE Tysabri gemacht wurden. Aber zuzutrauen ist denen alles!
Während ein Tysabri-Scheitern das für Elan wohl das Ende bedeutet, muss PDLI hier nur auf Royalties verzichten, die laut meiner Info 3% am Umsatz betragen hätten! Da kann sich jeder ausrechnen was das dann absolut gewesen wäre. Mehr als eingepreist!

Grüße
blb

[Isabartels]

ich denke dass die blöden Amis den Kurs heute in den keller schicken. Dasmit dem "eingepreist" hat leider noch nie funktioniert.
Gruss
Isa

[Isabartels]

Vorbörslich 15,98$.
das massaker bleibt wohl aus. Hätte ich auch nicht mehr verstanden!

[Isabartels]

Die Amis sind doch intelligenter als ich dachte!!

[Nostarowie]

Menschmeier!

Paar Tage ohne Börse und schon senkt sich das Theater!

Durch die neuerliche Elan-Tragik (welche nun auch meine ganz persönliche ist) sollte man doch PDLI eigentlich nachkaufen, oder?!
Werde den Verlauf morgen mal abwarten und evtl. nachlegen.

Gruß Nosta

[Isabartels]

Also ich versuche den Kursverlauf zu verstehen.

PDLI benötigt pro Tag 1000 Barrel Rohöl zur Herstellung von Antikörpern. Und weil Rohöl gerade teuer ist, drückt die roölabängigkeit natürlich den Kurs nach unten. Hab ich doch richtig verstanden oder???

[Nostarowie]

Bin immer wieder dankbar für gute erklärungen.

Na ja, ich wart mal noch.SL hab ich übrigens auch abgeschafft, ist hier doch besser.

Aber Öl wird auch wieder billiger.

[blb]

Mit Logik kommste bei den Amis nicht weit. Zur Zeit dazu noch das beschissene Stimmungumfeld bei Bios...

Dieses Jahr war da leider noch nicht viel zu holen außer bei meiner Medigene.

Hilft nur Durchhalten und sich die Sache ansehen oder Aussteigen und in die Ölbranche rein!

Grüße an alle!
blb

[Isabartels]

hiervon müssten wir profitieren, dawir vor Wochen ja auch unter der Negativmeldung gelitten haben:

13.04.2005 - 09:12
Elan nach positiver Tysabri-Studie +22%



Die beiden Biotechnologiepartner Biogen Idec und Elan Corp. präsentierten am Dienstag nach Börsenschluss vor dem American Academy of Neurology Phase III-Daten, wonach deren vom Markt genommenes Multiple Sklerose-Präparat Tysabri das Fortschreiten des Kranhkeitsverlaufes deutlich bremst.

Elan konnten infolge jener Meldung nachbörslich um 22,02% auf 4,60 USD durch die Decke gehen. Biogen legten nachbörslich um 1,5% auf 37,25 USD zu

[Isabartels]

Jede wette, dass diese meldung auch PDLI heute hochzieht!!

[Isabartels]

wastaxt Lang&Schwarz denn da für einen Mist. war dasjetzt eine schlechte nachricht???? ich fasse esicht!!

13.04. 12:04:23 11,75 EUR 11,95 EUR
Letzte Kursänderung: 10:52:51

[eck64]

Wenn du denkst, die taxen zu niedrig, dann musst du kaufen....

[Isabartels]

Bin leider schon voll investiert!!!

[Isabartels]

na also!!

Datum Zeit Bid Ask
13.04. 14:10:41 12,09 EUR 12,29 EUR
Letzte Kursänderung: 14:05:34

[Nostarowie]

Ruhe bewahren,

wird schon

[Nostarowie]

Ist euch schon mal aufgefallen das sich kein Schwein für PDLI interessiert?? (bis auf die Mitleser?)

Denke mal das wird sich noch gewaltig ändern!

[Isabartels]

Kurs zieht gerade an. Deshalb wohl:



15.04.2005 - 11:11
Roche u. Genentech mit positiven Studien



Der Schweizer Pharmakonzern Roche präsentierte gemeinsam mit seiner US-Tochter Genentech positive Studien zum Präparat Avastin zur Behandlung von Brustkrebs. Demach wurden bei Phase III-Versuchen von Avastin in Kombination mit einem Chemotherapeutikum erste positive Endergebnisse erzielt. So habe die Kombination der beiden Medikamente eine Erhöhung der Überlebensrate bei getesteten Patienten ergeben.

Weitere Vorgehensweise sei die Einreichung der Daten bei der US-Gesundheitsbehörde FDA um die Möglichkeit einer Zulassung der Medikamentenkombination auszuloten

[Isabartels]

Kurs in USA vorbörslich:

$16,16

[Isabartels]

altime-Kurse
Datum Zeit Bid Ask
15.04. 13:35:45 12,50 EUR 13,00 EUR
Letzte Kursänderung: 13:35:20

[Isabartels]

USA jetzt $16,50 !!

[blb]

Zumindest ein Lichtblick bei dem schlechten Marktumfeld...

Grüße und schönes Wochenende!
blb

[Isabartels]

Ebenfalls schönes Wochenende!! Mal schaun, wie hoch der Kurs heute geht. 17$ wären nett!!

[Isabartels]

$16,78

[Isabartels]

$ 16,90

[Nostarowie]

Uiuiui

hab eben meine Kiste angeschalten!

[blb]

Heute nochmal tolle News! Mit der Aktie werden wir noch viel Freude haben, um die 19$ ist auch noch ein Gap offen, das ist mein erstes Kursziel!

Grüße an alle!
blb

[amorphis]

noch mehr gute news...



Press Release Source: Protein Design Labs, Inc.

Protein Design Labs and Orphan Therapeutics Report Fast Track Designation for Terlipressin in Type 1 Hepatorenal Syndrome
Wednesday April 20, 4:00 pm ET

FREMONT, Calif. and LEBANON, New Jersey, April 20 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - News) and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

Designation as a Fast Track product indicates that the FDA will facilitate the development and expedite the review of a new drug that is intended to treat a serious or life-threatening condition, and that demonstrates the potential to address an unmet medical need. However, Fast Track designation does not mean that the FDA will expedite approval of the product nor does it increase the likelihood of approval of the product.

PDL`s wholly-owned subsidiary, ESP Pharma, Inc., has acquired from Orphan Therapeutics exclusive marketing, sales and distribution rights for terlipressin in the United States and Canada. Orphan Therapeutics holds the U.S. investigational new drug application for terlipressin and is conducting a Phase III clinical trial in the United States and Europe.

Steven Benner, M.D., Chief Medical Officer, said, "Fast Track status is a significant step in Orphan Therapeutics` efforts to develop and ultimately gain approval for terlipressin in an indication for which there is no approved therapy. We congratulate Orphan Therapeutics and look forward to their continued progress in developing this potentially life-saving therapeutic."

Peter Teuber, Ph.D., President of Orphan Therapeutics, said, "Working to address the significant unmet medical need in patients with type 1 HRS is the highest priority of our entire development team, and for all clinical experts involved in the Phase III trial around the country. The Fast Track status is a much welcomed recognition that a close and early interaction with the FDA on the development program, particularly for a small firm like ours, is critical to facilitate the development of terlipressin in patients with this life-threatening condition."

About Terlipressin

Terlipressin is a synthetic 12 amino acid peptide (1-triglycyl-8-lysine- vasopressin) derived from the natural hormone lysine-vasopressin. Due to its constrictive activity on vascular and extra-vascular smooth muscle cells (V-1 agonist), it reduces blood flow in the splanchnic area, and thereby lowers portal blood pressure. Terlipressin is currently not available in the United States, but has been marketed for more than 20 years outside the United States and is considered a standard of care for the treatment of esophageal variceal hemorrhage. More recently, it has become the most widely studied drug in hepatorenal syndrome, a rare but serious complication of liver cirrhosis for which there is no approved treatment.

About Hepatorenal Syndrome (HRS)

HRS is the development of a functional renal failure in patients with end-stage liver disease in the absence of any other cause of renal pathology. Type 1 HRS is characterized by rapid deterioration of renal function, with a median survival time of less than two weeks, unless liver transplantation is performed. The likely pathogenic mechanism leading to HRS is a vasoconstriction of the renal circulation, secondary to a marked arterial vasodilation in the splanchnic vascular bed, leading to reduction in effective arterial blood volume with subsequent homoeostatic activation of vasoconstrictor systems. The treatment of choice is liver transplantation, if the patient is suitable for transplantation and survives until a transplant is available.

The ongoing clinical study is a double-blind, placebo-controlled Phase III trial of terlipressin in patients with type I HRS (OT-0401). In this study, patients receive terlipressin, or placebo, given intravenously as 1-2 mg every six hours. Therapy is continued until creatinine decreases to less than or equal to 1.5 mg/dl for at least 48 hours, or for a total of 14 days, unless treatment fails or the patient undergoes liver transplantation (for more information see www.clinicaltrials.gov).

About Protein Design Labs

Protein Design Labs is a fully-integrated biopharmaceutical company focused on the development and commercialization of novel therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions and cancer. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. PDL markets several biopharmaceutical products in the United States through its wholly-owned subsidiary, ESP Pharma, Inc. Further information on PDL is available at www.pdl.com or by contacting James R. Goff, Senior Director, PDL Corporate Communications, 510-574-1421 or [e-mail].

About Orphan Therapeutics

Orphan Therapeutics, LLC is a privately held drug development company. It was founded in 2003 with the purpose of developing specialty products for rare diseases with a high unmet medical need. The initial focus is on developing and seeking FDA approval of intravenous terlipressin for the treatment of type 1 hepatorenal syndrome in the United States.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those in the forward-looking statements. Factors that may cause such differences are discussed in PDL`s Annual Report on Form 10-K for the year ended December 31, 2004, and other filings made with the Securities and Exchange Commission. In particular, there can be no assurance that the Phase III clinical trial of terlipressin will be completed or that terlipressin will be demonstrated to be safe and effective in the treatment of type 1 hepatorenal syndrome.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc.


Source: Protein Design Labs, Inc.

[blb]

Da könnt ihr euch die Unternehmenspräsentation runterladen:

http://www.pdl.com/index.cfm?navId=129

Grüße
blb

[Nostarowie]

Thanks @blb.

-Alles wird gut-

Gruss, nosta

[blb]

PDLI zieht weiter durch!

Grüße
blb

[blb]

Sehr gute Zahlen gestern! Wichtig sind die Zahlen ohne Einmaleffekte!

Protein Design Labs Announces First Quarter 2005 Financial Results
MONDAY, MAY 02, 2005 4:00 PM
- PR Newswire

FREMONT, Calif., May 2, 2005 /PRNewswire-FirstCall via COMTEX/ -- Protein Design Labs, Inc. (PDL) (PDLI) today reported a net loss of $83.9 million, or $0.87 per basic and diluted share, for the three months ended March 31, 2005, compared with a net loss of $12.6 million, or $0.13 per basic and diluted share, for the three months ended March 31, 2004. Excluding certain non-cash charges described in more detail below, the non-GAAP net loss for the first quarter of 2005 would have been $2.7 million, or $0.03 per basic and diluted share, compared with a non-GAAP net loss of $12.0 million, or $0.13 per basic and diluted share in the 2004 first quarter. Results for the period include financial performance for ESP Pharma, Inc. (ESP Pharma) for the brief operating period from March 23, 2005, the closing date of the previously announced acquisition, through the end of the calendar quarter.

Total operating revenues in the first three months of 2005 were $38.8 million, an increase of 40% over total revenues of $27.6 million in the first three months of 2004. The largest contributor to this revenue growth was a 51% increase in royalties, which totaled $33.2 million in the 2005 first quarter, compared with royalty revenues of $22.0 million in the 2004 first quarter. License and other revenues of $4.7 million in the first quarter of 2005 decreased from $5.6 million in the same three months in 2004. In addition, as a result of the ESP Pharma acquisition, PDL recognized net product sales revenues, which totaled $0.9 million for the last six days of the 2005 first quarter. PDL product revenues for the period reflected net sales of Cardene(R) IV for the control of hypertension when oral therapy is neither feasible or desirable; IV Busulfex(R), a conditioning agent used in connection with bone marrow transplants; and four off-patent branded products. Sales of Retavase(R), a product acquired in connection with the ESP Pharma acquisition, were not recorded in the quarter due to the timing of the product transition to ESP Pharma.

As of March 31, 2005, PDL had cash, cash equivalents, marketable securities and restricted investments totaling approximately $183.7 million, compared with $397.1 million at December 31, 2004. The March 31, 2005 balances reflected approximately $435 million in expenditures in the first quarter of 2005 related to the ESP Pharma and Retavase acquisitions, repayment of outstanding indebtedness of ESP Pharma of approximately $14 million, and planned capital expenditures of approximately $16.0 million in the quarter, which included approximately $8.0 million related to planned ongoing construction and validation of PDL`s manufacturing plant at Brooklyn Park, Minnesota. PDL received net proceeds of approximately $242 million from its February 2005 placement of convertible senior notes.

Total costs and expenses were $123.5 million in the first quarter of 2005, compared with $41.1 million in the same three months of 2004. Excluding certain non-cash charges, which consisted primarily of an acquired in-process research and development charge of $79.4 million related to the ESP Pharma acquisition, as well as the amortization of intangible assets associated with the Eos Biotechnology, Inc. and ESP Pharma acquisitions and the re-acquisition of rights to manufacture and market Zenapax(R) (daclizumab) in 2003, and stock-based compensation charges, non-GAAP total costs and expenses in the 2005 first quarter would have been $42.3 million compared to non-GAAP expenses of $40.5 million for the first quarter of 2004.

Research and development expenses increased slightly to $35.3 million in the 2005 first quarter, compared with $33.0 million in the same three months of 2004. The increase in research and development expenses reflected additional headcount and associated costs required to pursue research and clinical development programs, contract manufacturing and direct scale-up and manufacturing expense, and increased facility and equipment-related costs. Selling, general and administrative expenses of $7.7 million were essentially unchanged in the first quarter of 2005 compared to the first quarter of 2004.

Reconciliations of PDL`s GAAP results to non-GAAP results are included in the financial results tables accompanying this release.

Recent Corporate Developments

On March 24, 2005, PDL announced that it had completed its acquisition of ESP Pharma, a privately held, hospital-focused pharmaceutical company. ESP Pharma was founded in April 2002 around the acquisition of several therapeutics from Wyeth, including ESP Pharma`s leading product, Cardene IV.

Under the terms of the ESP Pharma acquisition agreement, all shares of ESP Pharma common and preferred stock were exchanged for 9,853,770 shares of PDL common stock and $325 million in cash. PDL also completed, through the purchase of ESP Pharma, the acquisition of certain product rights and assets relating to Retavase (reteplase) from Centocor, Inc., a biopharmaceutical operating company of Johnson & Johnson. Centocor received $110 million for the rights to manufacture, develop, market and distribute Retavase in the United States and Canada. Additional milestone payments of up to $45 million will be made if additional conditions relating to the ongoing clinical trials and manufacturing arrangements are satisfied. The total purchase price for ESP Pharma and Retavase was approximately $582 million.

2005 Forward-looking Guidance

The following statements are based on expectations as of May 2, 2005. These statements are forward-looking, and actual results may differ materially. Except for those assumptions and as expressly set forth below, these statements do not include the potential impact of new collaborations, material licensing arrangements or other strategic transactions.

We are updating our guidance from that previously provided on March 14 with respect to our projected GAAP results, in particular as they were expected to affect operating expenses. Specifically, our GAAP adjustments reflect (a) elimination of estimated stock compensation expenses of $10 to $15 million as a result of recent changes in the U.S. Securities and Exchange Commission position on the timing of mandatory stock option expense reporting which we do not plan to adopt until January 1, 2006; (b) adjustment to the estimated amount of acquired in-process research and development expenses related to the purchase of ESP Pharma and Retavase which we have decreased to $79.4 million from approximately $88 million; and (c) adjustment of the amortization of intangibles related to the acquisitions of Eos, ESP Pharma, Retavase and to our February 2005 convertible notes offering to $39 million from approximately $31 million. Our 2005 projected non-GAAP results do not include the foregoing expenses required under GAAP.

We are also updating our guidance from that previously provided on March 14 with respect to our projected non-GAAP results. We are not revising our previously provided guidance on total revenues for 2005. PDL anticipates that our total revenues will be in the range of approximately $250 to $260 million. Royalty revenues are expected to be in the range of approximately $112 to $115 million, and license and other revenues are anticipated to be approximately $30 million, an increase from the previously estimated $20 to $25 million. Royalty revenue estimates do not include further royalties in 2005 based on sales of Tysabri(R) antibody product from Biogen Idec and Elan, which is licensed under PDL`s humanization patents but was withdrawn from the market on February 28, 2005, and we have not increased our estimated royalties based on recently announced positive results for Genentech`s Herceptin(R) or Avastin(TM) antibody products. Consistent with our previous guidance, PDL currently believes that royalty revenues for each year from 2006 through 2008 should grow approximately 25% per year.

On a non-GAAP basis, net product sales for Cardene(R) IV, Retavase(R) and IV Busulfex(R) are expected to total approximately $93 to $95 million for the approximately nine-month period of sales following the close of the acquisition of ESP Pharma. Additionally, PDL anticipates compound annual growth rates of approximately 25% for net product sales of this group of three marketed products for each year from 2006 through 2008. Also for this group of products, PDL currently anticipates gross margins of at least 80% over the 2005 through 2008 period. We are reducing our estimates for net product sales of off-patent products from $25 million to a range of $16 to $20 million.

On a non-GAAP basis, during 2005 we anticipate research and development expenses in the range of $181 to $183 million, a reduction from previously estimated $184 to $186 million. We continue to expect to spend approximately $100 million to advance our clinical development programs for Nuvion(R), daclizumab and M200. We continue to anticipate sales and marketing expenses in the range of $42 to $44 million resulting primarily from the ESP Pharma acquisition. Finally, we anticipate general and administrative expenses for the full year 2005 in the range of $33 to $36 million, an increase from $31 to $33 million.

In addition, we expect interest income of approximately $7 million and interest expense of approximately $8 million.

Overall, for the full year 2005 we anticipate a GAAP net loss in the range of approximately $1.30 to $1.37 per basic and diluted share, and a non-GAAP net loss in the range of approximately $0.17 to $0.25 per basic and diluted share.

PDL now estimates that its year-end cash balances will be approximately $180 million, a change from the prior estimate of $200 million. This estimate takes into account anticipated capital expenditures of $38 to $42 million, approximately half of which represents final validation and completion of our new Brooklyn Park, Minnesota manufacturing facility; cash payments during 2005 of $325 million and $110 million for the acquisitions of ESP Pharma and Retavase, respectively; the receipt of approximately $242 million from the February 2005 sale of convertible notes, net of fees and expenses; and the repayment of approximately $14 million in ESP Pharma-related debt.

By year-end 2005, we estimate that our headcount will be in the range of 900 to 950, split approximately 70% in research and development, 15% in sales and marketing and 15% in general and administrative functions.

Clinical Development Update

Nuvion(R) (visilizumab, anti-CD3). On March 22, PDL reported that it had discussed with the U.S. Food and Drug Administration (FDA) the future development pathway for Nuvion for the treatment of intravenous steroid- refractory ulcerative colitis.

Following these discussions, PDL now expects to conduct two pivotal clinical trials and a retreatment study of Nuvion in the setting of intravenous steroid-refractory ulcerative colitis. The first pivotal study will be a Phase II / III clinical trial and is expected to begin this year. Assuming certain protocol-defined criteria are met at the time of the interim analysis, the second pivotal trial would be initiated. PDL anticipates initiating the retreatment study at the time of the Phase II / III study. The proposed protocols are expected to be reviewed in detail by the FDA. PDL expects to provide a further development update by the end of May 2005.

Additional data from an ongoing Phase I / II study of Nuvion will be presented in an oral presentation by Stephan A. Targan, M.D., Director, Cedars-Sinai Division of Gastroenterology and Professor, UCLA School of Medicine, on May 17 beginning at 11:30 a.m. at the Digestive Disease Week meeting to be held in Chicago.

Daclizumab (Zenapax(R), anti-CD25). PDL began in the first quarter of 2005 a single-dose Phase I study of PDL-manufactured daclizumab administered subcutaneously in healthy volunteers. This trial is expected to be followed by a multiple-dose study in healthy volunteers anticipated to be initiated this summer. A Phase II dose range-finding study of subcutaneously administered, PDL-manufactured daclizumab in asthma patients remains on schedule to begin in the first quarter of 2006. PDL also continues to evaluate the opportunity to develop daclizumab further in the setting of solid organ transplantation.

A randomized, placebo-controlled, Phase II study of daclizumab in patients with multiple sclerosis is pending initiation. We anticipate the first patient accrual in the second quarter of 2005. In this study, patients with active relapsing forms of MS will receive subcutaneous daclizumab at one of two dosage levels, or placebo, for six months in addition to their current beta-interferon treatment. The three-arm study is planned to enroll a total of 270 patients.

Ularitide. PDL on April 18 reported positive results from a Phase II clinical study, known as the SIRIUS II trial, of the atrial natriuretic peptide ularitide in patients with decompensated congestive heart failure (DHF).

The SIRIUS II trial was a randomized, double-blind, placebo-controlled clinical trial conducted at 19 centers in Europe. Primary endpoints in the study were change of pulmonary capillary wedge pressure (PCWP) and change in dyspnea (shortness of breath) score, both at six hours. A total of 221 patients were randomized equally to receive ularitide 7.5, 15, or 30 ng/kg/min given intravenously as a 24-hour infusion, or placebo. In the assessment of the primary endpoints, ularitide significantly reduced PCWP (p<0.05) and improved dyspnea score (p<0.05) in all three dose groups compared to placebo. The main adverse events through day three were dose-dependent decreases in blood pressure compared to placebo. Serum creatinine levels were unchanged during and after ularitide treatment when compared to placebo. The incidence of serious adverse events was similar for all three treatment groups and the placebo group.

The SIRIUS II clinical trial was conducted by CardioPep Pharma GmbH. Through the ESP Pharma acquisition, PDL acquired from CardioPep exclusive rights to conduct all subsequent development and exclusive marketing rights for ularitide for all indications in the United States, Canada, the European Union and Switzerland. To date, the clinical development of ularitide has taken place in Europe. A U.S. Investigational New Drug (IND) application has not yet been filed by CardioPep.

M200 (volociximab, anti-alpha5beta1 integrin antibody). Currently, M200 is being developed as an anti-angiogenic therapy for the treatment of solid tumors in open-label pilot Phase II studies. These trials, each of up to 40 patients, will further assess the tolerability of prolonged administration of M200 and look for evidence of clinical activity. Three clinical trials have now been opened and are enrolling patients. An additional pilot Phase II study is expected to open in the second quarter of 2005. Data from at least two of the initial Phase II studies is expected to be available for presentation during the ASCO meeting in June 2006.

In addition, PDL is planning a pilot Phase II trial of M200 administered intravenously in patients with age-related macular degeneration (AMD), which is expected to begin during the second half of 2005.

Terlipressin. PDL and privately held Orphan Therapeutics, LLC on April 20 reported that the FDA had granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

Designation as a Fast Track product indicates that the FDA will facilitate the development and expedite the review of a new drug that is intended to treat a serious or life-threatening condition and that demonstrates the potential to address an unmet medical need. However, Fast Track designation does not mean that the FDA will expedite approval of the product nor does it increase the likelihood of approval of the product.

Through its acquisition of ESP Pharma, PDL acquired from Orphan Therapeutics exclusive marketing, sales and distribution rights for terlipressin in the United States and Canada. Orphan Therapeutics holds the U.S. IND for terlipressin and is conducting a Phase III clinical trial in the United States and Europe. Orphan Therapeutics has obtained Orphan Drug status for this program.

Webcast Information

PDL will webcast a conference call live at 4:30 p.m. Eastern time today to review its financial results for the first quarter ended March 31, 2005, the status of its clinical development programs and its forward-looking information and guidance with respect to future results. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A link to the conference call webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. The webcast will be archived at www.pdl.com starting approximately one hour after completion of the webcast. A replay of the conference call will also be available by telephone from approximately 7 p.m. Eastern time on May 2 through 11:59 p.m. Eastern time on May 6, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States and enter conference ID number 21245638.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements include our expectations regarding financial results and the timing of clinical developments as well as other statements regarding our expectations. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The successful integration of ESP Pharma and Retavase as part of PDL; fluctuations in sales that may result from our integration of newly acquired operations, from changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses. In addition, PDL revenues depend on the success and timing of sales of our licensees and partners, including in particular the continued successful launch of Avastin(TM) antibody product by Genentech as well as the seasonality of sales of Synagis(R) from MedImmune, Inc. In addition, quarterly revenues may be impacted by our ability to maintain and increase our revenues from collaborative arrangements such as our co-development agreement with Roche. Our revenues and expenses would also be affected by new collaborations, material patent licensing arrangements or other strategic transactions.

Further, there can be no assurance that results from completed and ongoing clinical studies, described above, will be successful or that ongoing or planned clinical studies will be completed or initiated on the anticipated schedules. Other factors that may cause our actual results to differ materially from those, express or implied, in the forward-looking statements in this press release are discussed in our filings with the Securities and Exchange Commission. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

About PDL

Protein Design Labs is a fully-integrated biopharmaceutical company focused on the development and commercialization of novel therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions and cancer. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. PDL markets several biopharmaceutical products in the United States through its wholly-owned subsidiary, ESP Pharma, Inc. Further information on PDL is available at www.pdl.com or by contacting James R. Goff, Senior Director, PDL Corporate Communications, [phone] or [e-mail].

NOTE: Protein Design Labs, the PDL logo and Nuvion are registered U.S. trademarks of Protein Design Labs, Inc. Zenapax is a registered trademark of Roche. Cardene is a registered trademark of Roche Palo Alto. Retavase and Busulfex are registered trademarks of ESP Pharma, Inc., a wholly-owned subsidiary of PDL. Synagis is a registered U.S. trademark of MedImmune, Inc. Herceptin is a registered U.S. trademark and Avastin is a trademark of Genentech, Inc. Tysabri is a trademark of Elan.

PROTEIN DESIGN LABS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

(In thousands, except per share data )
Three months ended March 31,
2005 2004
Revenues:
Product sales, net $948 $--
Royalties 33,164 22,010
License and other 4,703 5,618

Total revenues 38,815 27,628

Costs and expenses:
Costs of product sales 1,137 --
Research and development 35,261 33,029
Selling, general and administrative 7,666 8,068
Acquired in-process research and
development 79,417 --
Total costs and expenses 123,481 41,097
Operating loss (84,666) (13,469)

Interest and other income, net 2,935 2,284
Interest expense (2,142) (1,385)

Loss before income taxes (83,873) (12,570)
Provision for income taxes 22 48

Net loss $(83,895) $(12,618)

Basic and diluted net loss per share $(0.87) $(0.13)

Shares used in computation of basic and
diluted net loss per share 96,754 94,000


CONSOLIDATED BALANCE SHEET DATA
(Unaudited)

March 31, December 31,
2005 2004*
(In thousands) (unaudited)

Cash, cash equivalents, marketable
securities, and restricted investments $183,666 $397,080
Total assets 1,048,777 713,732
Total stockholders` equity 470,543 412,510

* Derived from the December 31, 2004 audited consolidated financial
statements.


PROTEIN DESIGN LABS, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)


We use non-GAAP amounts that exclude charges related to acquired in- process research and development and certain other non-cash charges, including amortization of intangible assets, and stock-based compensation, as well as other non-recurring charges, such as costs incurred in connection with the extinguishment of our debt and restructuring charges. Management believes that these non-GAAP measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the company in its operations, as well as excluding expenses that, in management`s view, are unrelated to our core operations, the inclusion of which may make it more difficult for investors and financial analysts reporting on the company to compare our results from period to period. Our management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating the company`s operating performance and for budgeting and planning purposes.

(In thousands, except per share data)

Three months ended March 31,
2005 2004
GAAP Adjustment Non-GAAP GAAP Adjustment Non-GAAP
Revenues:
Product
sales, net $948 $948 $-- $--
Royalties 33,164 33,164 22,010 22,010
License and
other 4,703 4,703 5,618 5,618

Total
revenues 38,815 38,815 27,628 27,628

Costs and
expenses:
Costs of
product
sales 1,137 $(1,060)(1) 77 -- --
Research
and
development 35,261 (713)(2) 34,548 33,029 $(619)(2) 32,410
Selling,
general and
admini-
strative 7,666 (23)(2) 7,643 8,068 (14)(2) 8,054
Acquired
in-process
research and
development 79,417 (79,417)(3) -- -- -- --
Total costs
and
expenses 123,481 (81,213) 42,268 41,097 (633) 40,464
Operating
loss (84,666) 81,213 (3,453) (13,469) 633 (12,836)

Interest and
other income,
net 2,935 -- 2,935 2,284 -- 2,284
Interest
expense (2,142) -- (2,142) (1,385) -- (1,385)

Loss before
income
taxes (83,873) 81,213 (2,660) (12,570) 633 (11,937)
Provision
for income
taxes 22 -- 22 48 -- 48

Net loss $(83,895) $81,213 $(2,682)$(12,618) $633 $(11,985)

Basic and
diluted net
loss per
share $(0.87) $(0.03) $(0.13) $(0.13)

Shares used in
computation
of basic and
diluted net
loss per
share 96,754 96,754 94,000 94,000


(1) To exclude the ongoing, non-cash amortization of acquired product rights related to the ESP and Retavase acquisitions.

(2) To exclude (i) the ongoing, non-cash amortization of acquired intangible assets, including workforce, related to the Eos acquisition, and core technology, related to the purchase of certain patent rights from Roche and (ii) stock-based compensation charges related to modifications of stock options and stock options issued to non-employees.

(3) To exclude the non-cash charges of acquired in-process research and development, which relate to the ESP acquisition and the purchase of certain technology, that has not achieved technological feasibility.

SOURCE Protein Design Labs, Inc.

James R. Goff, Senior Director, Corporate Communications of Protein Design Labs,
Inc., [phone], or [e-mail]


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

[Nostarowie]

Jo ganz supi.

Allerdings scheinen die Amis Analphabeten zu sein.

Gruß Nosta

[blb]

Kursziel für meine Tradingpositon bleibt der Gapclose bei 20$, die langfristige Position bleibt natürlich weiterhin drin!

[blb]

Hoff das klappt noch mit dem Gapschluss, werd langsam ungeduldig!

Aktionär hat sie jetzt auch im Longtermdepot...

Grüße
blb

[Nostarowie]

Bin gestern raus, vielleicht wars,n Fehler vielleicht auch nich? Wer weis das schon.
Denke es steht nun ne kleine Konso an, aber definitiv ist bei PDLI mehr drin. Bilde mir aber bei Elan mehr ein und hab deshalb dort nochmal nachgeschaufelt.
Vielleicht brech ich mirs Genick vielleicht auch nich? Wer weis das schon.

Gruß Nosta

[blb]

Glückwunsch! Bei mir gehts nur um die Tradingposition, die Langfristposition verkauf ich so schnell nicht!

Grüße
blb

[blb]

PDLI hat heute im Zuge guter Genentech-News endlich das Gap geschlossen. Hab meine bei 15$ gekaufte Tradingposition mit gut 30% Gewinn komplett gegeben.

Die Langfristposition bleibt natürlich weiterhin drin!

Grüße
blb

[blb]

Die 20$ könnten bald Geschichte sein!
Merrill Lynch haben ein Kursziel von 26$!

Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.
WEDNESDAY, JUNE 22, 2005 8:00 AM
- PR Newswire

FREMONT, Calif., June 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- Protein Design Labs, Inc. (PDL) (PDLI) today reported that it has sublicensed to Genentech, Inc. (DNA) development and commercialization rights for antibody-drug conjugates directed against the PR1 antigen, which is frequently differentially expressed in prostate cancer. PDL will receive an upfront licensing fee, and is entitled to receive milestone payments and royalties on future sales under certain conditions.

PDL`s broad collaboration agreement with Seattle Genetics, Inc. (SGEN) provides PDL with rights to develop antibody-drug conjugates (ADCs) to certain targets, including PR1. An antibody directed against the PR1 antigen could lack the ability to kill cancer cells without an attached cell-killing agent such as the potent auristatin derivatives utilized in Seattle Genetics` ADC technology. By linking a drug to an antibody that targets PR1, it may be possible to identify new antibody-drug conjugate products to selectively kill prostate cancer cells while killing a lesser proportion of non-prostate cancer cells. Research related to the preclinical validation of a PR1 ADC, anti-TMEFF2 monomethyl auristatin E-conjugated antibodies in the treatment of prostate cancer was published in the August 2004 edition of Molecular Cancer Therapeutics.

Mark McDade, Chief Executive Officer, PDL, said, "We are pleased to partner our PR1 program with Genentech, an acknowledged leader in bio-oncology. Given PDL`s existing resources and our desire to bring focus to our clinical development programs, out licensing this program is the most efficient way to continue its development."

"This sublicense from PDL further expands our ongoing ADC collaboration with Genentech," commented Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We are excited by their continued interest in the technology for the potential treatment of cancer."

About Antibody Drug Conjugate Technology

Seattle Genetics` second-generation ADC technology utilizes the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. This ADC technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, potentially sparing non-target cells many of the toxic effects of traditional chemotherapy. ADCs can increase the therapeutic potential of the many antibodies that possess targeting ability but no inherent cell-killing activity.

About Prostate Cancer

Prostate cancer is the second leading cause of cancer death in the United States, second only to lung cancer. The American Cancer Society estimates that there will be approximately 232,000 new cases of prostate cancer in 2005, and over 30,000 deaths. The specific cause of prostate cancer has not yet been determined; however, certain risk factors including age, race, nationality, diet and family history have been associated with higher incidences. Currently, prostate cancer is detected by testing the amount of prostate-specific antigen (PSA) in the blood, or through a digital rectal exam. Current treatment consists of surgery and chemotherapy or radiation treatment, though new treatments are needed.

About Protein Design Labs

Protein Design Labs is a fully-integrated biopharmaceutical company focused on the development and commercialization of novel therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions and cancer. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. PDL markets several biopharmaceutical products in the United States through its wholly-owned subsidiary, ESP Pharma, Inc. Further information on PDL is available at www.pdl.com or by contacting James R. Goff, Senior Director, PDL Investor Relations, [phone] or [e-mail].

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those in the forward-looking statements. In particular, there can be no assurance that the PR1-Auristatin program will prove safe and effective in the treatment of prostate cancer or that PDL will receive related milestone and royalty payments. Other factors that may cause such differences are discussed in the Company`s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, and other filings made with the Securities and Exchange Commission.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc.

SOURCE Protein Design Labs, Inc.

James R. Goff, Senior Director, Investor Relations of Protein Design Labs,
[phone], or [e-mail]


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

[amorphis]

ist zwar schon ne woche alt...aber da es noch keiner gepostet hat...stelle ich es mal rein...

liest sich ganz nett...

Protein Design`s Broad Pipeline To Drive Growth
06.23.05, 3:34 PM ET

Wells Fargo Securities initiated coverage of Protein Deign Labs (nasdaq: PDLI - news - people ) with a "buy" rating as the biotech firm attempts to transition business models to product-driven sales from royalty-driven sales. "Protein Design`s humanization technology is used broadly in the biotech industry; in 2004, eight marketed products licensed under Protein Design humanization patents totaled more than $2.9 billion in worldwide sales, from seven of which Protein Design received $83.8 million in royalties," said Wells Fargo. "The recent acquisition of ESP Pharma provides PDL-marketed products with a growing and diverse high-margin operating revenue base. PDL now has a broad, proprietary pipeline that includes its own pipeline." Protein Design`s current license agreements generate royalty revenue streams from several products including Avastin and Raptiva, both marketed by Genentech (nyse: DNA - news - people ) and Synagis, marketed by MedImmune (nasdaq: MEDI - news - people ). The research firm has a $28 price target on shares of Protein Design, about 40% above current levels. "We expect royalties of $120 million in 2005 to grow to $316 million in 2010," said Wells Fargo. "We estimate the market potential of the company`s products to total $270 million by 2010."

[Fruehrentner]

nur um diesen thread nicht einschlafen zu lassen und als Erinnerung:

PROTEIN DESIGN LABS steigt immer nóch.

[blb]

Kein Wunder, da Genentech auch steigt und steigt und steigt. Mal im Ernst, die DNA-Zahlen gestern waren klasse, da kann bei dne nächsten PDLI-Zahlen nicht viel schief gehen!

Mein langfristiges Kursziel liegt >30$

Grüße
blb

[blb]

23$!

[Torussia]

Hallo blb,

stutzig macht mich aber die hohe Zahl der Insiderverkäufe? Oder wie beurteilst Du das?

Gruß
Torussia

[Frank888]

Kommen die Zahlen heute nachbörslich ? Oder eheer ?

[blb]

Zahlen kommen am 4.August. Da ist dann Anschnallen angesagt!

[Frank888]

lt. Aktionär informiert PDLI am 2. August über 2. Quartal

[metallix]

Dann wollen wir mal sehen ob da noch Saft drin ist...
Gruss,
Metallix

[blb]

Nachbörslich 2$ rauf! Aktuell eine wahre Cashmachine!

Biogen Idec and PDL Form Global Alliance to Develop and Commercialize Three Phase II Antibody Products
TUESDAY, AUGUST 02, 2005 4:03 PM
- PR Newswire

CAMBRIDGE, Mass. and FREMONT, Calif., Aug 02, 2005 /PRNewswire-FirstCall via COMTEX/ -- Biogen Idec (BIIB) and Protein Design Labs, Inc. (PDL) (PDLI) today announced a broad collaboration for the joint development, manufacture and commercialization of three Phase II antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications.

Under terms of the agreement, PDL will receive an upfront payment of $40 million, and Biogen Idec will purchase $100 million of common stock from PDL. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million. Of these, $560 million are related to development and $100 million are related to commercialization of collaboration products.

Biogen Idec and PDL will share equally the costs of all development activities and all operating profits from each collaboration product within the United States and Europe. The companies will jointly oversee development, manufacturing and commercialization plans for collaboration products and intend to divide implementation responsibilities to leverage each company`s capabilities and expertise. Each party will have co-promotion rights in the United States and Europe. Outside the United States and Europe, Biogen Idec will fund all incremental development and commercialization costs and pay a royalty to PDL on sales of collaboration products.

"We are very pleased to forge a comprehensive global collaboration on these three products with PDL," said Jim Mullen, President and CEO of Biogen Idec. "This partnership will expand our oncology presence in solid tumors, while strengthening our position as a leader in multiple sclerosis research and development."

Mark McDade, Chief Executive Officer, PDL, said, "As a world leader in the treatment of multiple sclerosis and the originator of the successful cancer treatment, Rituxan(R) (rituximab), we believe Biogen Idec is an outstanding partner with whom to globally develop and commercialize these three novel antibody products. We are obviously excited to forge this collaboration that advances our pipeline, accelerates our path to sustainable positive cash flow and paves the way to commercialization of the next wave of PDL products. From our perspective, this alliance enables both companies to share costs and risks of developing products that address large market opportunities, while leveraging our respective development, manufacturing and commercial strengths."

The closing of the transaction, including the stock purchase, will be subject to antitrust review and approval, and other standard closing conditions. The purchase of the stock will be at fair market value. The stock purchase agreement also provides for a registration statement to be filed for the common stock and the re-sale of the stock is subject to certain limitations.

About Daclizumab

Daclizumab is a humanized monoclonal antibody that binds to the IL-2 receptor on activated T cells, inhibiting the binding of IL-2 and the cascade of pro-inflammatory events contributing to organ transplant rejection and autoimmune and related diseases. A Phase II clinical trial of daclizumab in multiple sclerosis is ongoing. Rights to daclizumab in transplantation, asthma and related respiratory diseases are in partnership with Roche.

About M200 (volociximab)

Volociximab is a novel anti-angiogenic chimeric antibody directed against alpha5 beta1 integrin. Binding of the antibody to alpha5 beta1 integrin inhibits the formation of new blood vessels, a process necessary for tumor growth. Results from a Phase I study in advanced solid tumors suggest that volociximab was well tolerated and did not identify dose-limiting toxicities. Three Phase II clinical trials of volociximab in renal cell carcinoma, melanoma and pancreatic cancers were initiated in the first half of 2005. A fourth Phase II study in non-small cell lung cancer is anticipated to begin shortly. Preclinical data with volociximab suggest the antibody may also have potential as a treatment for age-related macular degeneration.

About HuZAF(TM) (fontolizumab)

Fontolizumab is a humanized antibody that binds to interferon-gamma, an important immunoregulatory cytokine with multiple activities, including up- regulation of MHC Class II molecule expression. Blocking interferon-gamma may be useful in treating a variety of autoimmune diseases.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

About PDL

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at www.pdl.com.

Conference Call and Webcast Information

Biogen Idec and PDL will conduct a conference call to discuss the collaboration agreement today, August 2, at 4:30 p.m. Eastern time. The conference call can be accessed by dialing [phone]. A live webcast of the conference call also will be available through the Biogen Idec website, www.biogenidec.com, as well the PDL website, www.pdl.com. Please connect to one of these websites at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. A replay, including the presentation materials, will be available at www.biogenidec.com and at www.pdl.com starting approximately one hour after completion of the webcast. A replay will also be available by telephone from approximately 6:30 p.m. Eastern time on August 2, 2005 through 6:30 p.m. Eastern time on August 10, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States and enter conference ID number 21256614.

Regarding PDL

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those in the forward-looking statements. In particular, there can be no assurance that the parties will successfully develop or achieve the milestone events on any of the products or that the conditions to the stock purchase agreement will be satisfied, that the parties will perform their obligations under the agreement as anticipated. While the parties are bound to proceed with certain obligations, the agreement contains provisions under which parties can reduce or eliminate their obligations to develop, manufacture and commercialize products, and no assurance can be given that either party will proceed with the development and commercialization of any product. Other factors that may affect the development and commercialization of products are discussed in PDL`s Annual Report on Form 10-K for the year ended December 31, 2004, and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 and in other filings made with the Securities and Exchange Commission. All statements included in this press release are based upon information available to PDL as of the date hereof, and PDL assumes no obligation to update any such forward-looking statements.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc.

Regarding Biogen Idec

This press release contains forward-looking statements regarding the development, manufacture and commercialization of products under the Biogen Idec/PDL collaboration. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Drug development generally involves a high degree of risk. For example, there is no assurance that the effectiveness of the products in larger clinical trials will be as expected or that safety issues will not arise. There is also no assurance that the development, manufacture or commercialization of these products will not be affected by unexpected technical or manufacturing hurdles or intellectual property disputes. For more detailed information on the risks and uncertainties associated with Biogen Idec`s drug development and other activities, see the periodic and other reports that Biogen Idec has filed with the Securities and Exchange Commission. Biogen Idec assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Protein Design Labs, Inc.

media, Jose Juves, Associate Director, Public Affairs, [phone], or investors,
Oscar Velastegui, Senior Manager, Investor Relations, [phone], both of Biogen
Idec; or Ami Knoefler, Senior Director, Corporate Communications


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved. ********************************************************************** As of Friday, 07-29-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 06-20-2005 for PDLI @ $19.80. (C) 2005 Comtex News Network, Inc. All rights reserved.

[amorphis]

these are hammer news... gut in pdli zu sein... guckt euch auch vphm an...auch sehr guter earnings-report heute abend!

[Fruehrentner]

@amorphis

ich habe PDL seit Anfang Juni auf der watchlist - dummerwesie bin ich nicht eingestiegen

Ist der Weg bis zunächst 30 Dollar jetzt frei? Was meinst Du?

Wo steht PDL nachbörslich in USA?

[amorphis]

blb...hab deinen kommentar zu vphm grad gelesen...guck sie dir näher an... es sollen ja auch noch neue wachstumstreiber in den 06/07 hinzu kommen...würde mir keine gedanken machen was das weitere wachstum betrifft!

trotzdem...pdli ist auch eine sehr gute wahl!realllllllyyyy good...

zu pdli-kann das jmd bestätigen das pdli ab 09/05...also noch dieses jahr profitabel sein wird?

This conference call will update financial guidance. Now with BIIB spliting the cost of development for Daclizumab (Multiple Sclerosis), Volociximab and HuZAF and Roche picking up the bills for Daclizumab (for Phase III moderate to severe Asthma: BLA expected in 2007), ESP pharma with profitable drugs and operations, PDLI should be profitable from September 05. Revenues from Avastin, Xolair, Raptiva, Mylotarg, Syndergis, Herceptin and possible future revenues from Lucentis, Numax, Tysabri, Omnitarg, MLN2704 and other 40 humanized monoclonal antibodies in trials.
PDLI owns Nuvion, Terlipressin, Ularitide which all are in late stages of development.

[amorphis]

[posting]17.429.226 von Fruehrentner am 02.08.05 23:45:15[/posting]nachbörse sieht gut aus soweit...etwa 2$ rauf!!!guck dir auch mal vphm an...wenn du in gute bios einsteigen möchtest...

pdli...denke 30 sind jetzt durchaus erstmal drin...würde mich nicht wundern wenn die ende des jahres bei über 40$ stehen!


LAST MATCH
Price 25.2800
Time 17:40:08.790

TODAY`S ACTIVITY
Orders 19,763
Volume 400,501
BUY ORDERS
SHARES PRICE
1,000 24.9000
1,300 24.8800
400 24.8500
125 24.8000
100 24.7600
100 24.0000
1,700 23.9500
2,000 23.8500
1,000 23.4000
50 22.7000
100 19.0000
100 10.6100
100 0.0100

SELL ORDERS
SHARES PRICE
100 25.3400
300 25.4000
251 25.4000
1,000 25.4200
100 25.4900
200 25.5000
300 25.5500
100 25.5800
100 25.5900
100 25.6900
100 25.8700
100 25.8900
50 25.9900
100 25.9900
50 26.4900

[amorphis]

LAST MATCH
Price 25.5000
Time 17:51:44.909

TODAY`S ACTIVITY
Orders 19,773
Volume 403,351

[Fruehrentner]

Auf VIROPHARMA bin ich erst vor ca. 1,5 Wochen aufmerksam geworden nd hate mich bisher nicht getraut rein zu gehen.
Das Ding ist schon enorm gelaufen - da jetzt noch rein??

[Fruehrentner]

@amorphis,

wie denkst du über INTERCELL und MOLOGEN?

[amorphis]

sorry...intercell und mologen habe ich mich nicht mit beschäftigt...man kann ja nicht überall sein...

halte derzeit vphm,pdli,medx,nbx an bios!
techs: chipmos und sigma design

würde mir vphm ansehen...trotz des anstiegs...der anstieg ist nicht auf luft gebaut...sondern es stehen starke earnings dahinter!guck dir mal die bewertung an?!!kgv um die 10-11...bei einem biotech-wert????also...dreimal so hoch werden sie bei einer weiteren positiven entwicklung durchaus in absehbarer zeit bewertet sein...

[Fruehrentner]

@amorphis

handelst du direkt in USA? Wenn ja, wie und wo?

Geht ja wohl kaum anders bei marktengen US-Aktien, bei denen kaum Volumen in D. ist.

[amorphis]

nein...ehrlich gesagt...nein... bin derzeit aber am überlegen...ob ich das in zukunft tun werde!habe bis vor kuzem nicht meinen fokus auf nasdaq werte gelegt...das hat sich jetzt seit einem jahr geändert...habe bisher immer in mehreren tranchen über münchen geordert...da in münchen annähernd kurse der heimatbörse gestellt werden...natürlich sind nicht immer alle stückzahlen verfügbar...aber wenn ich überlege einen neuen trade einzugehen...von sagen wir 10000-15000€...dann gehe ich nie so gerne direkt mit dem gesamtem betrag rein...und aufgeteilt auf 2-3 orders ist das dann durchaus gut machbar!

[Fruehrentner]

Also Beträge so zwischen 10.000 bis 30.000 EUR kann man getrost in München ordern, auch bei marktengen Werten (ggf. gestückelte Aufträge)?

Hast du gute Erfahrungen mit gemacht?

Und wie stehts mit dem Verkauf in gleicher Grössenordnung? Läuft das via München ebenfalls reibungslos?

[ProMaiLer]

hm, ich kauf prinzipiell in den usa bei solchen werten

die deutsche mit ihren mondpreisen... und wenn der preis mal ok ist, gibts kein angebot

[amorphis]

hatte bisher wirklich keine probleme...bin kein daytrader...ich lege meine trades schon mittelfristig an...also mindestens 3-6 monate...je nach news natürlich flexibel raus/rein...da ich nicht ständig hin und her springe...interessiert es mich eigtl nicht ob ich jetzt 10€ oder 20€ für eine order bezahle...wenn am ende ein paar 1000€ gewinn gegenüberstehen...who cares....

also wenn man nicht direkt für 10000€ auf einmal ordert...ist es eigtl kein problem...

[amorphis]

promailer...worüber nochmal?und...mit vphm zufrieden?

[Fruehrentner]

amorphis,

Meinung zu MYOGEN?

so, bin weg, Nacht!

[amorphis]

sehen auch sehr gut aus...bitte sieh es mir nach...das ich mich erst morgen zu MYOGEN äussern werde...werde sie mir ansehen...auch aus eigeninteresse...rein vom chart her... guts nächtle...

[blb]

Vorbörslich bei 26,5$!!! Dazu noch Zahlen morgen! Das wird ne Party!

Ärger mich ein wenig, dass ich die Tradingposition bei 15$ schon zu 20$ verscherbelt habe. Aber naja, man kann ned alles haben. Langfristiges Kursziel bleibt >30$!

[blb]

Tja, wie weit kann es gehen?

[amorphis]

CIBC raises buy target from $32 to $43.
First Albany Raises buy target from $25 to $28.

[Fruehrentner]

Und ich Idiot schau seit Anfang Juni den Kursen hinterhei bei PDL

Aber wenn man sich den Langfristchart ansieht - warum sollte es nicht bis 40 Dollar laufen?

[amorphis]

[posting]17.435.390 von Fruehrentner am 03.08.05 15:19:43[/posting]niemand ist ein idiot...man kann nicht immer alles perfekt machen!abhaken...draus lernen...die welle nach oben versuchen mitzunehmen (auch jetzt noch)...und wenn dann anzeichen kommen von einer korrektur...kapital absichern!

würde heute evtl erstmal den handelsverlauf abwarten...

[amorphis]

27,xx$???!!!

[metallix]

saftig ....saftig....

kann so bleiben....
Metallix

[metallix]

die 30 € kommen!

[blb]

@Fruehrentner: Immer kühlen Kopf bewahren! Ich sehe zwei mögliche Kursverläufe in den nächsten Monaten:

1. Mit den Zahlen morgen schaffen wir es, das Hoch um die 27,5$ zu knacken und es geht in einem Zug in den 30$-Bereich (unwahrscheinlich, da extrem überkauft!)

2. Wir schaffen es morgen trotz guter Zahlen nicht, das Hoch zu überwinden, schließen in den darauffolgenden Wochen das heutige Gap und im zweiten Anlauf gehts Richtung 30$!

Ich würde das 2. Szenario präferieren, zumal das alles einfach etwas zu schnell gehen würde in meinen Augen.

Abwarten!

Grüße
blb

[Boersenkrieger]

hab grad noch reste im depot gefunden von meinen jahr 2000-2001 sünden... protein design -15% nur noch (wußte gar nicht mehr daß ich noch welche habe )
um´s mal klar zu formulieren: was geht ab ?

[amorphis]

boersenkrieger... pdli ne depotleiche... freu dich doch!bald biste im plus...fettes abkommen mit biogen gestern gemeldet...bis zu 666mio$ sind drin...

[kgv1]

Wie lange geht das noch gut?
Kgv1

[blb]

Ich rechne heute mit hervorragenden Quartalszahlen, aber im Handelsverlauf mit Gewinnmitnahmen. Mal schaun!

Grüße
blb

[Boersenkrieger]

naja protein galt damals als ein sehr aussichtsreicher biotec... manchmal dauern die dinge eben länger ...werde sie jetzt wieder verfolgen... schon lustig irgendwie

[amorphis]

Press Release Source: Protein Design Labs, Inc.

PDL Announces Strong Second Quarter 2005 Financial Results
Thursday August 4, 4:00 pm ET
Total Revenues Increase 202% to $77.8 million
Company Now Expects Sustainable Positive Cash Flow by Q4 `05

FREMONT, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - News) today reported financial results for the second quarter of 2005. Financial highlights included:

ADVERTISEMENT
-- Product revenues of $35.3 million reflect the first full quarter of product sales following PDL`s acquisition of ESP Pharma, Inc. and Retavase®, both in March 2005.

-- Royalty revenues increase 52% to $37.5 million from $24.7 million in the second quarter of 2004.

-- GAAP net loss of $3.4 million compared with a net loss of $12.5 million in the second quarter of 2004; non-GAAP net income of $9.2 million compared with a non-GAAP net loss of $11.1 million in the 2004 second quarter.

-- Cash, cash equivalents, marketable securities and restricted investments totaled approximately $191.0 million as of June 30, 2005, compared with $397.1 million as of December 31, 2004. The June 30, 2005 cash balances did not include any payments from the Biogen Idec alliance, announced August 2, 2005, which includes an upfront payment of $40 million and equity investment of $100 million. Closing of the Biogen Idec transaction is contingent upon antitrust review and other standard closing conditions.

Mark McDade, Chief Executive Officer, PDL, said, "Second quarter and first half 2005 results reflect our initial performance in having ESP Pharma become part of PDL, with product sales in-line with our internal expectations for our first full commercial quarter. Meanwhile, our partners` success with breakthrough antibody products such as Avastin(TM), Herceptin® and Synagis® are driving the growth of PDL`s royalty revenues. As a result of this improved top-line performance in the first half, we have increased our revenue guidance for 2005. More significantly, this strong revenue growth from both products and royalties, combined with the economic impact of our new alliance with Biogen Idec, should enable PDL to become cash flow positive on a sustainable basis beginning in the fourth quarter of 2005, and therefore on a full-year basis for 2006. This is nearly a full year ahead of our plan following the acquisition of ESP Pharma this past March."

Total Operating Revenues:

Total operating revenues increased 202% to $77.8 million in the second quarter of 2005 from $25.8 million in the second quarter of 2004.

PDL recognized net product sales revenues of $35.3 million in the second quarter of 2005. Product revenues reflected the first full quarter of net sales of Cardene® IV for the short-term treatment of hypertension when oral therapy is not feasible or desirable; Retavase, used to dissolve coronary blood clots and improve blood flow in heart attack patients; IV Busulfex®, a conditioning agent used in connection with bone marrow transplants in chronic myelogenous leukemia; and four off-patent branded products. These products are marketed by PDL`s wholly-owned subsidiary, ESP Pharma, Inc., which PDL acquired March 23, 2005.

Royalty revenues increased 52% to $37.5 million, compared with royalty revenues of $24.7 million in the second quarter of 2004. PDL receives royalties based on worldwide net sales of seven antibody products licensed under PDL`s antibody humanization patents: Avastin(TM), Herceptin®, Xolair® and Raptiva® from Genentech, Inc.; Synagis® from MedImmune, Inc.; Mylotarg® from Wyeth and Zenapax®, marketed by Roche.

Total Costs and Expenses:

Total costs and expenses were $80.3 million in the second quarter of 2005, compared with $39.5 million in the second quarter of 2004. On a non-GAAP basis, total costs and expenses in the 2005 second quarter were $67.7 million compared to non-GAAP expenses of $38.1 million in the second quarter of 2004.

The cost of product sales was $20.1 million in the second quarter of 2005, compared with none in the comparable period of 2004, reflecting the addition of ESP Pharma in March 2005. Excluding non-cash amortization of product costs associated with the purchase of ESP Pharma and Retavase, cost of product sales were $8.2 million. Selling, general and administrative expenses increased to $19.8 million, compared to $7.5 million in the second quarter of 2004, primarily due to sales expenses associated with PDL`s newly acquired sales and marketing team.

Research and development expenses increased to $40.3 million in the second quarter of 2005, compared with $32.0 million in the same three months of 2004. The increase in research and development expenses reflects additional headcount and associated costs required to advance research and clinical development programs, contract manufacturing and direct scale-up and manufacturing expense, and increased facility and equipment-related costs.

NOTE: Non-GAAP results for the three- and six-month periods exclude certain non-cash charges, which consisted primarily of an acquired in-process research and development charge of $79.4 million in the first quarter of 2005 related to the ESP Pharma acquisition, as well as the amortization of intangible assets associated with the Eos Biotechnology, Inc. and ESP Pharma and Retavase acquisitions and the re-acquisition of rights to manufacture and market Zenapax® (daclizumab) in 2003, and stock-based compensation charges. Reconciliations of GAAP results to non-GAAP results are included in the tables accompanying this release.

Recent Corporate Developments:

-- On August 2, PDL and Biogen Idec announced a broad collaboration for the joint development, manufacture and commercialization of three phase 2 antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and certain other diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications. PDL will receive an upfront payment of $40.0 million and Biogen Idec will purchase $100 million of PDL common stock. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million.

-- In July, PDL acquired worldwide development and commercial rights for ularitide in all indications.

-- In early July, PDL began a phase 1 multiple-dose study of the PDL- produced subcutaneous formulation of daclizumab in healthy volunteers, on target to support the planned initiation of a phase 2b study of daclizumab in asthma by the first quarter of 2006.

-- In June, PDL announced a sublicense to Genentech, Inc. of development and commercialization rights for antibody-drug conjugates directed against the PR1 antigen, which is frequently differentially expressed in prostate cancer.

-- In May, PDL initiated enrollment in a 270-patient phase 2 clinical trial of daclizumab in multiple sclerosis.

-- In April, PDL reported positive top-line phase 2 results for ularitide in acute decompensated congestive heart failure; full results are expected to be presented in September.

-- In the first half of 2005, PDL initiated two separate studies of Nuvion® (visilizumab) in two distinct types of severe Crohn`s disease.

Upcoming Events:

PDL noted that upcoming clinical milestones and related events include the following:

-- Ularitide: Presentation of phase 2 data in acute decompensated heart failure (ADHF) at the European Society of Cardiology congress, September 4, and at the meeting of the Heart Failure Society of America, September 19; PDL also intends to file an IND in the U.S. and initiate clinical development in the U.S. this year.

-- Nuvion® (visilizumab): Begin phase 2/3 study in IV steroid- refractory ulcerative colitis in late 2005 or early 2006.

-- Host an R&D update for the financial community in early October in New York City.

2005 Forward-looking Guidance:

The following statements are based on expectations as of August 4, 2005. These statements are forward-looking and do not include the potential impact of new collaborations, material licensing arrangements or other strategic transactions.

-- PDL now anticipates that total operating revenues for 2005 will be in the range of approximately $255 to $271 million:

-- Net product sales for Cardene® IV, Retavase® and IV Busulfex® are expected to total approximately $100 to $105 million for the approximately nine-month period of sales following the close of the acquisition of ESP Pharma. PDL anticipates compound annual growth rates of approximately 25% for net product sales of this group of products for each year from 2006 through 2008. PDL continues to anticipate gross margins on a non-GAAP basis of approximately 80% for this group of products over the 2005 through 2008 period. The estimate for net product sales of off-patent products is in a range of $15 to $18 million.

-- Royalty revenues are expected to be in the range of approximately $120 to $125 million, and license and other revenues are reduced to a range of approximately $20 to $23 million due to the timing of expenses subject to reimbursement under collaborations. PDL continues to believe that royalty revenues for each year from 2006 through 2008 should grow at least 25% per year on a compounded basis.

-- Non-GAAP expenses are anticipated to be as follows: cost of product sales are expected to total approximately $23 million, research and development expenses are anticipated to be in a range of $163 to $168 million, a reduction of roughly $20 million from prior guidance. Selling, general and administrative expenses for the full year 2005 are expected to be in a range of $73 to $76 million.

-- For the full year 2005, PDL anticipates a GAAP net loss in the range of approximately $1.12 to $1.20 per basic and diluted share, and on a non-GAAP basis, financial results in a range from a net loss of approximately $0.05, based on a weighted average of approximately 103 million shares outstanding, to net income of approximately $0.02 per basic and diluted share, based on a weighted average of approximately 130 million shares outstanding for the year. PDL expects to be cash flow positive on a sustainable basis beginning in the fourth quarter of 2005, and therefore on a full-year basis for 2006. Quarterly results will vary due to some seasonality in the sales of royalty- bearing products.

-- PDL now estimates that its year-end 2005 cash balances will be in excess of approximately $350 million. This ending balance assumes the impact of the Biogen Idec transaction, representing roughly $150 million in additional year-end cash compared to prior guidance of May 2, 2005, $140 million of which is from the upfront payment and the equity purchase components, with the remaining $10 million due to increased revenues and operational efficiencies.

-- PDL expects that headcount at year-end 2005 will be in the range of 950 to 975. This figure includes the effect of increasing the original ESP Pharma sales force from 66 representatives at the time of acquisition to the targeted 100 to 105 range at year-end. To date, PDL has added more than 30 sales representatives and maintained a high level of retention.

Webcast:

PDL will webcast a conference call live at 4:30 p.m. Eastern time today to review its financial results for the second quarter ended June 30, 2005, the status of its clinical development programs and its forward-looking information and guidance with respect to future results. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A link to the conference call webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. The webcast will be archived at www.pdl.com starting approximately one hour after completion of the webcast. A replay of the conference call will also be available by telephone from approximately 6:30 p.m. Eastern time on August 4, 2005 through 6:30 p.m. Eastern time on August 12, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States and enter conference ID number 21254918.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements include our expectations regarding financial results, our expectations that our agreement with Biogen Idec will close, and the timing of clinical developments as well as other statements regarding our expectations. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The successful integration of ESP Pharma and Retavase as part of PDL; changes in our development plans as we and Biogen Idec consider development plans and alternatives; fluctuations in sales that may result from our integration of newly acquired operations; from changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses. In addition, PDL revenues depend on the success and timing of sales of our licensees, including in particular the continued success of Avastin(TM) antibody product by Genentech as well as the seasonality of sales of Synagis® from MedImmune, Inc. In addition, quarterly revenues may be impacted by our ability to maintain and increase our revenues from collaborative arrangements such as our co- development agreements with Biogen Idec and Roche. Our revenues and expenses would also be affected by new collaborations, material patent licensing arrangements or other strategic transactions.

Further, there can be no assurance that results from completed and ongoing clinical studies, described above, will be successful or that ongoing or planned clinical studies will be completed or initiated on the anticipated schedules. Other factors that may cause our actual results to differ materially from those, express or implied, in the forward-looking statements in this press release are discussed in our filings with the Securities and Exchange Commission. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

About PDL:

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at www.pdl.com.

NOTE: Protein Design Labs, the PDL logo and Nuvion are registered U.S. trademarks and HuZAF is a trademark of Protein Design Labs, Inc. Zenapax is a registered trademark of Roche. Cardene is a registered trademark of Roche Palo Alto. Retavase and Busulfex are registered trademarks of ESP Pharma, Inc., a wholly-owned subsidiary of PDL. Herceptin and Raptiva are registered trademarks and Avastin is a trademark of Genentech, Inc. Xolair is a trademark of Novartis AG. Synagis is a registered U.S. trademark of MedImmune, Inc. Mylotarg is a registered U.S. trademark of Wyeth.

PROTEIN DESIGN LABS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

(In thousands, except per share data )

Three months ended Six months ended
June 30, June 30,
2005 2004 2005 2004
Revenues:
Product sales,
net $35,345 $-- $36,293 $--
Royalties 37,528 24,731 70,692 46,741
License and other 4,888 1,052 9,591 6,670

Total revenues 77,761 25,783 116,576 53,411

Costs and expenses:
Costs of product
sales 20,135 -- 21,272 --
Research and
development 40,339 32,009 75,600 65,038
Selling, general
and
administrative 19,806 7,450 27,472 15,518
Acquired in-
process research
and development -- -- 79,417 --
Total costs and
expenses 80,280 39,459 203,761 80,556
Operating loss (2,519) (13,676) (87,185) (27,145)

Interest and
other income,
net 1,873 2,583 4,808 4,867
Interest expense (2,709) (1,351) (4,851) (2,736)

Loss before
income taxes (3,355) (12,444) (87,228) (25,014)
Provision for
income taxes 65 8 87 56

Net loss $(3,420) $(12,452) $(87,315) $(25,070)

Basic and diluted
net loss per share $(0.03) $(0.13) $(0.87) $(0.27)

Shares used in
computation of
basic and diluted
net loss per share 103,705 94,587 100,230 94,294


CONSOLIDATED BALANCE SHEET DATA
(Unaudited)

June 30, December 31,
2005 2004*
(In thousands) (unaudited)

Cash, cash equivalents, marketable
securities and restricted
investments $190,978 $397,080
Total assets 1,054,896 713,732
Total stockholders` equity 477,593 412,510

*Derived from the December 31, 2004 audited consolidated financial
statements.


PROTEIN DESIGN LABS, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

We use non-GAAP amounts that exclude certain non-cash charges, including amounts related to the amortization of intangible assets and stock-based compensation. Management believes that these non-GAAP measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the Company in its operations. Our management uses these non-GAAP financial measures in evaluating the Company`s operating performance and for budgeting and planning purposes.

(In thousands, except per share data )
Three months ended June 30,

2005
GAAP Adjustment Non-GAAP
Revenues:
Product Sales $35,345 $35,345
Royalties 37,528 37,528
License and other 4,888 4,888

Total revenues 77,761 77,761

Costs and expenses:
Cost of Product Sales 20,135 (11,905) 8,230
Research and development 40,339 (496) 39,843
Selling, general and administrative 19,806 (170) 19,636
Acquired in-process research and
development --
Total costs and expenses 80,280 (12,571) 67,709
Operating loss (2,519) 12,571 10,052

Interest and other income, net 1,873 1,873
Interest expense (2,709) (2,709)

Loss before income taxes (3,355) 12,571 9,216
Provision for income taxes 65 65

Net income (loss) $(3,420) $12,571 $9,151

Net income (loss) per share:
Basic $(0.03) $0.09

Diluted $(0.03) $0.09

Shares used in computation of net
income (loss) per share:
Basic 103,705 106,151

Diluted 103,705 103,705


2004
GAAP Adjustment Non-GAAP
Revenues:
Product Sales $-- $--
Royalties 24,731 24,731
License and other 1,052 1,052

Total revenues 25,783 25,783

Costs and expenses:
Cost of Product Sales -- --
Research and development 32,009 (1,377) 30,632
Selling, general and administrative 7,450 (14) 7,436
Acquired in-process research and
development --
Total costs and expenses 39,459 (1,391) 38,068
Operating loss (13,676) 1,391 (12,285)

Interest and other income, net 2,583 2,583
Interest expense (1,351) (1,351)

Loss before income taxes (12,444) 1,391 (11,053)
Provision for income taxes 8 8

Net income (loss) $(12,452) $1,391 $(11,061)

Net income (loss) per share:
Basic $(0.13) $(0.12)

Diluted $(0.13) $(0.12)

Shares used in computation of net
income (loss) per share:
Basic 94,587 94,587

Diluted 94,587 94,587


PROTEIN DESIGN LABS, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

We use non-GAAP amounts that exclude certain non-cash charges, including amounts related to the amortization of intangible assets and stock-based compensation. Management believes that these non-GAAP measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the Company in its operations. Our management uses these non-GAAP financial measures in evaluating the Company`s operating performance and for budgeting and planning purposes.

(In thousands, except per share data )
Six months ended June 30,
2005
GAAP Adjustment Non-GAAP
Revenues:
Product Sales $36,293 $36,293
Royalties 70,692 70,692
License and other 9,591 9,591

Total revenues 116,576 116,576

Costs and expenses:
Costs of product sales 21,272 (12,964) 8,308
Research and development 75,600 (1,167) 74,433
Selling, general and administrative 27,472 (310) 27,162
Acquired in-process research and
development 79,417 (79,417) --
Total costs and expenses 203,761 (93,858) 109,903
Operating loss (87,185) 93,858 6,673

Interest and other income, net 4,808 4,808
Interest expense (4,851) (4,851)

Income (loss) before income taxes (87,228) 93,858 6,630
Provision for income taxes 87 87

Net income (loss) $(87,315) $93,858 $6,543

Net income (loss) per share:
Basic $(0.87) $0.06

Diluted $(0.87) $0.07

Shares used in computation of net
income (loss) per share:
Basic 100,230 102,665

Diluted 100,230 100,230

2004
GAAP Adjustment Non-GAAP
Revenues:
Product Sales $-- $--
Royalties 46,741 46,741
License and other 6,670 6,670

Total revenues 53,411 53,411

Costs and expenses:
Costs of product sales -- --
Research and development 65,038 (1,995) 63,043
Selling, general and administrative 15,518 (28) 15,490
Acquired in-process research and
development -- --
Total costs and expenses 80,556 (2,023) 78,533
Operating loss (27,145) 2,023 (25,122)

Interest and other income, net 4,867 4,867
Interest expense (2,736) (2,736)

Income (loss) before income taxes (25,014) 2,023 (22,991)
Provision for income taxes 56 56

Net income (loss) $(25,070) $2,023 $(23,047)

Net income (loss) per share:
Basic $(0.27) $(0.24)

Diluted $(0.27) $(0.24)

Shares used in computation of net
income (loss) per share:
Basic 94,294 94,294

Diluted 94,294 94,294



Source: Protein Design Labs, Inc.

[blb]

Wie erwartet Hammerzahlen! Natürlich durch die Übernahme eindrucksvolle Wachstumsraten, aber selbst die Lizenzeinnahmen für sich genommen explodieren ja förmlich. Genentech sei Dank!!!

[Fruehrentner]

wie steht PDLI nachbörslich in USA?

[amorphis]

LAST MATCH
Price 27.4300
Time 17:22:52.856

TODAY`S ACTIVITY
Orders 39,833
Volume 781,762

[blb]

@Fruehrentner: Ich würd den Kursen nicht unbedingt hinterherlaufen. Falls du trotzdem unbedingt rein willst, geh doch erstmal nur mit nem Teil rein. Schätze, das Gap wird früher oder später geschlossen werden!

[amorphis]

LAST MATCH
Price 27.5800
Time 17:41:26.258

TODAY`S ACTIVITY
Orders 39,959
Volume 802,294

[amorphis]

Protein Design narrows its losses
By Russ Britt, MarketWatch
Last Update: 5:06 PM ET Aug. 4, 2005
E-mail it | Print | Alert | Reprint |

LOS ANGELES (MarketWatch) -- Protein Design Labs Inc. said Thursday that it narrowed its losses during the second quarter and offered a full-year forecast that beat street estimates thanks to better-than-expected sales of several antibody products.
Free! Sign up here to receive our Internet Daily e-Newsletter!
TRADING CENTER



INFORMATION FOR PDLI:
Create an alert for PDLI

Add PDLI to my portfolio

More cool charts on PDLI

Discuss PDLI
NEWS FOR PDLI
Updates, advisories and surprises
Protein Design loss narrows; forecast beats estimates
Network Appliance shares fall in evening trades
More news for PDLI

TRACK THESE TOPICS
My Portfolio Alerts
Company: Protein Design Labs Inc Add
Create
Get breaking news sent directly to your in-box
Create a Portfolio | Create an Alert

Protein Design (PDLI: news, chart, profile) reported a second-quarter net loss of $3.42 million, or 3 cents a share, compared with a loss last year of $12.5 million, or 13 cents a share. Revenue for the Fremont, Calif.-based biopharmaceutical company was $77.8 million vs. last year`s $25.8 million.

Under non-GAAP, or generally accepted accounting practices, Protein Design would have reported earnings of 9 cents a share, beating the 5-cent forecast from analysts polled by Thomson First Call.

Protein Design said it now expects full-year earnings to fall between a 5-cent loss and a 2-cent gain, well ahead of the current First Call forecast of a 19-cent loss.

The company also increased its revenue outlook for the year, predicting a range of $255 million to $271 million. The First Call estimate is for $263.1 million.

Protein Design shares were off 33 cents, or 1.3%, to $25.91 at the close. After hours, the company`s shares rose 99 cents, or 3.8%, to $26.90.

***********************************************************





Stock News : Althea Chang Email This Story Print This Story

Protein Design Lifts Forecast

By Althea Chang
TheStreet.com Staff Reporter
8/4/2005 5:31 PM EDT
Click here for more stories by Althea Chang

Protein Design Labs (PDLI:Nasdaq - commentary - research) boosted its revenue forecast and reported quarterly earnings that were ahead of Wall Street`s estimates, sending its shares higher in after-hours trading Thursday.

The Fremont, Calif., biotech reported a loss of $3.4 million, compared with a loss of $12.5 million in the year-ago quarter. On a per-share basis, Protein Design lost 3 cents a share vs. 13 cents a year earlier.

Excluding charges, the company reported income of $9.2 million, or 9 cents a share, compared with 5 cents analysts expected for the latest quarter.

Revenue was $77.8 million, up from $25.8 million a year ago but below the $79.3 million analysts expected. Royalty revenue rose 52% to $37.5 million from $24.7 million. Product revenue totaled $35.3 million, reflecting the first full quarter of product sales following the acquisitions of ESP Pharma and Retavase.

Additionally, the company increased its full-year revenue guidance to between $255 million and $271 million, compared with its previously expected $250 million to $260 million.

Shares of Protein Design were up 94 cents, or 3.6%, to $26.85 in extended trading.

"Second quarter and first half 2005 results reflect our initial performance in having ESP Pharma become part of PDL, with product sales in line with our internal expectations for our first full commercial quarter. Meanwhile, our partners` success with breakthrough antibody products such as Avastin, Herceptin and Synagis are driving the growth of PDL`s royalty revenues," said Mark McDade, the company`s CEO.

Protein Design receives royalty payments from Genentech (DNA:NYSE - commentary - research), the maker of the first two drugs, under a license agreement. Synagis is marketed by MedImmune (MEDI:Nasdaq - commentary - research).

McDade said the company should have positive cash flow by the fourth quarter, thanks to strong products and royalty revenue growth, plus the effect of its new development and marketing agreement with Biogen Idec (BIIB:Nasdaq - commentary - research).

[amorphis]

und dat ding rennt...



LAST MATCH
Price 27.6800
Time 18:10:23.415

TODAY`S ACTIVITY
Orders 40,069
Volume 822,114

[amorphis]

3.08.2005 - 15:09
PROTEIN Design explodiert vorbörslich
(©GodmodeTrader - http://www.godmode-trader.de/)

PROTEIN Design (PDLI) : 26,60 $ (+14,16%)

Aktueller Tageschart (log) seit Dezember 2003 (1 Kerze = 1 Tag).

Kurz-Kommentierung: PROTEIN Design Labs übersprang am 21.07.2005 die Pullbacklinie seit Juni 2001 und generierte ein mittelfristiges Kaufsignal. Heute springt der Kurs vorbörslich deutlich nach oben und wird voraussichtlich über 26,00 $ eröffnen. Damit sollte das Hoch des Jahres 2004 bei 27,58$ bald erreicht werden. Angesichts der Kursdynamik ist jederzeit mit einer volatilen Korrektur zu rechnen, die nicht tiefer als 20,65 - 22,00 $ gehen sollte. Hier verläuft neben der zentralen Horizontalunterstützung auch die gebrochene Pullbacklinie und der Aufwärtstrend seit März. Oberhalb des Hochs des Jahres 2004 bei 27,58$ ist der nächste signifikante Widerstandsbereich erst bei 45,46 $ auszumachen.

[amorphis]

LAST MATCH
Price 27.8500
Time 18:25:47.446

TODAY`S ACTIVITY
Orders 40,201
Volume 844,269

[amorphis]

Press Release Source: Protein Design Labs, Inc.

/C O R R E C T I O N -- Protein Design Labs, Inc./
Thursday August 4, 7:31 pm ET

In the press release, PDL Announces Strong Second Quarter 2005 Financial Results, issued earlier today by Protein Design Labs, Inc. (Nasdaq: PDLI - News) over PR Newswire, we are advised by the client that the number of shares used in the computation of net income (loss) per share were transposed. For the Three months ended June 30 2005, on a non-GAAP basis, the numbers should read "Basic - 103,705" and "Diluted - 106,151" rather than "Basic - 106,151" and "Diluted - 103,705"; and for the Six months ended June 30, 2005, on a non-GAAP basis, the numbers should read "Basic - 100,230" and "Diluted - 102,665" rather than "Basic - 102,665" and "Diluted - 100,230", as originally issued inadvertently.

The corrected portion of each table follows:

Three months ended June 30,
2005
GAAP Adjustment Non-GAAP
Shares used in computation of net
income (loss) per share:
Basic 103,705 103,705

Diluted 103,705 106,151


Six months ended June 30,
2005
GAAP Adjustment Non-GAAP
Shares used in computation of net
income (loss) per share:
Basic 100,230 100,230

Diluted 100,230 102,665


No other amounts in tables have been revised or changed.


------

PDL Announces Strong Second Quarter 2005 Financial Results

FREMONT, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - News) today reported financial results for the second quarter of 2005. Financial highlights included:

-- Product revenues of $35.3 million reflect the first full quarter of product sales following PDL`s acquisition of ESP Pharma, Inc. and Retavase®, both in March 2005.

-- Royalty revenues increase 52% to $37.5 million from $24.7 million in the second quarter of 2004.

-- GAAP net loss of $3.4 million compared with a net loss of $12.5 million in the second quarter of 2004; non-GAAP net income of $9.2 million compared with a non-GAAP net loss of $11.1 million in the 2004 second quarter.

-- Cash, cash equivalents, marketable securities and restricted investments totaled approximately $191.0 million as of June 30, 2005, compared with $397.1 million as of December 31, 2004. The June 30, 2005 cash balances did not include any payments from the Biogen Idec alliance, announced August 2, 2005, which includes an upfront payment of $40 million and equity investment of $100 million. Closing of the Biogen Idec transaction is contingent upon antitrust review and other standard closing conditions.

Mark McDade, Chief Executive Officer, PDL, said, "Second quarter and first half 2005 results reflect our initial performance in having ESP Pharma become part of PDL, with product sales in-line with our internal expectations for our first full commercial quarter. Meanwhile, our partners` success with breakthrough antibody products such as Avastin(TM), Herceptin® and Synagis® are driving the growth of PDL`s royalty revenues. As a result of this improved top-line performance in the first half, we have increased our revenue guidance for 2005. More significantly, this strong revenue growth from both products and royalties, combined with the economic impact of our new alliance with Biogen Idec, should enable PDL to become cash flow positive on a sustainable basis beginning in the fourth quarter of 2005, and therefore on a full-year basis for 2006. This is nearly a full year ahead of our plan following the acquisition of ESP Pharma this past March."

Total Operating Revenues:

Total operating revenues increased 202% to $77.8 million in the second quarter of 2005 from $25.8 million in the second quarter of 2004.

PDL recognized net product sales revenues of $35.3 million in the second quarter of 2005. Product revenues reflected the first full quarter of net sales of Cardene® IV for the short-term treatment of hypertension when oral therapy is not feasible or desirable; Retavase, used to dissolve coronary blood clots and improve blood flow in heart attack patients; IV Busulfex®, a conditioning agent used in connection with bone marrow transplants in chronic myelogenous leukemia; and four off-patent branded products. These products are marketed by PDL`s wholly-owned subsidiary, ESP Pharma, Inc., which PDL acquired March 23, 2005.

Royalty revenues increased 52% to $37.5 million, compared with royalty revenues of $24.7 million in the second quarter of 2004. PDL receives royalties based on worldwide net sales of seven antibody products licensed under PDL`s antibody humanization patents: Avastin(TM), Herceptin®, Xolair® and Raptiva® from Genentech, Inc.; Synagis® from MedImmune, Inc.; Mylotarg® from Wyeth and Zenapax®, marketed by Roche.

Total Costs and Expenses:

Total costs and expenses were $80.3 million in the second quarter of 2005, compared with $39.5 million in the second quarter of 2004. On a non-GAAP basis, total costs and expenses in the 2005 second quarter were $67.7 million compared to non-GAAP expenses of $38.1 million in the second quarter of 2004.

The cost of product sales was $20.1 million in the second quarter of 2005, compared with none in the comparable period of 2004, reflecting the addition of ESP Pharma in March 2005. Excluding non-cash amortization of product costs associated with the purchase of ESP Pharma and Retavase, cost of product sales were $8.2 million. Selling, general and administrative expenses increased to $19.8 million, compared to $7.5 million in the second quarter of 2004, primarily due to sales expenses associated with PDL`s newly acquired sales and marketing team.

Research and development expenses increased to $40.3 million in the second quarter of 2005, compared with $32.0 million in the same three months of 2004. The increase in research and development expenses reflects additional headcount and associated costs required to advance research and clinical development programs, contract manufacturing and direct scale-up and manufacturing expense, and increased facility and equipment-related costs.

NOTE: Non-GAAP results for the three- and six-month periods exclude certain non-cash charges, which consisted primarily of an acquired in-process research and development charge of $79.4 million in the first quarter of 2005 related to the ESP Pharma acquisition, as well as the amortization of intangible assets associated with the Eos Biotechnology, Inc. and ESP Pharma and Retavase acquisitions and the re-acquisition of rights to manufacture and market Zenapax® (daclizumab) in 2003, and stock-based compensation charges. Reconciliations of GAAP results to non-GAAP results are included in the tables accompanying this release.

Recent Corporate Developments:

-- On August 2, PDL and Biogen Idec announced a broad collaboration for the joint development, manufacture and commercialization of three phase 2 antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and certain other diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications. PDL will receive an upfront payment of $40.0 million and Biogen Idec will purchase $100 million of PDL common stock. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million.

-- In July, PDL acquired worldwide development and commercial rights for ularitide in all indications.

-- In early July, PDL began a phase 1 multiple-dose study of the PDL- produced subcutaneous formulation of daclizumab in healthy volunteers, on target to support the planned initiation of a phase 2b study of daclizumab in asthma by the first quarter of 2006.

-- In June, PDL announced a sublicense to Genentech, Inc. of development and commercialization rights for antibody-drug conjugates directed against the PR1 antigen, which is frequently differentially expressed in prostate cancer.

-- In May, PDL initiated enrollment in a 270-patient phase 2 clinical trial of daclizumab in multiple sclerosis.

-- In April, PDL reported positive top-line phase 2 results for ularitide in acute decompensated congestive heart failure; full results are expected to be presented in September.

-- In the first half of 2005, PDL initiated two separate studies of Nuvion® (visilizumab) in two distinct types of severe Crohn`s disease.

Upcoming Events:

PDL noted that upcoming clinical milestones and related events include the following:

-- Ularitide: Presentation of phase 2 data in acute decompensated heart failure (ADHF) at the European Society of Cardiology congress, September 4, and at the meeting of the Heart Failure Society of America, September 19; PDL also intends to file an IND in the U.S. and initiate clinical development in the U.S. this year.

-- Nuvion® (visilizumab): Begin phase 2/3 study in IV steroid- refractory ulcerative colitis in late 2005 or early 2006.

-- Host an R&D update for the financial community in early October in New York City.

2005 Forward-looking Guidance:

The following statements are based on expectations as of August 4, 2005. These statements are forward-looking and do not include the potential impact of new collaborations, material licensing arrangements or other strategic transactions.

-- PDL now anticipates that total operating revenues for 2005 will be in the range of approximately $255 to $271 million:

-- Net product sales for Cardene® IV, Retavase® and IV Busulfex® are expected to total approximately $100 to $105 million for the approximately nine-month period of sales following the close of the acquisition of ESP Pharma. PDL anticipates compound annual growth rates of approximately 25% for net product sales of this group of products for each year from 2006 through 2008. PDL continues to anticipate gross margins on a non-GAAP basis of approximately 80% for this group of products over the 2005 through 2008 period. The estimate for net product sales of off-patent products is in a range of $15 to $18 million.

-- Royalty revenues are expected to be in the range of approximately $120 to $125 million, and license and other revenues are reduced to a range of approximately $20 to $23 million due to the timing of expenses subject to reimbursement under collaborations. PDL continues to believe that royalty revenues for each year from 2006 through 2008 should grow at least 25% per year on a compounded basis.

-- Non-GAAP expenses are anticipated to be as follows: cost of product sales are expected to total approximately $23 million, research and development expenses are anticipated to be in a range of $163 to $168 million, a reduction of roughly $20 million from prior guidance. Selling, general and administrative expenses for the full year 2005 are expected to be in a range of $73 to $76 million.

-- For the full year 2005, PDL anticipates a GAAP net loss in the range of approximately $1.12 to $1.20 per basic and diluted share, and on a non-GAAP basis, financial results in a range from a net loss of approximately $0.05, based on a weighted average of approximately 103 million shares outstanding, to net income of approximately $0.02 per basic and diluted share, based on a weighted average of approximately 130 million shares outstanding for the year. PDL expects to be cash flow positive on a sustainable basis beginning in the fourth quarter of 2005, and therefore on a full-year basis for 2006. Quarterly results will vary due to some seasonality in the sales of royalty- bearing products.

-- PDL now estimates that its year-end 2005 cash balances will be in excess of approximately $350 million. This ending balance assumes the impact of the Biogen Idec transaction, representing roughly $150 million in additional year-end cash compared to prior guidance of May 2, 2005, $140 million of which is from the upfront payment and the equity purchase components, with the remaining $10 million due to increased revenues and operational efficiencies.

-- PDL expects that headcount at year-end 2005 will be in the range of 950 to 975. This figure includes the effect of increasing the original ESP Pharma sales force from 66 representatives at the time of acquisition to the targeted 100 to 105 range at year-end. To date, PDL has added more than 30 sales representatives and maintained a high level of retention.

Webcast:

PDL will webcast a conference call live at 4:30 p.m. Eastern time today to review its financial results for the second quarter ended June 30, 2005, the status of its clinical development programs and its forward-looking information and guidance with respect to future results. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A link to the conference call webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. The webcast will be archived at www.pdl.com starting approximately one hour after completion of the webcast. A replay of the conference call will also be available by telephone from approximately 6:30 p.m. Eastern time on August 4, 2005 through 6:30 p.m. Eastern time on August 12, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States and enter conference ID number 21254918.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements include our expectations regarding financial results, our expectations that our agreement with Biogen Idec will close, and the timing of clinical developments as well as other statements regarding our expectations. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The successful integration of ESP Pharma and Retavase as part of PDL; changes in our development plans as we and Biogen Idec consider development plans and alternatives; fluctuations in sales that may result from our integration of newly acquired operations; from changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses. In addition, PDL revenues depend on the success and timing of sales of our licensees, including in particular the continued success of Avastin(TM) antibody product by Genentech as well as the seasonality of sales of Synagis® from MedImmune, Inc. In addition, quarterly revenues may be impacted by our ability to maintain and increase our revenues from collaborative arrangements such as our co- development agreements with Biogen Idec and Roche. Our revenues and expenses would also be affected by new collaborations, material patent licensing arrangements or other strategic transactions.

Further, there can be no assurance that results from completed and ongoing clinical studies, described above, will be successful or that ongoing or planned clinical studies will be completed or initiated on the anticipated schedules. Other factors that may cause our actual results to differ materially from those, express or implied, in the forward-looking statements in this press release are discussed in our filings with the Securities and Exchange Commission. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

About PDL:

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at www.pdl.com.

NOTE: Protein Design Labs, the PDL logo and Nuvion are registered U.S. trademarks and HuZAF is a trademark of Protein Design Labs, Inc. Zenapax is a registered trademark of Roche. Cardene is a registered trademark of Roche Palo Alto. Retavase and Busulfex are registered trademarks of ESP Pharma, Inc., a wholly-owned subsidiary of PDL. Herceptin and Raptiva are registered trademarks and Avastin is a trademark of Genentech, Inc. Xolair is a trademark of Novartis AG. Synagis is a registered U.S. trademark of MedImmune, Inc. Mylotarg is a registered U.S. trademark of Wyeth.

PROTEIN DESIGN LABS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

(In thousands, except per share data )

Three months ended Six months ended
June 30, June 30,
2005 2004 2005 2004
Revenues:
Product sales,
net $35,345 $-- $36,293 $--
Royalties 37,528 24,731 70,692 46,741
License and other 4,888 1,052 9,591 6,670

Total revenues 77,761 25,783 116,576 53,411

Costs and expenses:
Costs of product
sales 20,135 -- 21,272 --
Research and
development 40,339 32,009 75,600 65,038
Selling, general
and
administrative 19,806 7,450 27,472 15,518
Acquired in-
process research
and development -- -- 79,417 --
Total costs and
expenses 80,280 39,459 203,761 80,556
Operating loss (2,519) (13,676) (87,185) (27,145)

Interest and
other income,
net 1,873 2,583 4,808 4,867
Interest expense (2,709) (1,351) (4,851) (2,736)

Loss before
income taxes (3,355) (12,444) (87,228) (25,014)
Provision for
income taxes 65 8 87 56

Net loss $(3,420) $(12,452) $(87,315) $(25,070)

Basic and diluted
net loss per share $(0.03) $(0.13) $(0.87) $(0.27)

Shares used in
computation of
basic and diluted
net loss per share 103,705 94,587 100,230 94,294


CONSOLIDATED BALANCE SHEET DATA
(Unaudited)

June 30, December 31,
2005 2004*
(In thousands) (unaudited)

Cash, cash equivalents, marketable
securities and restricted
investments $190,978 $397,080
Total assets 1,054,896 713,732
Total stockholders` equity 477,593 412,510

*Derived from the December 31, 2004 audited consolidated financial
statements.


PROTEIN DESIGN LABS, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

[Fruehrentner]

Shit! Einstieg verpasst, auf der watchlist seit Anfang Juni gehabt

[Martina1966]

Habe innerhalb eines Monats bereits 2x gekauft und wieder verkauft (erst vorgestern!!!). Wer hat eine Ahnung, wie so ein Kursverlauf nach der Bekanntgabe von positiven Zahlen normalerweise verläuft? Rentiert sich ein Einstieg heute noch, oder soll man erst mal bis Montag warten? Würde gerne mittelfristig einsteigen .. Keine Ahnung, ob die Aktien jetzt kurzfristig nochmal runtergehen?

[Martina1966]

Habe diese Aktie innerhalb eines Monats 2x gekauft und wieder verkauft - immer mit etwas plus. Würde jetzt gerne mittelfristig einsteigen. Besteht eine Chance, daß die Aktien nächste Woche nochmal runtergehen oder wird sie jetzt weiter ansteigen? Rentiert sich ein Einstieg heute noch?

[perry2]

# Martina,
dachte es kommt noch ein 3.Posting... .
70% aller Gaps werden binnen 6 Wochen geschlossen - sagt die Statistik.
Die guten Zahlen sind allgemein erwartet worden, Bios sind zuletzt gut gelaufen und der Gesamtmarkt schwächelt.
Spricht also alles für Gewinnmitnahmen. Insofern wäre ein Abstauberlimit bei 24$ (bzw. 20€) am erfolgversprechenden.
Oder eine kleine Position knapp über dem Schlusskurs von gestern in den Markt legen. Das Risiko dabei auf die Nase zu fallen ist eher gering und du erhöhst deine Chancen.
Perry

[amorphis]

martina...ich würde nicht allzu lange warten...siehe chartanalyse weiter vorne... normal sollte bald der weg bis in die 45$ region frei sein... sentiment ist super...kleine rücksetzer...aber dann immer immer wieder große schritte zur zeit bei den bios!pdli und vphm...derzeit 1. wahl...greez

[perry2]

Dein Wort in Gottes Gehör! Für 40$ brauchts noch viel Geduld.
Perry

[amorphis]

ja...geduld heißt bei mir das wir sie dieses jahr noch sehen... nicht morgen....

[blb]

@amorphis: Ich bleib dabei, dass Hoch knacken wir nicht im ersten Anlauf!
Kann jedem nur raten keinen Kursen hinterherzulaufen. Lieber einmal Pech gehabt als richtig auf die Schnauze gefallen!

Grüße
blb

[amorphis]

huhuhuhuhuhu... die rede ist auch nicht von schnell...bei 25% plus in 10 tagen rede ich doch nicht von schnell...oder über 50% in drei monaten...hm oder knapp 100% in knapp nem halben jahr...voll öde und langsam das teil hey...the trend is ur friend...oder wie wars?ob man jetzt sofort rein geht oder nicht...hm...ich würde die orders auch auf 3-4 wochen aufteilen...um die ganzen spekulativen käufe die die aktie bis dahin weiter treiben werden zu verpassen weil im september die nächsten paar bio-meetings sind auf denen pdli vertreten ist und gewisse studien bekannt gibt... also...hm...schwere frage...rein nicht rein?so lange es steigt erstmal rein...sonst hätte ich auch nicht in vphm einsteigen dürfen...als sie bei 6 waren!ich finde eher es wird ja auch mal langsam zeit für ne richtig übertriebene biotech-rally...

[blb]

Irgendwie finde ich es auch lustig, dass sich monatelang niemand für bestimmte Werte interessiert und dann plötzlich, wenn der Zug schon im nächsten Bahnhof angekommen ist, wollen alle rein...

Grüße
blb

[Fruehrentner]

Heute in USA 2 gigantische Umsatzspitzen im Intraday-Chart!



http://aktien.onvista.de/charts.html?ID_OSI=88174&MONTHS=0&I…

[amorphis]

blb...also das phänomen ist nicht neu oder? ich habe mein erstes pdli invest vor mehreren jahren gemacht...so richtig eingekauft habe ich mich in den letzten beiden jahren...mein durchschnitt liegt etwa bei 12€...pdli macht meine 3. größte position an biotechs aus-nach vphm und nbx-halte zudem medx...

in welchen bios bist du schwerpunktmäßig drin?fahre im gegensatz zu früher bei den bios eine andere strategie...habe früher immer möglichst breit gestreut...was zur folge hatte das ich nicht alle werte ausreichend gut verfolgen konnte...und dann schlechte werte zu spät als solche erkannt habe...ausserdem hatten erfolgsaktien immer zu wenig gewicht...

seitdem ich mir 3-4 werte aussuche auf welche ich mich konzentriere hat sich das auch deutlich in der performance ausgezahlt...ein wert der (wie zuletzt pdli) 100% an wert gewinnt...schlägt sich dann direkt 20-25% im depotwert nieder...statt zuvor vielleicht 5% zu bewirken...

habe keine probleme mich auf der anderen seite von schlechten werten zu trennen...bin zuletzt aus enzn und mlnm mit verlust raus...meiner meinung nach holt man am schnellsten entstandene verluste rein...wenn man sich auf die guten werte konzentriert...möglichst werte die einen trend ausgebildet haben...oder ohne fundamentale ernsthafte gründe stark gefallen sind (wie z.b. imcl)...wie sieht deine strategie aus?und welche werte verfolgst du schwerpunktmässig bzw in welche investierst du schwerpunktmässig?hälst du dich nur bei den bios auf...oder auch bei tech werten?

greez...amorphis

[kgv1]

Bei 20€ gerne wieder(vorher lieber niet)
Kgv1

[amorphis]

und...nehmen wir heute die 28?

[blb]

Nee, das Gap zieht den Kurs wieder etwas runter. Aktie total überkauft, Konsolidierung wäre nur gesund...

[amorphis]

ja...das sehe ich jetzt auch... vorhin sah es vorbörslich aber fast danach aus...

[amorphis]

8-8-05 Prudential Equity Group, LLC
PDLI: ULARITIDE SHOWS STRONG RESULTS AND GREAT POTENTIAL
Protein Design Labs PDLI | $27.23 |
NASDAQ Jason Zhang, Ph.D. • 212.778.7328 • [e-mail]
Current: Overweight
Target: $32.00
Industry: Favorable
section entitled Important Disclosures.
Current 12/06 $0.14E 194.5X
Shares: 106.01 m
HIGHLIGHTS
reported.
same time frame.
• We reiterate our Overweight Rating and $32 price target.
DISCUSSION
Ularitide Overview
results for ularitide’s Phase II (SIRIUS II) trial were reported
In an abstract released by the Heart Failure Society`s 9th Annual Scientific Meeting, strong results
from ularitide`s SIRIUS II trial for the treatment of acute decompensated heart failure (DHF) were
• In 221 patients randomized, ularitide demonstrated clinical improvements in rates of dyspnea and
pulmonary-capillary wedge pressure (PCWP) changes. More importantly, statistically significant
decreases in mortality rates, as compared to placebo, were reported for the highest dose group.
• When we compare ularitide to Natrecor (nesiritide), J&J`s controversial blockbuster, it seems that
PDL`s drug is better in terms of efficacy and lack of side effects. We are particularly impressed that
ularitide showed a 30-day mortality rate of only about 3.0% while Natrecor has shown 7.2% in the time frame.
• Furthermore, we are encouraged that ularitide failed to show a statistically significant elevation of serum creatinine at 24, 48, and 72 hours.
• We feel that these results are remarkable and likely to attract more attention to this potential blockbuster drug.
• We reiterate our Overweight Rating and $32 price target.

[amorphis]

http://www.fool.com/news/commentary/2005/commentary05081610.…

[amorphis]

http://www.fool.com/news/commentary/2005/commentary05082513.…

[perry2]

http://www.fool.com/news/commentary/2005/commentary05081610.…
Aller guten Dinge sind 3.
P.

[blb]

Langsam kann man mit Staffellimits einsteigen, wer noch nicht drin ist. Restrisiko Gapclose würde ich sagen...

[amorphis]

Protein Design heart drug works well in trial
Sun Sep 4, 2005 05:00 AM ET
By Ben Hirschler

STOCKHOLM, Sept 4 (Reuters) - An experimental drug from U.S. biotechnology firm Protein Design Labs Inc. (PDLI.O: Quote, Profile, Research) can relieve symptoms and cut mortality in patients with advanced heart failure, researchers said on Sunday.

Results of a Phase II clinical trial found that ularitide -- a key new product for the company -- helped patients with acute decompensated congestive heart failure (ADHF), without causing kidney toxicity.

Maintaining kidney function is particularly important in patients with decompensated congestive heart failure, which occurs when the heart is unable to maintain adequate circulation of blood in the body`s tissues.

Trial investigator Dr. Veselin Mitrovic of the Kerckhoff Clinic, Bad Nauheim, Germany, said ularitide was an exciting potential new treatment for heart failure.

"Ularitide holds significant potential to address unmet needs in management of ADHF," he said.

"We didn`t see any erosion of renal (kidney) function, which is very important because heart failure is a cardio-renal syndrome."

Results of the study, involving 221 patients, showed those on the drug had reduced pressure in the pulmonary veins and improved shortness of breath scores, compared to patients given a placebo.

The researchers also found there was a reduction in hospital stays among patients taking the medicine and a fall in mortality 30 days after treatment, although these factors were not the primary endpoints of the study.

The death rate among those patients given a placebo was 13.2 percent while mortality among those on ularitide was between 1.8 and 3.8 percent, depending on which of three doses of the drug was given.

FURTHER STUDIES PLANNED

The results of the study were presented at the European Society of Cardiology congress in Stockholm. Protein Design had already told investors in April that the study had produced positive results, but without giving details.

Dr. Steve Benner, the company`s medical director, said further studies were now planned and researchers aimed to assess the benefits of ularitide in patients with earlier disease.

"We anticipate that the next studies will explore a slightly different patient group, and we would expect a new Phase II trial will probably get under way in the U.S. and Europe at the very end of this year or the start of next year," he told Reuters.

No decision has yet been taken on when to initiate pivotal Phase III trials, which Benner said would likely involve between 2,000 and 3,000 patients.

Industry analysts believe that ularitide, if successful, could have blockbuster sales potential.

It will compete with Johnson & Johnson`s (JNJ.N: Quote, Profile, Research) similar product Natrecor, which is already on the market in the United States, though not in Europe.

Natrecor has been a commercial success but it ran into controversy earlier this year after a medical journal linked it to worsened kidney function.

Ularitide is a synthetic form of a naturally occurring human protein produced in the kidney, where it regulates levels of fluid and sodium.


© Reuters 2005. All Rights Reserved.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq and all other quotes delayed by at least 15 minutes. Reuters does not endorse the views or opinions given by any third party content provider.

[amorphis]

Press Release Source: Protein Design Labs

Phase 2 Ularitide Study Highlighted at European Society of Cardiology Congress
Sunday September 4, 6:30 am ET
SIRIUS II Trial Suggests Ularitide Holds Promise as New Treatment for Acute Decompensated Heart Failure

FREMONT, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - News) today announced positive data from a phase 2 clinical study of ularitide -- the synthetic version of a natriuretic peptide produced in the kidney known as urodilatin -- as a potential treatment for patients with acute decompensated heart failure (ADHF). The data from the SIRIUS II trial were presented at the annual European Society of Cardiology (ESC) Congress, the largest cardiology meeting in Europe, which is taking place September 3-7 in Stockholm, Sweden.

ADVERTISEMENT
[-56033]
"The results of the SIRIUS II study show ularitide to be well-tolerated and indicate clear, dose-dependent favorable effects in treating the symptoms of ADHF without compromising kidney function," said Veselin Mitrovic, M.D., Medical Director of the Research Unit / Kerckhoff Clinic, Bad Nauheim. "Based on the overall findings, ularitide holds potential as a treatment for ADHF patients."

"We are very pleased with the results of the SIRIUS II trial and are optimistic about ularitide`s potential as a treatment for ADHF patients based on data to date," said Steve Benner, M.D., Senior Vice President and Chief Medical Officer, PDL. "We are committed to moving ularitide ahead, and therefore look forward to initiating new clinical studies in the United States and Europe to facilitate its global development."

The SIRIUS II trial was a randomized, double-blind, placebo-controlled clinical trial conducted at 19 centers across Europe. A total of 221 patients were randomized equally to receive ularitide 7.5, 15, or 30 ng/kg/min given intravenously as a 24-hour infusion, or placebo. The two primary endpoints in the study were change in dyspnea (shortness of breath) score and change in pulmonary capillary wedge pressure (PCWP), a measurement of lung vessel pressure, at six hours. Secondary endpoints included serum creatinine levels (a standard measure of kidney function), length of hospital stay and mortality.

Ularitide treatment was associated with a significantly improved dyspnea score (p<0.05) in all three dosing groups compared to placebo. Dyspnea was assessed using a standard dyspnea scale, which measures a patient`s perception of their change in shortness of breath from the start of drug therapy. More patients reported moderate to marked improvement in dyspnea in all of the three treatment groups compared to placebo.

The findings also demonstrated a significant decrease in pulmonary pressure (p<0.05) as measured by PCWP at six hours. These changes were also associated with an increase in cardiac index (a measure of heart function) in the 15 and 30 ng/kg/min groups. At six hours, PCWP dropped 10-12 mmHg on average from baseline for those treated with ularitide, compared to those on placebo, for whom PCWP dropped 4 mmHg from baseline.

Additional SIRIUS II Results

Secondary endpoints of the SIRIUS II study evaluated serum creatinine levels, length of hospital stay and mortality.

Serum creatinine levels were unchanged in patients treated with ularitide compared to placebo through 72 hours. This finding suggests that ularitide did not negatively affect kidney function in study patients. Length of hospital stay, measured in median hours in hospital, was lower for the 15 and 30 ng/kg/min groups, compared to the placebo and 7.5 ng/kg/min groups. The length of hospital stay was lowest for the 15 ng/kg/min (122 hours) and 30 ng/kg/min (158 hours) groups, compared to the placebo (200.5 hours) and 7.5 ng/kg/min (192 hours) groups.

There was no increase in mortality in the ularitide treatment groups compared to placebo. The mortality rate through day 30 was higher in the placebo group compared to the three ularitide groups: 13.2% in the placebo group and 3.3% (p=0.080, compared to placebo), 3.8% (p=0.16), and 1.8% (p=0.029) in the 7.5, 15 and 30 ng/kg/min groups, respectively.

Ularitide was well tolerated by patients in the study. The most frequent adverse event was hypotension, which occurred in 1.9% of placebo patients and in 8.3%, 11.3%, and 16.4% of patients in the 7.5, 15, and 30 ng/kg/min groups, respectively. Other adverse events that occurred in greater than 2% of the ularitide-treated patients were blood pressure decrease (5.4% ularitide vs. 0% placebo), cardiac failure (4.8% ularitide vs. 1.9% placebo), sweating increase (4.2% ularitide vs. 0% placebo), dizziness (3.6% ularitide vs. 1.9% placebo), and asthenia (2.4% ularitide vs. 0% placebo). The frequency of serious adverse events through day 30 was comparable among the groups.

SIRIUS II results will also be presented as a poster at the 9th Annual Scientific Meeting of the Heart Failure Society of America on September 19 in Boca Raton, Florida.

The SIRIUS II clinical trial was conducted by CardioPep Pharma GmbH. PDL holds exclusive development and marketing rights for ularitide for all indications worldwide. PDL intends to file a U.S. IND later this year and to proceed with the global development of ularitide as a treatment for ADHF.

About Ularitide

Ularitide is a synthetic form of urodilatin, which is a naturally occurring human protein that belongs to the family of natriuretic peptides and is produced in the kidney where it regulates levels of fluid and sodium. Urodilatin is excreted into the urine and exists in low levels in the systemic blood circulation. The peptide was first isolated by scientists affiliated with the group of Wolf-Georg Forssmann at Heidelberg University, and has been developed by a German company, CardioPep Pharma GmbH.

When injected into the blood stream, ularitide causes relaxation of blood vessels, specifically in the arteries that feed the kidneys, lungs and heart, and stimulates natriuresis (excretion of abnormal amounts of sodium into the urine) and diuresis (increase in urination). These effects suggest a potential therapeutic role for ularitide in patients with ADHF.

About Acute Decompensated Heart Failure

Congestive heart failure is a serious chronic medical condition in which the heart is unable to maintain adequate circulation of blood in the tissues of the body or to pump out the venous blood returned to it by the venous circulation. In the advanced stages of heart failure, the heart is unable to meet the body`s demand for oxygen and congestion or fluid retention can occur in the lungs and other areas throughout the body. Patients who experience a gradual or sudden worsening of CHF may experience severe symptoms resulting in ADHF. Patients with ADHF require emergency treatment and can require hospitalization.

ADHF can result from an acute event (e.g. heart attack, acute myocardial infarction). During an acute episode, the inability of the heart to adequately circulate blood throughout the body worsens, kidney function may be diminished and the patient may experience difficulty in breathing.

According to current statistics from the American Heart Association, there are about five million heart failure patients in the United States, and 550,000 new cases of heart failure diagnosed in the United States every year. This includes 10 out of every 1,000 people over the age of 65. Of newly diagnosed patients under the age of 65, about 80 percent of the men and 70 percent of the women will die within eight years. In people diagnosed with heart failure, sudden cardiac death occurs at six to nine times the rate of the general population. In the United States alone, there are approximately one million hospitalizations per year for ADHF.

About Protein Design Labs

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at www.pdl.com.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those in the forward-looking statements. Factors that may cause such differences are discussed in the Company`s Annual Report on Form 10-K for the year ended December 31, 2004, in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 and in other filings made with the Securities and Exchange Commission. In particular, results obtained in the phase 2 study may not be predictive of results to be obtained in the additional evaluations that would be necessary to demonstrate ularitide to be safe and effective in the treatment of decompensated congestive heart failure, nor can there be assurance that PDL will initiate subsequent clinical trials of ularitide. All statements included in this press release are based upon information available to PDL as of the date hereof, and PDL assumes no obligation to update any such forward-looking statements.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc.

[amorphis]

06.09.05 16:05 Uhr

29,41 USD

+9,21 % [+2,48]

[amorphis]

Date Research Firm Action From To
6-Sep-05 First Albany Upgrade Buy Strong Buy

[blb]

Was für eine Aktie!!!!!

[blb]

Neues 3-Jahres-Hoch!

[amorphis]

pdli entwickelt sich wirklich sehr sehr gut in letzter zeit!von der fundamentalen seite her...kommt einiges!denke...auf sicht von 2-3 jahren sind alte hochs erreichbar!

[blb]

Naja amorphis, das Ding ist mittlerweile 3 Milliarden schwer. Das sollte man schon bedenken. Für mich aber weiterhin eines der besten Bioinvestments und Qualität hat eben seinen Preis, siehe Amgen, Genentech, Gilead und Konsorten...

[amorphis]

lass sie doch 3 mrd kosten...die entwicklung des cash-flow wird das schon rechtfertigen...schliesslich soll dieser ab dem nächsten quarter bedeutend steigen...

[amorphis]

AP
Protein Design Shares Jump on Heart Data
Tuesday September 6, 12:50 pm ET
Protein Design Shares Shoot to 52-Week High on Positive Data for Heart Failure Drug

NEW YORK (AP) -- Protein Design Labs Inc. shares shot up 9 percent Tuesday after the company presented data over the weekend that suggested its experimental heart failure drug may work better and have fewer safety concerns than an existing treatment.

ADVERTISEMENT
Patients with severe heart failure -- marked by the heart`s rapidly deteriorating ability to pump blood -- are often given a drug called Natrecor to relax the muscles that surround blood vessels, improving blood flow and easing breathing problems. However, research has suggested that the drug, made by Johnson & Johnson`s Scios unit, may increase the risk of a patient`s dying in the first month after treatment and may lead to kidney problems.

On Sunday, Protein Design gave more detailed data of a potential competitor to Natrecor called Ularitide. Prudential analyst Jason Zhang wrote in a report that the mid-stage data were "strong" and noted that Ularitide did not appear to have any serious safety issues, including no signs of impaired kidney function. The Fremont, Calif.-based company had reported in April that the drug met the study`s primary endpoints.

First Albany Capital`s David Webber upgraded Protein Design`s stock to a "Strong Buy" from "Buy," noting that Dr. Marco Metra of the Italy`s University of Brescia said Ularitide`s effect on blood circulation appears greater than Natrecor`s.

Metra noted that the comparison is imperfect without a head-to-head study, but Webber called the preliminary comparison promising and said the safety concerns plaguing Netrecor could give Ularitide a window to take significant market share.

"Although Ularitide probably will not reach the market until 2009, its emergence as a potential major product ... persuades us that PDL is now staged to be in the next wave of biotech core holdings," Webber wrote in his note to clients. He added that the company`s royalty stream and specialty pharmaceutical operations look strong, particularly combined with its recent partnership with Biogen Idec Inc., and raised his price target to $35 from $32.

Protein Design shares hit a 52-week high of $29.54 in morning Nasdaq trading, and were recently up $2.42, or 9 percent, at $29.35. The stock has been climbing since March and is up about 43 percent so far this year.

Ularitide and Natrecor are both derived from naturally occurring human proteins that stimulate the excretion of excess sodium into the urine. Before Natrecor was approved in 2001, heart failure patients were given nitroglycerin or diuretics. The Johnson & Johnson drug posted sales of about $400 million in 2004.

[austin_power69]

WIr haben die wichtige Marke von 27,92$ deutlich durchbrochen. Nun gibt es nur noch eine Richtung, nach oben. Die Aktie dürfte deutlich an dynamik gewinnen!

First Albany haben heute die Aktie von Protein Design Labs (Nachrichten) von „buy“ auf „strong buy“ aufgestuft. Das Kursziel wurde von 32 auf 35 Dollar angehoben. Zuvor hatte das Unternehmen Testdaten veröffentlicht, wonach sein Präparat „Ularitide“ dem gängigen Konkurrenzpräparat „Netrecor“ bei der Behandlung von Herzinsuffizienz überlegen sein dürfte (wir berichteten).

Wie der für das Unternehmen zuständige Analyst ausführte, hätten die von der Universität Brescia erhobenen Daten gezeigt, dass Ularitide offenbar bessere Therapieerfolge erzielt habe. Zwar sei dies noch keine umfassende Vergleichsstudie gewesen, so dass keine voreiligen Schlüsse gezogen werden dürften. Die Daten seien jedoch vielversprechend. Die Tatsache, dass Netrecor zudem erhebliche Nebenwirkungen aufweise, eröffne die Chance, dass Ularitide dem Konkurrenzpräparat eines Tages erhebliche Marktanteile wegnehmen könnte. Netrecor erbrachte in den USA 2004 einen Umsatz von 400 Millionen Dollar.

Zwar, so der Analyst weiter, komme Ularitide voraussichtlich erst 2009 auf den Markt. Die Entwicklung zeige aber, dass Protein Design Labs auf dem Weg zu einem Kern-Investment im Biotech-Sektor seien. Dies gelte insbesondere angesichts der bereits üppig fließenden Umsatzvergütungen aus Kooperationsabkommen und der neu abgeschlossenen Partnerschaft mit Biogen Idec.

An der Nasdaq können sich Protein Design Labs derzeit um 10,25 Prozent auf 29,69 Dollar verbessern.



wohlgemerkt sind dies erst Testdaten. Wenn sich erst bestätigt, was dort erwartet wird, dann haben wir noch eine Menge Luft nach oben.

[amorphis]

Market Scan
Protein Design Heart Drug Has Strong Chance To Succeed
Peter Kang, 09.06.05, 4:30 PM ET

Protein Design Labs

Prudential Equity Group maintained an "overweight" rating on Protein Design Labs (nasdaq: PDLI - news - people ) after the biotechnology firm released favorable mid-stage data for its experimental heart drug Ularitide.

The data, presented over the weekend at the European Society of Cardiology in Stockholm, showed positive outcomes for the trial`s two primary endpoints for statistically significant efficacy and safety.

"Overall, we left Stockholm with a rather positive view of Ularitide and its prospects as the Phase II data presented gave us a clearer understating of its effects," said Prudential.

The research firm said Ularitide will likely be held to more stringent standards as a result of the recent "controversy" regarding Natrecor, a heart drug made by Scios, a unit of Johnson & Johnson. "But nonetheless, we feel that Ularitide has a strong chance in achieving clinical and commercial success and we await further results from larger trials," said Prudential. An article published in the New England Journal of Medicine last July suggested Natrecor may lead to kidney problems and possibly higher mortality rates.

The research firm reiterated a $32 price target on the stock. In early August, Protein Design Labs announced a $140 million pact with Biogen Idec (nasdaq: BIIB - news - people ) to co-develop three mid-stage antibiotic drugs.

[austin_power69]

FSE: 4.17EUR. Es geht weiter.....


Update Protein Design Labs Inc.: Strong Buy
Quelle: First Albany
Datum: 06.09.05


In ihrer Analyse vom Dienstag, 6. September 2005 stufen die Analysten von First Albany die Aktie des Unternehmens Protein Design Labs Inc. von "Buy" auf "Strong Buy" herauf. Das Kursziel für die Aktie liegt momentan bei 35 $.

[austin_power69]

die kleine Pause tut gut, die nächsten Tage geht es stramm auf die 25EUR zu!!!

[amorphis]

Market Scan
Biogen Restructuring Bodes Well For Protein Design
Peter Kang, 09.09.05, 3:10 PM ET

Protein Design Labs

Prudential Equity Group maintained an "overweight" rating on Protein Design Labs (nasdaq: PDLI - news - people ) after partner Biogen Idec (nasdaq: BIIB - news - people ) announced a major restructuring that will cut 17% of its work force and save $200 million to $300 million.

Biogen Idec also announced the departure of its head of research. Prudential said the restructuring could be a positive for the alliance between Biogen Idec and Protein Design Labs announced on Aug. 2 to co-develop three experimental drugs. "We think the change could actually enhance the collaboration between the two companies, since one reason for the Biogen Idec restructuring was to cut internal costs and increase funds for external business development and research opportunities," said Prudential. "Biogen Idec even specified that its external business development commitment will be $200 million in 2006 as compared to only $50 million in 2005."

The research firm noted that one potential negative impact could be the timing of certain clinical trials conducted by Biogen Idec as there is now a potential for delays due to management changes.

Prudential reiterated a $35 price target on Protein Design Labs. "Overall, we believe the change at Biogen Idec should have a neutral to positive impact on Protein Design`s stock price," said Prudential

[amorphis]

http://biz.yahoo.com/prnews/050912/sfm127.html?.v=12

[Fruehrentner]

amorphis,

kam diese Meldung heute nachbörslich in USA?

[amorphis]

die news sind seit dem 2.8. bekannt...greez (wollte es nur der vollständigkeit halber posten, da es heute als pr kam) wird höchstens das bereits bekannte in die köpfe der anleger bringen...

[goldmaki]

12.09.2005 22:02
PDL Announces Successful Closing of Global Alliance With Biogen Idec to Develop and Commercialize Three Phase II Antibody Products

FREMONT, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) today announced the successful closing of its previously-announced collaboration with Biogen Idec (Nachrichten) following the satisfaction of all closing conditions, including expiration of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. On August 2, 2005, PDL and Biogen Idec announced the broad collaboration for the joint development, manufacture and commercialization of three Phase II antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications.

At the closing, PDL received an upfront payment of $40 million, and Biogen Idec purchased common stock from PDL for aggregate proceeds to PDL of approximately $100 million. The shares purchased are subject to certain lock-up restrictions. If multiple products are developed successfully in multiple indications and all milestones are achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million. Of these, $560 million are related to development and $100 million are related to commercialization of collaboration products.

About PDL

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at http://www.pdl.com/.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those in the forward-looking statements. In particular, there can be no assurance that the parties will successfully develop or achieve the milestone events on any of the products or that the parties will perform their obligations under the agreement as anticipated. While the parties are bound to proceed with certain obligations, the agreement contains provisions under which parties can reduce or eliminate their obligations to develop, manufacture and commercialize products, and no assurance can be given that either party will proceed with the development and commercialization of any product. Other factors that may affect the development and commercialization of products are discussed in PDL`s Annual Report on Form 10-K for the year ended December 31, 2004, and in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 and in other filings made with the Securities and Exchange Commission. All statements included in this press release are based upon information available to PDL as of the date hereof, and PDL assumes no obligation to update any such forward-looking statements.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks and HuZAF is a trademark of Protein Design Labs, Inc.

[austin_power69]

Kurzfristiges Kursziel : 28,80EUR!!! Es ist also noch Luft drin und wohlgemerkt das ist nur kurzfristig. Langfristig sehen wir wieder alte Höchststände!

[austin_power69]

23,40EUR, wir kommen der Sache immer näher.

[kgv1]

Um die 21 gerne wieder,
Kgv1

[metallix]

Flieger; flieg in die Sonne....
der 30 € entgegen...meinetwegen...usw.

Gruss an die
Mitinvestierten

Metallix

[austin_power69]

die 30 haben wir bald!!!

[austin_power69]

was war denn Freitag los?
Big News gabs ja nicht...

[blb]

Schaut euch die Genentech-Zahlen heute an und ihr wisst, was uns demnächst bei PDLI erwartet!

Grüße
blb

[austin_power69]

Protein Design Labs: Kursziel 31 Dollar

Aus dem Hause JMP Securities kommt die Bestätigung des "market outperform"-Ratings für die Aktie von Protein Design Labs (Nachrichten) mit einem Kursziel von 31 Dollar.

[maxmosch]

hallo
weiß jemand bescheid über die geschäftszahlen?
die sind so weit ich weiß am ersten rausgekommen.
danke im vorraus
maxmosch

[amorphis]

die zahlen sind schon da?!

aber erstmal...

Form 8-K for PROTEIN DESIGN LABS INC/DE

3-Nov-2005

Entry into Material Agreement, Financial Statements and Exhibits


Item 1.01 Entry into a Material Definitive Agreement.

On October 28, 2005, Protein Design Labs, Inc., a Delaware corporation ("PDL") and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, "Roche") executed an Amended and Restated Co-Development and Commercialization Agreement and a Second Amended and Restated Worldwide Agreement (collectively, the "Agreements"). The Agreements amended the Amended and Restated WORLDWIDE Agreement dated October 1, 2003 and the Co-Development and Commercialization Agreement dated September 14, 2004 between Roche and PDL (the "Prior Agreements").

The Agreements expand the existing relationship between the parties to include the co-development and commercialization of daclizumab for organ transplant patients on longer term, maintenance therapy ("transplant maintenance"). The Agreements provide that PDL will receive a $10 million upfront payment and may receive up to $145 million in development and commercialization milestone payments if the development of daclizumab in transplant maintenance is successful. Roche and PDL will share global development costs equally. PDL will have the option to co-promote daclizumab for transplant maintenance in the United States and will share in the profits in the United States, and PDL will receive royalties on net sales of the product in transplant maintenance outside the United States.

The Agreements also provide that PDL will not exercise its option to promote Zenapax for prevention of acute kidney transplant rejection, and PDL is no longer required to make a payment for such right that would otherwise be due in 2007. The Agreements also amended the royalty obligations of Roche with respect to future sales of Zenapax in the existing transplant indication by including a revenue threshold below which royalties are not due. The other provisions of the Prior Agreements were not materially altered by the Agreements.

The press release announcing the transaction and containing a description of certain other terms of the Agreements is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

die zahlen...viel spaß beim lesen!


Press Release Source: Protein Design Labs, Inc.

PDL Announces Third Quarter 2005 Financial Results
Tuesday November 1, 4:00 pm ET
Strong revenue growth reflects addition of net product sales and increased royalties versus prior year quarter
Company increases full-year revenue guidance for marketed products and royalties

FREMONT, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - News) today reported financial results for the third quarter and first nine months of 2005. Financial highlights included:

-- Third quarter net product sales of $43.1 million, an increase of 22%
versus the prior quarter in 2005.
-- A 52% increase in royalty revenues to $26.0 million from $17.1 million
in the third quarter of 2004.
-- Total costs and expenses included an asset impairment charge of $15.2
million related to the reduced value of off-patent branded products,
expected to be divested, and $7.3 million for fees and milestones to
collaborative partners.
-- GAAP net loss of $39.4 million in the third quarter compared with a net
loss of $13.6 million in the third quarter of 2004; non-GAAP net loss
of $11.5 million compared with a non-GAAP net loss of $12.6 million in
the 2004 third quarter.
-- GAAP net loss of $126.7 million for the first nine months of 2005,
compared to a $38.7 million net loss in the same period of 2004; non-
GAAP net loss for the first nine months of 2005 was $5.0 million, a
substantial improvement compared to the $35.7 million non-GAAP loss
incurred in the first nine months of 2004.
-- Total cash, cash equivalents, marketable securities and restricted
investments of approximately $332.7 million as of September 30, 2005.

Mark McDade, Chief Executive Officer, PDL, said, "Our third quarter financial results are reflective of our ongoing integration of a focused, new commercial capability. We`re seeing solid combined net sales growth of our three actively marketed, recently acquired products, with both Cardene® and IV Busulfex® experiencing strong unit and dollar growth for the period. We have established greater presence in the hospital marketplace by adding roughly 40 sales representatives, bringing our total sales force to 105 talented individuals. Meanwhile, our partners` success with breakthrough antibody products such as Avastin(TM), Herceptin® and Synagis® continues to grow PDL`s royalty revenues. Coupled with the positive economic impact of our new alliances with Biogen Idec, and with this morning`s announcement, Roche, we believe we are tracking well toward our stated aim of turning cash flow positive in the fourth quarter and sustainably on a full-year basis in 2006."

Total Operating Revenues and Cash Balances:

Total operating revenues increased 288% to $76.7 million in the third quarter of 2005 from $19.8 million in the third quarter of 2004.

PDL achieved net product sales of $43.1 million in the third quarter of 2005. Of this, net sales of Cardene® IV, Retavase® and IV Busulfex® for the quarter totaled approximately $38.0 million, while net sales of the four off-patent branded products, marketed by PDL`s wholly-owned subsidiary, ESP Pharma, Inc., were approximately $5.1 million for the quarter.

Royalty revenues increased 52% to $26.0 million, compared with royalty revenues of $17.1 million in the third quarter of 2004. PDL currently receives royalties based on worldwide net sales of seven antibody products licensed under PDL`s antibody humanization patents: Avastin(TM), Herceptin®, Xolair® and Raptiva® from Genentech, Inc.; Synagis® from MedImmune, Inc.; Mylotarg® from Wyeth and Zenapax®, marketed by Roche. License and other revenues increased 184% to $7.5 million, compared with $2.7 million in the comparable quarter of 2004, primarily as a result of revenue recognized under the new Biogen Idec collaboration.

Cash, cash equivalents, marketable securities and restricted investments totaled approximately $332.7 million as of September 30, 2005. The September 30, 2005 balances include a $40.0 million upfront payment from Biogen Idec and proceeds of the sale of approximately 4.0 million shares of common stock to Biogen Idec of approximately $100 million, related to the companies` collaborative agreement for the co-development, manufacture and commercialization of three Phase II antibodies.

Costs and Expenses:

The cost of product sales was $22.2 million in the third quarter of 2005. Excluding non-cash amortization of product costs associated with the purchases of ESP Pharma and Retavase, pro forma cost of product sales was $10.3 million. Selling, general and administrative expenses increased to $26.8 million, compared to $7.7 million in the third quarter of 2004, primarily due to sales expenses associated with PDL`s newly acquired and growing sales team as well as the initiation of new Retavase promotional efforts late in the third quarter of 2005.

Research and development expenses increased to $49.5 million in the third quarter of 2005, compared with $27.3 million in the same three months of 2004. The third quarter 2005 research and development expenses include expenses of $42.2 million consisting of increased clinical trial efforts, manufacturing- related efforts and planned growth in personnel in these areas. In addition, research and development expenses included approximately $7.3 million of fees and milestone payments related to product-related assets and new technology. These payments included roughly $6.0 million related to the acquisition of additional commercial and development rights for ularitide and milestone payments to partners for continued successful clinical development of ularitide and terlipressin.

Total costs and expenses were $113.7 million in the third quarter of 2005, compared with $35.0 million in the third quarter of 2004, reflecting the full integration of ESP Pharma and Retavase, and support of wholly new marketing efforts. Total costs and expenses in the third quarter included a $15.2 million impairment charge related to a revaluation of the off-patent branded products acquired as part of the ESP Pharma acquisition; a sale of these off- patent branded products is expected to be concluded during the fourth quarter of 2005. On a non-GAAP basis, total costs and expenses in the 2005 third quarter were $85.9 million compared to non-GAAP expenses of $34.0 million in the third quarter of 2004.

For the nine months ended September 30, 2005, GAAP total costs and expenses were $317.5 million compared with $115.5 million for the comparable 2004 period, and non-GAAP total costs and expenses were $195.8 million compared with $112.6 million for the comparable 2004 period.

Note: Non-GAAP results for the three- and nine-month periods reported exclude certain non-cash charges, which consisted primarily of an acquired in- process research and development charge in the first quarter of 2005 related to the ESP Pharma acquisition, an asset impairment charge related to the off- patent branded products as well as the amortization of intangible assets associated with the Eos Biotechnology, Inc. and ESP Pharma and Retavase acquisitions and the re-acquisition of rights to manufacture and market Zenapax® (daclizumab) in 2003, and stock-based compensation charges. Reconciliations of GAAP results to non-GAAP results for periods presented are included in the tables accompanying this release. The forward-looking guidance set forth in the 2005 full-year guidance discussion below excludes certain non-cash charges identified above based on current estimates for the full year as follows: $79.4 million for an acquired in-process research and development charge; $15.2 million asset impairment charge for off-patent branded products; $39.0 million for amortization of intangible assets; and $1.0 million in stock compensation charges. In total, these adjustments are expected to reduce the GAAP reported operating loss by approximately $134.6 million.

Full-year 2005 Forward-looking Guidance:

The following statements are based on current expectations as of November 1, 2005, and PDL undertakes no obligation to update this information. These statements are forward-looking and do not include the potential impact of additional collaborations, material licensing arrangements or other strategic transactions.

-- PDL now anticipates that total operating revenues for 2005 will be in
the range of approximately $266 to $282 million.
-- For the approximately nine-month period of sales following the close
of the acquisition of ESP Pharma in March 2005, net product sales
for Cardene® IV, Retavase® and IV Busulfex® are expected to
total approximately $108 to $113 million. PDL reaffirms previously
guided compound annual growth rates of approximately 25% for net
product sales of this group of products for each year from 2006
through 2008.
-- Royalty revenues are expected to be in the range of approximately
$125 to $130 million, and license and other revenues are expected to
fall in a range of approximately $25 to $30 million, including
approximately $20 million in reimbursements and payments from Roche
and Biogen Idec under our collaborative arrangements. PDL reaffirms
our previously stated guidance that royalty revenues for each year
from 2006 through 2008 should grow at least 25% per year on a
compounded basis.
-- PDL expects to divest the off-patent branded products, and their
expected contribution to net product sales for the remainder of the
year is minor. Guidance for full-year sales has been reduced to $8
to $9 million for 2005.
-- PDL continues to anticipate gross margins on a non-GAAP basis of
approximately 80% for Cardene IV, Retavase and IV Busulfex over the
2005 through 2008 period.
-- Non-GAAP expenses are anticipated to be as follows: cost of product
sales is expected to total approximately $26 million; research and
development expenses are anticipated to be in a range of approximately
$163 to $168 million; and selling, general and administrative expenses
for the full year 2005 are expected to be in a range of $78 to $80
million.
-- For the full year 2005, PDL anticipates a GAAP net loss in the range of
approximately $1.26 to $1.38 per basic and diluted share, and on a non-
GAAP basis, in a range from net income of $0.03 cents to a net loss of
approximately $0.04 cents per share. Per share basic calculations are
anticipated to be based on a weighted average of approximately 103
million shares outstanding for the year. Quarterly results are
expected to continue to vary due to some seasonality in the sales of
certain royalty-bearing products. PDL reaffirms our expectation of
positive cash flow for the fourth quarter of 2005, and on a full-year
basis for 2006.
-- PDL estimates that its year-end 2005 cash balances will be
approximately $350 million.
-- PDL expects that headcount at year-end 2005 will be approximately 975,
at the high end of previous guidance as additional headcount are added
to support collaborations and clinical development of the pipeline, in
particular in preparation for the first half of 2006 and the planned
initiation of potentially pivotal studies for Nuvion® and completion
of the Phase III study of terlipressin.

Webcast:

PDL will webcast a conference call live at 4:30 p.m. Eastern time today to review its financial results for the third quarter ended September 30, 2005, the status of its clinical development programs and its forward-looking information and guidance with respect to future results. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A link to the conference call webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. The webcast will be archived at www.pdl.com starting approximately one hour after completion of the webcast. A replay of the conference call will also be available by telephone from approximately 6:30 p.m. Eastern time on November 1, 2005 through 6:30 p.m. Eastern time on November 6, 2005. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States and enter conference ID number 21266718.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements include our expectations regarding financial results, our expectations regarding the continuation of existing and new collaborative agreements, the possibility that the off-patent branded products will be sold and the anticipated sale price for those products, and the timing of clinical developments as well as other statements regarding our expectations. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The continued successful integration of ESP Pharma and Retavase as part of PDL, including the retention of the sales force; changes in our development plans as we and our collaborators consider development plans and alternatives; factors affecting the clinical timeline such as enrollment rates and availability of clinical materials; fluctuations in sales that may result from our integration of newly acquired operations; changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses. In addition, PDL revenues depend on the success and timing of sales of our licensees, including in particular the continued success of Avastin and Herceptin antibody products by Genentech, Inc. as well as the seasonality of sales of Synagis from MedImmune, Inc. In addition, quarterly revenues may be impacted by our ability to maintain and increase our revenues from collaborative arrangements such as our co- development agreements with Biogen Idec and Roche. Our net income will be affected by state and federal taxes, and our revenues and expenses would be affected by new collaborations, material patent licensing arrangements or other strategic transactions.

Further, there can be no assurance that results from completed and ongoing clinical studies, described above, will be successful or that ongoing or planned clinical studies will be completed or initiated on the anticipated schedules. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the Securities and Exchange Commission. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

About PDL:

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at www.pdl.com.

Protein Design Labs, the PDL logo and Nuvion are registered U.S. trademarks and HuZAF is a trademark of Protein Design Labs, Inc. Zenapax is a registered trademark of Roche. Cardene is a registered trademark of Roche Palo Alto. Retavase and Busulfex are registered trademarks of ESP Pharma, Inc., a wholly-owned subsidiary of PDL. Herceptin and Raptiva are registered trademarks and Avastin is a trademark of Genentech, Inc. Xolair is a trademark of Novartis AG. Synagis is a registered U.S. trademark of MedImmune, Inc. Mylotarg is a registered U.S. trademark of Wyeth.

Financial tables attached


PROTEIN DESIGN LABS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

(In thousands, except per share data)

Three months ended Nine months ended
September 30, September 30,
2005 2004 2005 2004
Revenues:
Product sales, net $43,144 $-- $79,437 $--
Royalties 26,003 17,131 96,695 63,872
License and other 7,536 2,653 17,127 9,323

Total revenues 76,683 19,784 193,259 73,195

Costs and expenses:
Costs of product sales 22,209 -- 43,481 --
Research and development 49,480 27,326 125,080 92,364
Selling, general and
administrative 26,795 7,664 54,267 23,182
Asset impairment charge 15,225 -- 15,225 --
Acquired in-process research
and development -- -- 79,417 --
Total costs and expenses 113,709 34,990 317,470 115,546
Operating loss (37,026) (15,206) (124,211) (42,351)

Interest and other income, net 2,027 2,822 6,835 7,689
Interest expense (2,671) (1,193) (7,522) (3,929)

Loss before income taxes (37,670) (13,577) (124,898) (38,591)
Provision for income taxes 1,680 12 1,767 68

Net loss $(39,350) $(13,589) $(126,665) $(38,659)

Basic and diluted net loss per
share $(0.37) $(0.14) $(1.24) $(0.41)

Shares used in computation of
basic and diluted net loss per
share 105,272 95,196 101,910 94,771


PROTEIN DESIGN LABS, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

We use non-GAAP amounts that exclude certain non-cash charges, including amounts related to the amortization of intangible assets, asset impairment charge and stock-based compensation. Management believes that these non-GAAP measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the Company in its operations. Our management uses these non-GAAP financial measures in evaluating the Company`s operating performance and for budgeting and planning purposes.

(In thousands, except per share data)

Three months ended September 30,
2005 2004

Adjust- Adjust-
GAAP ment Non-GAAP GAAP ment Non-GAAP


Revenues:
Product Sales $43,144 $43,144 $-- $--
Royalties 26,003 26,003 17,131 17,131
License and
other 7,536 7,536 2,653 2,653

Total revenues 76,683 76,683 19,784 19,784

Costs and
expenses:
Cost of Product
Sales 22,209 $(11,907) 10,302
Research
and
development 49,480 (554) 48,926 27,326 $(958) 26,368
Selling,
general
and
administrative 26,795 (118) 26,677 7,664 (14) 7,650
Asset
impairment
charge 15,225 (15,225) --

Total costs and
expenses 113,709 (27,804) 85,905 34,990 (972) 34,018
Operating loss (37,026) 27,804 (9,222) (15,206) 972 (14,234)

Interest and
other income,
net 2,027 2,027 2,822 2,822
Interest
expense (2,671) (2,671) (1,193) (1,193)

Loss before
income taxes (37,670) 27,804 (9,866) (13,577) 972 (12,605)
Provision for
income taxes 1,680 1,680 12 12

Net loss $(39,350) $27,804 $(11,546) $(13,589) $972 $(12,617)

Net loss per
basic and
diluted
share: $(0.37) $(0.11) $(0.14) $(0.13)

Shares used in
computation of
net loss per
basic and
diluted
share: 105,272 105,272 95,196 95,196


PROTEIN DESIGN LABS, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

We use non-GAAP amounts that exclude certain non-cash charges, including amounts related to the amortization of intangible assets, asset impairment charge and stock-based compensation. Management believes that these non-GAAP measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the Company in its operations. Our management uses these non-GAAP financial measures in evaluating the Company`s operating performance and for budgeting and planning purposes.

(In thousands, except per share data)

Nine months ended September 30,
2005 2004

Adjust- Adjust-
GAAP ment Non-GAAP GAAP ment Non-GAAP

Revenues:
Product
Sales $79,437 $79,437 $-- $--
Royalties 96,695 96,695 63,872 63,872
License
and other 17,127 17,127 9,323 9,323

Total
revenues 193,259 193,259 73,195 73,195

Costs and
expenses:
Costs of
product
sales 43,481 $(24,870) 18,611
Research
and
development 125,080 (1,721) 123,359 92,364 $(2,954) 89,410
Selling,
general and
admini-
strative 54,267 (428) 53,839 23,182 (42) 23,140
Asset
impairment
charge 15,225 (15,225) --
Acquired
in-process
research and
development 79,417 (79,417) -- -- --
Total costs
and expenses 317,470 (121,661) 195,809 115,546 (2,996) 112,550
Operating loss (124,211) 121,661 (2,550) (42,351) 2,996 (39,355)

Interest and
other income,
net 6,835 6,835 7,689 7,689
Interest
expense (7,522) (7,522) (3,929) (3,929)

Loss before
income
taxes (124,898) 121,661 (3,237) (38,591) 2,996 (35,595)
Provision for
income taxes 1,767 1,767 68 68

Net loss $(126,665) $121,661 $(5,004) $(38,659) $2,996 $(35,663)

Net loss per
basic and
diluted
share: $(1.24) $(0.05) $(0.41) $(0.38)

Shares used
in
computation
of net loss
per basic
and diluted
share: 101,910 101,910 94,771 94,771



CONSOLIDATED BALANCE SHEET DATA
(Unaudited)

(In thousands)
September 30, December 31,
2005 2004*

Cash, cash equivalents, marketable securities
and restricted investments $332,678 $397,080
Total assets 1,176,127 713,732
Total stockholders` equity 551,974 412,510

*Derived from the December 31, 2004 audited consolidated financial
statements.


CONSOLIDATED STATEMENT OF CASH FLOW DATA
(Unaudited)

(In thousands)
Three months ended Nine months ended
September 30, 2005 September 30, 2005

Net loss $(39,350) $(126,665)
Adjustments to reconcile net loss
to net cash provided by operating
activities 42,540 144,631
Changes in assets and liabilities 28,452 11,252
Net cash provided by operating
activities $31,642 $29,218

[blb]

Ja kamen diese Woche. Waren nicht so dolle! Allerdings einige Sondereinflüsse, die Tendenz stimmt!

[amorphis]

bizjournals.com
Protein Design Labs inks license deal with Merck
Tuesday January 3, 5:06 pm ET

Protein Design Labs Inc. sold Merck & Co. non-exclusive licenses for some of its antibody patents, PDL said Tuesday.

Fremont-based PDL didn`t say how much Merck paid, but said Merck made an upfront payment for the licenses and will pay milestones and royalties on any sales of products developed using the technology.

PDL (NASDAQ: PDLI - News) seeks to develop and sell treatments for inflammatory and autoimmune diseases, acute cardiac disorders and for cancer. It sells many of its products through its subsidiary, ESP Pharma Inc.

Merck (NYSE: MRK - News) is based in Whitehouse Station, N.J.

Published January 3, 2006 by San Francisco Business Times

[Fruehrentner]

und ausgerechnet heute neues vom Schmierenblatt "Der Aktionär" heut zu PDLI:

Protein Design Labs im Depot halten

Nach Ansicht der Experten vom Anlegermagazin "Der Aktionär" sollten Anleger die Aktie von Protein Design Labs (ISIN US74369L1035/ WKN 883428) im Depot halten.

Die Aktien von Protein Design Labs hätten jüngst deutlich zulegen können. Zuvor seien im Markt wiederholt Gerüchte aufgetaucht, denen zufolge Genentech an einer Übernahme von Protein Design Labs interessiert sein solle.

Das Kursziel für die Aktie werde auf 30 Euro angehoben.

Investoren sollten die Protein Design Labs-Aktie im Depot halten, so die Experten von "Der Aktionär".
Quelle: AKTIENCHECK.DE
04.01.2006

[amorphis]

ach was bios angeht hat schweinebacke schon oft genug nen guten riecher bewiesen...und...pdli ist eh kein wert den ein blättchen aus deutschland beeinflussen kann...

[amorphis]

29,96 USD

+5,34 % [+1,52]

sehr ordentlich...wenn die 30 erstmal nachhaltig genommen werden...kanns relativ schnell gehen...

[Fruehrentner]

@amorphis,


die Anleger in USA haben wohl alle "DER AKTIONÄR" gelesen gestern!

[amorphis]

wie erwartet...pdli hat die 30$ genommen und jetzt sollte der weg erstmal frei sein...40$ wir kommen...

[Fruehrentner]

@amorphis

ich wollte gerade dasselbe posten

Wünschen wir uns beiden, dass es so kommen wird!

Die monatelange Seitwärtsphase war auch ein wenig zermürbend, aber sie hat eine gute Basis für den weiteren, gesunden Kursanstieg geschaffen.

[metallix]

natürlich..............,
hat jemand gezweifelt?
Die 40 werden kommen.... bis dann

Gruss,
Metallix

[blb]

Interessant werden die Genentech-Zahlen, die demnächst kommen. Die sind nicht unwichtig für PDLI!

Einfach geil die Bios zur Zeit, so macht Börse Spass!

Grüße
blb

[amorphis]

[posting]19.621.917 von blb am 09.01.06 20:06:34[/posting]jepp...die zahlen von dna werden sicherlich sehr interessant für pdli...

eine pr ist out...

Press Release Source: PDL BioPharma, Inc.

Protein Design Labs Becomes PDL BioPharma
Monday January 9, 3:49 pm ET
Company to Update Progress and Unveil "Vision 2010" at JPMorgan 24th Annual Healthcare Conference

FREMONT, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (Nasdaq: PDLI - News) announced that effective today the company will be known as PDL BioPharma, Inc. to better reflect its status as a commercial company focused on discovering, developing and marketing innovative therapies for severe or life threatening illnesses. The company will continue to be traded on the NASDAQ stock market under the ticker symbol PDLI.

ADVERTISEMENT
"Over the last several years, we have fundamentally changed the company through accomplishments aimed at accelerated commercial capabilities. As a result, we are now a hospital-focused, fully-integrated biopharmaceutical company with multiple marketed products, important royalty-bearing agreements based on our humanized antibody platform and a diverse later-stage product pipeline focused primarily on acute and life threatening diseases," said Mark McDade, Chief Executive Officer, PDL BioPharma. "We believe we are well positioned to bring novel therapies to patients in need, and expect to perform on a high growth pace over the next five years. Importantly, we also expect to be cash flow positive on a full-year basis for 2006."

The transition to the new name coincides with the integration of ESP Pharma, Inc. into PDL BioPharma. ESP Pharma had been operating as a wholly- owned subsidiary of Protein Design Labs since its acquisition in the first quarter of 2005. The ESP Pharma acquisition enabled PDL to reach its commercialization goal two years ahead of schedule. The company now markets Cardene® IV (nicardipine hydrochloride) for short-term treatment of hypertension when oral therapy is not feasible or desirable, Retavase® (reteplase) for acute myocardial infarction (AMI), and IV Busulfex® (busulfan), a pre-conditioning agent used in connection with bone marrow transplantation in chronic myelogenous leukemia. PDL has grown its hospital- focused sales and operations team in North America to approximately 125 people, an increase of about 40 sales representatives, since the March 2005 acquisition.

Later this week, PDL BioPharma also will be introducing "Vision 2010," a five-year strategic plan to achieve continued growth. CEO Mark McDade will discuss "Vision 2010" on January 11 during his presentation at the JPMorgan 24th Annual Healthcare Conference in San Francisco.

About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering humanized antibody technology. Currently, PDL BioPharma`s diverse late-stage product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. For more information, go to www.pdl.com.

The information in this press release should be considered accurate only as of the date of the release. PDL has no intention of updating and specifically disclaims any duty to update the information in this press release. This press release contains forward-looking statements involving risks and uncertainties, including statements regarding growth and cash flow, and PDL`s actual results may differ materially from those in the forward- looking statements. Factors that may cause such differences include actual outcomes of product development programs, competitive developments and the company`s ability to achieve product sales objective, and other factors discussed in PDL`s filings with the Securities and Exchange Commission.

PDL BioPharma, the PDL BioPharma logo, Retavase and Busulfex are considered trademarks of PDL BioPharma, Inc. Cardene is a registered trademark of Hoffmann-La Roche.

[amorphis]

bizjournals.com
Protein Design changes name
Monday January 9, 5:05 pm ET

Protein Design Labs Inc. changed its name on Monday to PDL BioPharma Inc.

The Fremont company (NASDAQ: PDLI - News) said the new name better reflects its changed focus as a company seeking drugs to treat severe illnesses.

The name change comes as PDL incorporates its wholly-owned subsidiary, ESP Pharma Inc., which it bought a year ago.

PDL`s stock symbol will not change.

Mark McDade, the company`s CEO, said PDL expects to be cash flow positive for the full year 2006.

Published January 9, 2006 by San Francisco Business Times

[amorphis]

Press Release Source: Human Genome Sciences, Inc.

Human Genome Sciences Licenses Worldwide Intellectual Property Rights for Target Antigen to PDL BioPharma
Tuesday January 10, 7:01 am ET

ROCKVILLE, Md. and FREMONT, Calif., Jan. 10 /PRNewswire-FirstCall/ -- CoGenesys, a division of Human Genome Sciences, Inc. (Nasdaq: HGSI - News), and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI - News) today announced that the companies have entered into a worldwide licensing agreement that provides PDL certain exclusive rights to intellectual property for an undisclosed target antigen discovered by Human Genome Sciences.

ADVERTISEMENT
(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

Under terms of the agreement, CoGenesys is entitled to an upfront licensing fee, development milestone payments and royalties on future sales of antibody therapeutics developed by PDL against the target. PDL also will provide CoGenesys with access to its antibody humanization technology platform. Additional terms were not disclosed.

"We are delighted to partner with CoGenesys to enable further development of this novel preclinical therapeutic program," said Richard Murray, Ph.D., Senior Vice President, Chief Scientific and Technical Officer, PDL. "We believe this is an exciting and promising target, one that reflects the novelty and strength of our early stage pipeline."

"We are pleased that our CoGenesys division has completed the agreement with PDL and look forward to supporting PDL`s progress in developing innovative antibody-based therapeutics based on the target antigen to which rights have been granted," said H. Thomas Watkins, President and Chief Executive Officer of Human Genome Sciences. "We are also pleased that the agreement provides CoGenesys with access to PDL`s humanization platform, which will help enable CoGenesys` own internal discovery and development programs."

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering humanized antibody technology. Currently, PDL BioPharma`s diverse late-stage product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. For more information, go to www.pdl.com.

Human Genome Sciences is a company with the mission to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. For additional information on Human Genome Sciences, please visit our web site at www.hgsi.com. In December 2005, Human Genome Sciences announced the decision to spin off CoGenesys (which will include the license agreement with PDL) as an independent company, contingent on a successful completion of CoGenesys funding.

[Simbasi]

hallo an alle
heute hat pdl. eine spezialkonferenz gegeben.
weiß da jemand bescheid was da raus kam?
da dachte man das die 30 dollar geknackt wären und nun gehts leider wieder abwärts.
gruss

[amorphis]

die 30 sind geknackt...alles im lot....nur ein wenig druck wg dna....sonst nichts!

[amorphis]

von der conference

Co says they are targeting for positive cash flow full year 2006. Co says in 2006 they are preparing the first N.D.A in U.S. They plan on establishing E.U operation also in 2006. In 2007 they plan the launch of terlipressin in type 1 H.R.S in US. In 2008 they plan to file Nuvion B.L.A in US and EU and 2009 file ularitide M.A.A in EU. In 2010 launch ularitide in E.U. The co says they would like to reach #1 or #2 in dollar market share for their marketed drugs and expand commercial operations to Europe The co wants to reach $1 bln in total operating revs by 2010, and deliver top and bottom line growth of 25% annually. Cardene is key growth driver sees 2008 sales goal in excess of $100 mln. Retavase plan on rebuilding A.M.I franchise sees 2008 goal of $75 mln. IV Busulfex 2009 sales of greater than $30 mln

[Simbasi]

was hat das mit dna zu bedeuten?
denn mein englisch ist sehr bescheiden.:
es sieht meiner meinung nicht gut aus,daß wir die 30 halten ,denn vorbörslich stehen sie doch um einiges darunter

[amorphis]

[posting]19.676.331 von Simbasi am 12.01.06 14:33:04[/posting]DNA ist das kürzel von genentech...denke der zusammenhang ist bekannt?! greez

[amorphis]

Press Release Source: National Heart Lung and Blood Institute

`Wait and See` Approach to Heart Attack Warning Signs May Contribute to Poor Survival Rates
Tuesday January 24, 7:30 am ET
National Awareness Program Urges Americans to `Act in Time to Heart Attack Signs`

NEW YORK, Jan. 24 /PRNewswire/ -- Many U.S. adults lack critical knowledge about heart attack warning signs beyond the so-called "Hollywood Heart Attack" -- the sudden, crushing chest pain that is often depicted in the movies and on television, according to a new Harris Interactive® survey commissioned by PDL BioPharma, Inc. This knowledge gap, coupled with a "wait and see" approach in seeking timely treatment, may contribute to the nearly one-half million heart-attack related deaths in the United States annually.(1)

According to the survey:

-- Only two in five (40%) U.S. adults would seek medical attention if
they experienced common heart attack symptoms (sickness to the
stomach, lightheadedness, and pain or soreness in the arm, back or
neck) for several minutes -- the majority (59%) would wait and see if
the symptoms passed, and only 14% would call 9-1-1.
-- Only about half of U.S. adults (56%) think calling 9-1-1 (or their
10-digit local emergency number) for an ambulance is the first step
to take if they (or someone they are with) are experiencing heart
attack symptoms.
-- Only 35% of U.S. adults who have been diagnosed with a heart attack,
or have a friend or family member who has been diagnosed with a heart
attack, called 9-1-1 (or their 10-digit local emergency number) as
the first step.
-- Less than half of U.S. adults (48%) realize that a heart attack can
be stopped once it has begun.

To combat the ongoing awareness gap about heart attacks and how to respond, Act in Time to Heart Attack Signs, a National Heart Lung and Blood Institute (NHLBI) public education campaign, is being revitalized through the sponsorship of PDL BioPharma. The campaign, originally launched in 2001 by the NHLBI, urges Americans to learn the various warning signs of a heart attack and call 9-1-1 immediately in order to save lives.

"The vision of Act in Time has always been to save lives by increasing the woefully low number of heart attack patients who are treated within the first hour of experiencing symptoms," said Elizabeth G. Nabel, M.D., Director of NHLBI. "While we`ve made great strides in educating Americans about heart attack warning signs in order to drive earlier treatment, this survey demonstrates that there`s still work to be done to win the war against heart attacks."

An estimated 1.2 million Americans suffer heart attacks each year and approximately 494,400 of them die. Nearly half of heart attack deaths occur before the person reaches the hospital. Most heart attack victims wait two or more hours after symptom onset before seeking medical help, often because they do not realize they`re having a heart attack.(2)

"Tragically, many patients, expecting to experience sudden, crushing chest pain, don`t recognize the less dramatic symptoms of a heart attack, don`t seek prompt treatment and, therefore, don`t receive powerful life-saving therapies in time," said William E. Boden, M.D., national spokesperson for Act in Time. "We hope to reverse that trend with this education program."

According to Dr. Boden, Director of Cardiovascular Clinical Trials at Hartford Hospital, and Professor of Medicine, University of Connecticut School of Medicine, the most common heart attack warning signs include pain or discomfort in the center of the chest; discomfort in one or both arms, back, neck, jaw, or stomach; shortness of breath; and other signs, such as breaking out in a cold sweat, nausea, and light-headedness.

The survey also found that:

-- While 85% of U.S. adults recognized chest discomfort as a heart
attack warning sign, significantly fewer adults are aware that
discomfort in the neck (36%), back (32%), jaw (30%) or stomach (23%)
are also symptoms of a heart attack.
-- Less than half (46%) of U.S. adults who have been diagnosed with a
heart attack or have a friend or family member who has been diagnosed
with a heart attack indicated that they/their friend or family
members actually experienced chest discomfort.

"It is essential that Americans become familiar with all of the heart attack warning signs, because every second counts when it comes to a heart attack," Dr. Boden emphasized. "Clot-dissolving drug therapy or dilation of a blocked coronary artery with balloon angioplasty and stenting can stop, or interrupt, a heart attack, limiting or preventing debilitating or deadly heart muscle damage. However, these treatments are most effective when administered within one hour of symptom onset. "Dr. Boden went on to explain that delay in symptom recognition will inevitably delay prompt treatment, hence, patient education about heart attack warning signs is paramount.

The Act in Time campaign offers informative, easy-to-read educational materials for the public including a brochure, wallet card and educational video. Several hospitals and health systems across the country also will be distributing the Act in Time materials and conducting related education events in 2006. Information on obtaining the Act in Time materials, as well as in-depth results of the PDL BioPharma survey conducted by Harris Interactive can be found at www.actintime2006.com.

[Simbasi]

da siehts nicht wirklich gut aus.
vor kurzem dachte man daß die 30 dollar geknackt sind,und seit dem dümpelt der kur zw. 28 und 29,5

[Simbasi]

heute recht gut gehalten.
der gesamtmarkt abwärts und pdl 1prozent im plus.
vielleicht gehts doch bald über die 30 dollar.

[xhagra]

Desoxyribonucleic Acid, die englische und international gebräuchliche Abkürzung für Desoxyribonukleinsäure (DNS)

Die Desoxyribonukleinsäure (DNS), meist nach der englischen Bezeichnung deoxyribonucleic acid mit DNA abgekürzt, ist ein Makromolekül, das in der Vererbung als Träger der Information dient. Anhand dieser Information, die in einer bestimmten Form, dem genetischen Code, in die DNA eingeschrieben ist, werden Proteine synthetisiert. Das Makromolekül ist aus den chemischen Elementen Kohlenstoff, Wasserstoff, Sauerstoff, Phosphor und Stickstoff zusammengesetzt. Die DNA ist eine Nukleinsäure.

Die deutsche Abkürzung DNS wird im wissenschaftlichen Sprachgebrauch und zunehmend auch in der Umgangssprache aufgrund der international gebräuchlichen englischen Abkürzung DNA seltener verwendet. Die internationale Abkürzung vermeidet zudem Verwechslungen mit dem Domain Name System (DNS) des Internets.

[blb]

Starke Zahlen! :super:

PDL BioPharma Announces Fourth Quarter and Full Year 2005 Financial Results
MONDAY, FEBRUARY 27, 2006 4:00 PM
- PR Newswire

FREMONT, Calif., Feb 27, 2006 /PRNewswire-FirstCall via COMTEX/ -- PDL BioPharma, Inc. (PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2005.

"Our product and operating revenue increases, during both the fourth quarter and full year, reflect a growing commercial presence in the acute-care hospital market with three proprietary marketed products in Cardene(R) IV, Retavase(R) and IV Busulfex(R)," said Mark McDade, Chief Executive Officer, PDL. "In addition, royalty revenues from our partners` successful breakthrough antibody products continued to grow, and our new alliances with both Biogen Idec and Roche are bringing important expertise and resources to further propel our clinical-stage pipeline. This overall performance led to positive cash flow from operations for the fourth quarter and the year as well as profitability on a non-GAAP basis. We currently expect to sustain positive non-GAAP earnings for the full year 2006, while advancing our growing pipeline and pushing ahead toward our long-term aims."

PDL`s non-GAAP financial results are based on adjusted EBITDA, and the details of the calculation of these non-GAAP financial measures and reconciliation to GAAP financial results are included in the attached financial tables. These non-GAAP results are based upon earnings before interest income, interest expense, income taxes, depreciation and amortization (EBITDA), further adjusted to exclude certain non-cash and other charges, including acquired in-process research and development, asset impairment charges and stock-based compensation.

2005 Financial Results:

-- PDL reported a GAAP net loss of $23.1 million, or $0.22 per basic and diluted share, in the fourth quarter of 2005 compared with a net loss of $14.6 million, or $0.15 per basic and diluted share, in the fourth quarter of 2004.

-- Fourth quarter 2005 non-GAAP net income was $7.5 million, or $0.07 per basic and $0.06 per diluted share, compared with a non-GAAP net loss of $11.9 million, or $0.12 per basic and diluted share, in the fourth quarter of 2004.

-- For the full year 2005, the GAAP net loss was $149.8 million, or $1.45 per basic and diluted share, compared to $53.2 million, or $0.56 per basic and diluted share in 2004.

-- PDL reported non-GAAP net income for full year 2005 of $16.2 million, or $0.16 per basic and $0.15 per diluted share, compared to a non-GAAP net loss of $42.1 million, or $0.44 per basic and diluted share in 2004.

-- Cash, cash equivalents, marketable securities and restricted investments totaled approximately $333.9 million as of December 31, 2005, compared to $397.1 million as of December 31, 2004.

Total Operating Revenues:

-- Total operating revenues for the 2005 fourth quarter were $83.7 million compared to $22.8 million in the same period of 2004, an increase of 266 percent.

- PDL achieved net product sales of $39.0 million in the fourth quarter of 2005. Net sales of Cardene(R) IV, Retavase(R) and IV Busulfex(R) for the quarter totaled approximately $36.7 million, while net sales of the four off- patent branded products were approximately $2.3 million. PDL did not report sales from marketed products in 2004.

- Royalty revenues for the fourth quarter of 2005 increased 67 percent to $33.4 million compared with $19.9 million in the year-ago quarter. PDL currently receives royalties based on worldwide net sales of seven antibody products licensed under PDL`s antibody humanization patents: Avastin(TM), Herceptin(R), Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc.; Mylotarg(R) from Wyeth and Zenapax(R), marketed by Roche.

- License and other revenues during the fourth quarter of 2005 increased to $11.3 million from $2.9 million in the same period of 2004, primarily as a result of revenue recognized under the new Biogen Idec collaboration, including $1.4 million of revenue recognized from amortization of upfront or milestone payments received in prior periods.

-- Full-year 2005 revenues increased to $276.9 million from $96.0 million in 2004, an increase of 188 percent. PDL achieved net product sales of $118.4 million for the full year 2005. Of this, net sales of Cardene IV, Retavase and IV Busulfex for the year totaled $109.1 million, and net sales of four off-patent branded products were $9.3 million. Net product sales reflected approximately nine months of product sales in 2005 following the acquisition of ESP Pharma, Inc. effective March 23, 2005. Full year 2005 royalty revenues rose to $130.1 million from $83.8 million in 2004. License and other revenues increased to $28.4 million in 2005, compared with $12.2 million for the full 12 months of 2004.

Costs and Expenses:

-- Total costs and expenses were $107.8 million in the fourth quarter of 2005, compared with $38.8 million in the fourth quarter of 2004, reflecting the integration of ESP Pharma and Retavase, the initiation of new marketing efforts and expanded clinical development activities. On a non-GAAP basis, total costs and expenses in the fourth quarter of 2005 were $76.0 million compared to $34.7 million in the fourth quarter of 2004.

- The cost of product sales was $16.8 million in the fourth quarter of 2005 compared with no such costs in the fourth quarter of 2004, when PDL did not yet have marketed products. The non-GAAP cost of product sales was $6.2 million in the 2005 fourth quarter, with the difference due to the exclusion of amortization of certain acquisition-related costs.

- Research and development expenses increased to $47.0 million in the fourth quarter of 2005, compared with $30.2 million in the year-ago period. The increase reflected expanded clinical trial efforts for Nuvion(R), ularitide and daclizumab, manufacturing-related costs and additional personnel in these areas.

- Selling, general and administrative expenses increased to $28.0 million during the fourth quarter of 2005, compared with $8.6 million in the fourth quarter of 2004, primarily due to selling expenses associated with PDL`s growing sales team as well as the initiation of new promotional efforts late in the third quarter of 2005.

- Total costs and expenses in the 2005 fourth quarter included asset impairment charges of $16.0 million, primarily related to PDL`s option to re-acquire from Roche rights to Zenapax for prevention of acute renal transplant rejection, which it will not exercise under an expanded collaboration announced in November 2005.

-- Total costs and expenses were $425.3 million for the full year 2005, compared with $154.4 million in 2004. Non-GAAP total costs and expenses were $260.7 million in 2005 compared to $138.6 million for the full 12 months of 2004.

- For the full year 2005, the cost of product sales was $60.3 million compared with no such costs in 2004, when PDL did not yet have marketed products. The non-GAAP cost of product sales was $24.8 million for the full year 2005, with the difference due to amortization of certain acquisition- related costs.

- Research and development expenses increased to $172.0 million in 2005, compared with $122.6 million in the full year 2004. The increase reflected expanded clinical development activities for the company`s mid- and late-stage products, manufacturing-related costs and additional personnel in these areas.

- Selling, general and administrative expenses increased to $82.3 million for the full year 2005, compared with $31.8 million in 2004, primarily due to sales expenses associated with the marketing of Cardene, Retavase and Busulfex following the March 2005 acquisitions of ESP Pharma and Retavase.

Note: PDL`s non-GAAP financial results are based on adjusted EBITDA. Reconciliations of GAAP results to non-GAAP results for the reported periods are included in the tables accompanying this release. Non-GAAP results for the three- and 12-month periods ended December 31, 2005 and 2004 exclude certain non-cash and other charges. For the full year 2005, these consisted primarily of the following: an acquired in-process research and development charge of $79.4 million related to the ESP Pharma acquisition; asset impairment charges of $15.5 million related to the off-patent branded products and of $15.8 million related to the option to re-acquire rights to manufacture and market Zenapax for acute renal transplant rejection; the amortization of intangible assets of $37.6 million associated with the Eos Biotechnology, Inc., ESP Pharma and Retavase acquisitions and the re-acquisition from Roche of rights to develop and market Zenapax in indications other than transplantation; depreciation expenses for fixed assets of $15.4 million; and stock-based compensation charges of $1.0 million. Our non-GAAP results include upfront license and certain milestone payments that are recognized over time, which totaled $9.2 million for the fiscal year related to the Biogen Idec and Roche collaborations.

2006 Forward-looking Guidance:

The following statements are based on current expectations as of February 27, 2006, and PDL undertakes no obligation to update this information. These statements are forward-looking and do not include the potential impact of additional collaborations, material licensing arrangements or other strategic transactions.

-- PDL anticipates total operating revenues for 2006 in a range of approximately $405 million to $435 million, including $175 million to $185 million in net product revenues and $170 million to $180 million in royalties. Revenue guidance also includes license fees and total collaboration revenues (expense reimbursement and the amortization of upfront fees and milestone payments) of approximately $60 million to $70 million.

-- On a non-GAAP basis, PDL anticipates total costs and expenses in 2006 as follows: cost of product sales to be approximately $40 million; research and development expenses in a range of approximately $230 million to $240 million, reflecting significant planned investments for clinical development of later stage and partnered products, as well as select development activities to support currently marketed products; and selling, general and administrative expenses in a range of approximately $90 million to $100 million.

-- For the full year 2006, PDL anticipates adjusted EBITDA in a range of approximately $44 million to $54 million, or on a diluted per share basis, in the range of $0.38 to $0.47. This forward-looking guidance excludes certain non-cash charges based on current estimates for the full year 2006, including the impact of stock option compensation expense in a range of approximately $32 million to $38 million, and the amortization of certain expenses of approximately $44 million related to the acquisitions of ESP Pharma and Retavase, and the re-acquisition from Roche of rights to develop and market Zenapax in indications other than transplantation. Other items that could affect the reconciliation cannot be estimated at this time because they depend upon future events.

-- For the full year 2006, PDL anticipates ending the year with more than $370 million in cash, cash equivalents, marketable securities and restricted investments. This figure includes the repayment of a $30 million note receivable, plus interest, from Exelixis, Inc., expected in May 2006.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL`s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements include our expectations regarding financial results, our expectations regarding the continuation of existing and new collaborative agreements, the possibility that the off-patent branded products will be sold and the anticipated sale price for those products, and the timing of clinical developments as well as other statements regarding our expectations. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The continued successful integration of ESP Pharma and Retavase as part of PDL, including the retention of the sales force; changes in our development plans as we and our collaborators consider development plans and alternatives; factors affecting the clinical timeline such as enrollment rates and availability of clinical materials; changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses. In addition, PDL revenues depend in part on the success and timing of sales of our licensees, including in particular the continued success of Avastin and Herceptin antibody products by Genentech, Inc. as well as the seasonality of sales of Synagis(R) from MedImmune, Inc. Quarterly revenues may be impacted by our ability to maintain and increase our revenues from collaborative arrangements such as our co-development agreements with Biogen Idec and Roche. Our revenues and expenses would be affected by new collaborations, material patent licensing arrangements or other strategic transactions.

Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the Securities and Exchange Commission. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering humanized antibody technology. Currently, PDL BioPharma`s diverse late-stage product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. For more information, please see our website at www.pdl.com.

NOTE: PDL BioPharma, the PDL BioPharma logo, Retavase and Busulfex are considered trademarks and Nuvion is a registered U.S. trademark of PDL BioPharma, Inc. Zenapax is a registered trademark of Roche. Cardene is a registered trademark of Hoffmann-La Roche. Herceptin and Raptiva are registered trademarks and Avastin is a trademark of Genentech, Inc. Xolair is a trademark of Novartis AG. Synagis is a registered U.S. trademark of MedImmune, Inc. Mylotarg is a registered U.S. trademark of Wyeth.

PDL BIOPHARMA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

(In thousands, except per share data )
Three months ended Twelve months ended
December 31, December 31,
2005 2004 2005 2004
Revenues:
Product sales, net $39,012 $-- $118,449 $--
Royalties 33,373 19,935 130,068 83,807
License and other 11,268 2,894 28,395 12,217

Total revenues 83,653 22,829 276,912 96,024

Costs and expenses:
Cost of product sales 16,776 -- 60,257 --

Research and
development 46,959 30,199 172,039 122,563
Selling, general and
administrative 28,028 8,624 82,295 31,806
Asset impairment
charges 16,044 -- 31,269 --
Acquired in-process
research and
development -- -- 79,417 --
Total costs and
expenses 107,807 38,823 425,277 154,369
Operating loss (24,154) (15,994) (148,365) (58,345)

Interest and other
income, net 2,781 2,523 9,616 10,212
Interest expense (2,655) (1,099) (10,177) (5,028)

Loss before income
taxes (24,028) (14,570) (148,926) (53,161)
Income taxes expense
(benefit) (899) 12 868 80

Net loss $(23,129) $(14,582) $(149,794) $(53,241)

Basic and diluted
net loss per
share $(0.22) $(0.15) $(1.45) $(0.56)

Shares used in
computation of
basic and diluted
net loss per
share 107,512 95,613 103,311 94,982


PDL BIOPHARMA, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)


We use certain non-GAAP financial measures in evaluating our operating performance. These non-GAAP financial results are based upon earnings before interest income, interest expense, income taxes, depreciation and amortization (EBITDA), further adjusted to exclude certain non-cash and other charges, including acquired in-process research and development, asset impairment charges and stock-based compensation. We believe that these non-GAAP financial measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the Company in its operations.

(In thousands, except per share data )
Three months ended December 31,
2005
GAAP Adjustments Non-GAAP
Revenues:
Product sales, net $39,012 $39,012
Royalties 33,373 33,373
License and other 11,268 11,268

Total revenues 83,653 83,653

Costs and expenses:
Cost of product sales 16,776 $(10,565)(1) 6,211
Research and development 46,959 (4,371)(2) 42,588
Selling, general and
administrative 28,028 (820)(3) 27,208
Asset impairment charges 16,044 (16,044)(4) --

Total costs and expenses 107,807 (31,800) 76,007
Operating income (loss) (24,154) 31,800 7,646

Interest and other income, net 2,781 (2,889)(5) (108)
Interest expense (2,655) 2,655 --

Income (loss) before income taxes (24,028) 31,566 7,538
Income taxes expense (benefit) (899) 899 --

Net income (loss) $(23,129) $30,667 $7,538

Net income (loss) per basic share $(0.22) $0.07

Net income (loss) per diluted share $(0.22) $0.06

Shares used in computation of net
income (loss) per basic share 107,512 107,512

Shares used in computation of net
income (loss) per diluted share 107,512 116,514


(In thousands, except per share data )
Three months ended December 31,
2004
GAAP Adjustments Non-GAAP
Revenues:
Product sales, net $-- $--
Royalties 19,935 19,935
License and other 2,894 2,894

Total revenues 22,829 22,829

Costs and expenses:
Cost of product sales
Research and development 30,199 $(3,563)(2) 26,636
Selling, general and
administrative 8,624 (526)(3) 8,098
Asset impairment charges -- --

Total costs and expenses 38,823 (4,089) 34,734
Operating income (loss) (15,994) 4,089 (11,905)

Interest and other income, net 2,523 (2,505)(5) 18
Interest expense (1,099) 1,099 --

Income (loss) before income taxes (14,570) 2,683 (11,887)
Income taxes expense (benefit) 12 (12) --

Net income (loss) $(14,582) $2,695 $(11,887)

Net income (loss) per basic share $(0.15) $(0.12)

Net income (loss) per diluted share $(0.15) $(0.12)

Shares used in computation of net
income (loss) per basic share 95,613 95,613

Shares used in computation of net
income (loss) per diluted share 95,613 95,613


(1) Amortization of intangible assets for our marketed products in Q4`05.
(2) Depreciation expenses for our fixed assets ($3.8M
in Q4`05, $2.9M in Q4`04), and amortization of intangible assets
associated with the Eos Biotechnology, Inc. acquisition and the re-
acquisition from Roche of rights to Zenapax ($0.6M in Q4`05,
$0.6M in Q4`04).
(3) Depreciation expenses for our fixed assets ($0.4M in Q4`05, $0.2M in
Q4`04), and stock-based compensation ($0.4M in Q4`05, $0.3M in Q4`04).
(4) Asset impairment charges for off-patent brands of $0.2M and
write-off of option to re-acquire rights to manufacture and market
Zenapax for acute renal transplant rejection of $15.8M in Q4`05.
(5) Interest income.


PDL BIOPHARMA, INC.
NON-GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)


We use certain non-GAAP financial measures in evaluating our operating performance. These non-GAAP financial results are based upon earnings before interest income, interest expense, income taxes, depreciation and amortization (EBITDA), further adjusted to exclude certain non-cash and other charges, including acquired in-process research and development, asset impairment, stock-based compensation and restructuring charges. We believe that these non-GAAP financial measures enhance an investor`s overall understanding of our financial performance and future prospects by reconciling more closely to the actual cash expenses of the Company in its operations.

(In thousands, except per share data )
Years ended December 31,
2005
GAAP Adjustments Non-GAAP
Revenues:
Product sales, net $118,449 $118,449
Royalties 130,068 130,068
License and other 28,395 28,395

Total revenues 276,912 276,912

Costs and expenses:
Cost of product sales 60,257 (35,434)(1) 24,823
Research and development 172,039 (16,396)(2) 155,643
Selling, general and
administrative 82,295 (2,094)(3) 80,201
Asset impairment charges 31,269 (31,269)(4) --
Acquired in-process research
and development 79,417 (79,417) --
Total costs and expenses 425,277 (164,610) 260,667
Operating income (loss) (148,365) 164,610 16,245

Interest and other income, net 9,616 (9,664)(5) (48)
Interest expense (10,177) 10,177 --

Income (loss) before income taxes (148,926) 165,123 16,197
Income taxes expense 868 (868) --

Net income (loss) $(149,794) $165,991 $16,197

Net income (loss) per basic share $(1.45) $0.16

Net income (loss) per diluted share $(1.45) $0.15

Shares used in computation of net
income (loss) per basic share 103,311 103,311

Shares used in computation of net
income (loss) per diluted share 103,311 109,222


Years ended December 31,
2004
GAAP Adjustments Non-GAAP
Revenues:
Product sales, net $-- $--
Royalties 83,807 83,807
License and other 12,217 12,217

Total revenues 96,024 96,024

Costs and expenses:
Cost of product sales
Research and development 122,563 (14,280)(2) 108,283
Selling, general and
administrative 31,806 (1,519)(3) 30,287
Asset impairment charges
Acquired in-process research
and development -- --
Total costs and expenses 154,369 (15,799) 138,570
Operating income (loss) (58,345) 15,799 (42,546)

Interest and other income, net 10,212 (9,739)(5) 473
Interest expense (5,028) 5,028 --

Income (loss) before income taxes (53,161) 11,088 (42,073)
Income taxes expense 80 (80) --

Net income (loss) $(53,241) $11,168 $(42,073)

Net income (loss) per basic share $(0.56) $(0.44)

Net income (loss) per diluted share $(0.56) $(0.44)

Shares used in computation of net
income (loss) per basic share 94,982 94,982

Shares used in computation of net
income (loss) per diluted share 94,982 94,982


(1) Amortization of intangible assets for our marketed products in 2005.
(2) Depreciation expenses for our fixed assets ($14.2M in 2005, $11.0M in
2004), amortization of intangible assets associated with the Eos
Biotechnology, Inc. acquisition and the re-acquisition from Roche of
rights to Zenapax ($2.1M in 2005, $2.5M in 2004), restructuring
charges (none in 2005, $0.3M in 2004), and stock-based compensation
($0.2M in 2005, $0.6M in 2004).
(3) Depreciation expenses for our fixed assets ($1.2M in 2005, $0.8M in
2004), and stock-based compensation ($0.8M in 2005, $0.6M in 2004).
(4) Asset impairment charges for off-patent brands of $15.5M and write-off
of option to re-acquire rights to manufacture and market Zenapax for
acute renal transplant rejection of $15.8M in 2005.
(5) Interest income.


CONSOLIDATED BALANCE SHEET DATA
(Unaudited)

December 31, December 31,
2005 2004*
(In thousands) (unaudited)

Cash, cash equivalents, marketable
securities and restricted
investments $333,922 $397,080
Total assets 1,170,262 713,732
Total stockholders` equity 531,144 412,510

*Derived from the December 31, 2004 audited consolidated financial
statements.


CONSOLIDATED STATEMENT OF CASH FLOW DATA
(Unaudited)

Three months ended Year ended
December 31, 2005 December 31, 2005

Net loss $(23,129) $(149,794)
Adjustments to reconcile net loss to
net cash provided by operating
activities 22,858 167,489
Changes in assets and liabilities 2,368 13,620
Net cash provided by operating
activities $2,097 $31,315


SOURCE PDL BioPharma, Inc.

Ami Knoefler, Senior Director, Corporate and Investor Relations, [phone], or
[e-mail]; or James R. Goff, Senior Director, Investor Relations,
[phone], or [e-mail], both of PDL BioPharma, Inc.


http://www.prnewswire.com


Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Thursday, 02-23-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 01-23-2006 for PDLI @ $27.58. (C) 2006 Comtex News Network, Inc. All rights reserved.

[Simbasi]

sieht doch nicht schlecht aus bei den amis
vielleicht gehts jetzt mal ein wenig weiter rauf

[Frank888]

gibt es Neuigkeiten? Kurs knapp 33 $

[eck64]

Tysabri soll doch wieder zugelassen werden....

[Simbasi]

ne ganze menge umsatz drüben!
heute schon 1,2 mio.aktien.
nach nichtmal zwei stunden

[[KERN]Codex]

Antwort auf Beitrag Nr.: 20.581.814 von eck64 am 08.03.06 19:18:52

klar wird es das, war soo klar

[eck64]

Antwort auf Beitrag Nr.: 21.420.749 von [KERN]Codex am 03.05.06 19:03:21

Was für news gibts denn?

[Sinne]

Verlust im 1.Quartal26,2mio $ verglichen mit 83,9 mio $ im ganzen Jahr 05.

[amorphis]

ausverkauf bei pdli heute...ab sofort wieder auf der wl...puh...wenn sich das ganze beruhigt hat...ist pdli wieder ein strong buy...

[Nissie]

sind hier alle ausgestiegel oder ist der Laden pleite

[Fruehrentner]

Antwort auf Beitrag Nr.: 22.363.860 von Nissie am 30.06.06 15:48:39

frag ich mich auch.

Sieht nach Bodenbildung aus.

Meinungen?

[Nissie]

Antwort auf Beitrag Nr.: 23.603.940 von Fruehrentner am 24.08.06 22:25:37

scheint ja langsam aufwärts zu gehen. Hoffentlich bleibt das so.

[Nissie]

PDL BioPharma Rights Plan

By TSC and IRIS Staff
8/28/2006 11:21 AM EDT




Biopharmaceutical company PDL BioPharma (PDLI - commentary - Cramer's Take) said Monday that its board adopted a stockholder rights plan to encourage potentially hostile suitors to negotiate with the company's board of directors.
The Fremont, Calif.-based company said that the 10-year plan includes a provision that requires a committee of independent directors of PDL to evaluate the rights plan at least every three years in order to consider whether the maintenance of the rights plan continues to be in the best interests of the company and its stockholders.

The rights plan was not adopted in response to any unsolicited third-party attempt to acquire the company, PDL said.

The company's stock was trading up 25 cents, or 1.3%, at $18.89 Monday.


RELATED NEWS TO THIS ARTICLE
Harris Boosts Dividend
Semtech Names Chairman
Telephone Data Profit Jumps

[Nissie]

ein schönes Plus in den USA kommt heute wohl dazu

[Nissie]

Antwort auf Beitrag Nr.: 23.658.131 von Nissie am 28.08.06 21:00:33

nach gestrigem erneuten Anstieg werden wir in den nächstn Tagen die 20 USD erreichen.

[Nissie]

PDL BioPharma: Roche Ends Co-Devt Of Daclizumab In Asthma



DOW JONES NEWSWIRES

PDL BioPharma Inc. (PDLI) is evaluating opportunities for a new collaboration in developing the Daclizumab drug as a treatment for asthma, after Roche Holding AG (RHHBY) ended its involvement in the development.

The Fremont, Calif., biopharmaceutical company said it would need a partner to further develop the drug for asthma.

The company said it will provide details regarding the impact of the changes, including an anticipated cut in 2006 research and development costs, in its third-quarter financial results conference call.

PDL said Roche's decision has no effect on their ongoing collaboration to develop the drug in transplant maintenance.

The companies will proceed with planned Phase II studies for Daclizumab in transplants in 2007, PDL said.

-Sara Leitch; 201-938-5400; [e-mail]

[Nissie]

auch heute in USA wieder zugelegt.

[Fruehrentner]

Antwort auf Beitrag Nr.: 23.692.610 von Nissie am 30.08.06 22:38:39

Der charttechn. Ausbruch scheint zu gelingen...

[Nissie]

Nun geht es endlich aufwärts, vielleicht werden alte Höchststände wieder erreicht. Ob sich ein weiterer Einstieg lohnt?

[Nissie]

wieder vielversprechender Start mit 0,15 Ct. Das wird noch was.

[Fruehrentner]

Ich glaube, den charttechnischen Boden hat PDLI hinter sich gelassen.

Meinungen?

Leider habe ich keine Ahnung, wie es fundamental aktuell aussieht.
Weiss jemand mehr?

[Fruehrentner]

Der Kurs zieht weiterhin gemächlich aber konstant an - und keiner merkt's.

Der Kurseinbruch war wohl übertrieben.

[amorphis]

Antwort auf Beitrag Nr.: 24.661.950 von Fruehrentner am 16.10.06 17:25:20

Press Release Source: PDL BioPharma, Inc.

PDL BioPharma Announces Physician Survey Results on Heart Attack Treatment Presented at American College of Emergency Physicians Scientific Assembly
Monday October 16, 9:58 am ET
Survey shows physicians recognize need for improved heart attack treatment and may be unfamiliar with latest treatment guidelines

FREMONT, Calif., Oct. 16 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI - News) announced today that in a research survey of U.S. cardiologists and emergency physicians, a considerable number (24%) were unaware of current heart attack treatment guidelines, with a majority (61%) believing that there is a significant opportunity to improve heart attack treatment in the U.S. by improving patient education about early heart attack symptoms and the need to expedite treatment to quickly restore blood flow to the heart. The results of the survey, which was supported by the company, were presented by W. Frank Peacock, M.D., Vice Chief of Emergency Medicine Research at Cleveland Clinic, at the American College of Emergency Physicians (ACEP) Scientific Assembly, taking place October 15-18 in New Orleans, La.

ADVERTISEMENT
"We found a lack of physician awareness of national treatment guidelines in the U.S., which means many patients may not be receiving the life-saving treatments they need in a timely manner," stated Dr. Peacock. "The goal of heart attack management is to minimize damage to the heart muscle caused by a lack of blood flow stemming from a clogged artery. Each minute that ticks by without treatment translates to more damage, disability and potential death. A systematic, coordinated approach to restoring blood flow to the heart - either mechanically through a balloon angioplasty or through clot-dissolving drug therapy when angioplasty is not possible - is paramount to fixing the system. However, this will only occur if patients learn to properly identify heart attack symptoms when they arise and promptly call 9-1-1 and emergency physicians and cardiologists overcome barriers to work together toward a solution."

The survey showed that a substantial percentage of the survey participants (24% of emergency physicians and cardiologists) were not at all familiar or only somewhat familiar with the 2004 American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (STEMI). The ACC/AHA guidelines focus largely on crucial timing needed to administer both mechanical and pharmacological methods to restore blood flow to the heart while causing as little damage to the patient as possible.

The STEMI guidelines recommend mechanical reperfusion via percutaneous coronary intervention (PCI) if a patient can undergo the procedure within 90 minutes of establishing medical contact (known as the door-to-balloon time). If it is deemed that a patient cannot undergo PCI within this 90-minute timeframe, the STEMI guidelines recommend pharmacologic reperfusion via fibrinolytic therapy within 30 minutes (known as the door-to-needle time).

Yet, according to more than half (53%) of the physicians surveyed, fibrinolysis-eligible patients would only sometimes, rarely or never receive a fibrinolytic when the time to PCI exceeds 90 minutes after establishing medical contact. Nearly 70% of the physicians surveyed reported that it is not realistic that STEMI patients can undergo PCI within 90 minutes of medical contact, because in many cases, patients need to be transferred from a non-PCI capable hospital to a PCI-capable hospital. Further, according to one in five physicians, it is not realistic that STEMI patients can undergo PCI within 90 minutes of medical contact even when there is a PCI-capable lab at the initial hospital to which they are transported or present themselves directly.

The company supported this survey as part of its commitment to improving heart attack management in the U.S. The survey was conducted by Harris Interactive®.

About the Harris Interactive® Study

This study included interviews with 1,014 U.S. adults ages 18+ who are physicians that either practice primarily in a hospital setting or have admitting privileges at a hospital, including 505 cardiologists and 509 emergency medicine physicians. Data are weighted to be representative of their respective populations: the total combined population of cardiologists and emergency medicine physicians, as well as the individual populations of cardiologists and emergency medicine physicians. The sampling error for the total sample of cardiologists and emergency medicine physicians (n=1,014) is +/- 3.4 percentage points. The sampling error for the sample of cardiologists (n=505) is +/- 5.1 percentage points. The sampling error for the sample of emergency medicine physicians (509) is +/- 4.6 percentage points. All surveys were conducted online between December 8 and December 16, 2005 and averaged 15 minutes in length. Respondents were recruited using the AMA Master File. Potential physicians were mailed an alert letter that included an URL link and individual password for the survey.

About Harris Interactive®

Harris Interactive is the 12th largest and fastest-growing market research firm in the world. The company provides research-driven insights and strategic advice to help its clients make more confident decisions which lead to measurable and enduring improvements in performance. Harris Interactive is widely known for The Harris Poll, one of the longest running, independent opinion polls and for pioneering online market research methods. Harris Interactive serves clients worldwide through its United States, Europe and Asia offices, its wholly-owned subsidiary Novatris in France and through a global network of independent market research firms. More information about Harris Interactive may be obtained at www.harrisinteractive.com.

About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering antibody humanization technology. Currently, PDL's diverse product pipeline includes investigational compounds in Phase 2 or Phase 3 clinical development for inflammation and autoimmune diseases, cardiovascular disorders and cancer. The company's research platform is focused on the discovery and development of antibodies for the treatment of cancer and autoimmune diseases. For more information, please see PDL's website at www.pdl.com.

PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

[amorphis]

Press Release Source: PDL BioPharma, Inc.

PDL BioPharma Announces Supplement to Prospectus for Resale of $250 Million Convertible Senior Notes Filed With the SEC
Friday October 13, 3:01 pm ET

FREMONT, Calif., Oct. 13 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI - News) today announced the filing with the U.S. Securities and Exchange Commission of Prospectus Supplement No. 1 to the Prospectus contained in Post-Effective Amendment No. 2 to Form S-3 Registration Statement relating to the 2.00% Convertible Senior Notes due 2012 in an aggregate amount of $250.0 million. The offering of the notes was completed in February 2005 pursuant to Rule 144A under the Securities Act of 1933, as amended.

ADVERTISEMENT
About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering antibody humanization technology. Currently, PDL's diverse product pipeline includes investigational compounds in Phase 2 or Phase 3 clinical development for inflammation and autoimmune diseases, cardiovascular disorders and cancer. The company's research platform is focused on the discovery and development of antibodies for the treatment of cancer and autoimmune diseases. For more information, please see PDL's website at www.pdl.com .

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

[amorphis]

um euren thread mal up-to-date zu halten...das waren die letzten news...

[amorphis]

hier heißt es...pdl sei ein guter kauf für biogenidec...

http://biz.yahoo.com/fool/060914/115825843515.html?.v=1

greez

[Fruehrentner]

@amorphis,

danke für die infos

[Sylvester20]

Antwort auf Beitrag Nr.: 24.669.040 von Fruehrentner am 16.10.06 22:35:39

Danke, dass du mich darauf aufmerksam gemacht hast, dass unter dem alten Namen gepostet wird...

[Fruehrentner]

Antwort auf Beitrag Nr.: 24.712.170 von Sylvester20 am 18.10.06 22:45:51

keine Ursache, gern geschehen

[Sylvester20]

PDL BioPharma hat ein gut diversifiziertes Geschäftsmodell im Biotechnologie-Sektor mit hohen Wachstumsraten durch die SMART-Antikörpertechnologie. Aufgrund einer aussichtsreichen Pipeline mit sechs vielversprechenden Wirkstoffen in Phase 2/3 zählt PDL zu den potenziellen Übernahmekandidaten. In 2006 wird ein Finanzüberschuss erwartet, was für das Unternehmen die wichtige Schwelle zum Gewinn bedeutet...

[blb]

Bin hier aus charttechnischen Gründen rein zu 20$. Kursziel wäre das Gap bei 27$, passable New natürlich vorausgesetzt.

[blb]

Sieht gut aus, hält sich trotz schlechtem Umfeld prima. Wenn die Zahlen gut kommen, lockt das Gap mittelfristig.

[blb]

Die Zahlen wurden leider nach einem kurzen nachbörslichen Anstieg negativ aufgenommen. Den genauen Grund kenne ich nicht, fand den Bericht äußerst passabel.

Viele Grüße
blb

[Fruehrentner]

Der Kurs hat sich vom jüngsten Einbruch schnell erholt.

Mal weiter beobachten!

[blb]

Die 200-Tag-Linie ist durchbrochen, jetzt kann es zügig aufwärts gehen!

Grüße
blb

[amorphis]

das ist net gut...

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn…

[blb]

Naja, klingt natürlich ned so dolle, allerdings wär der Vertrag e im Mai ausgelaufen. Wird morgen sicher mit gehörigem Gap eröffnen, wichtig wäre, wir können die 200-Tage-Linie halten...

Mal schaun...

Grüße
blb

[Fruehrentner]

Antwort auf Beitrag Nr.: 25.579.575 von amorphis am 21.11.06 22:31:31

Roche ist auch bei Antisoma ausgestiegen - und schau, was danach der Antisoma Kurs gemacht hat.

[blb]

Verlust hält sich ja in Grenzen, ich bleib dabei, Kursziel 27 Dollar!

Grüße
blb

[blb]

Gibts News?????

[amorphis]

Antwort auf Beitrag Nr.: 25.624.015 von blb am 23.11.06 16:32:54

kann absolut nix finden!!!!demnach nein!denke da ist jemand auf den dicken spread reingefallen und hat den makler in fr was verdienen lassen...

[blb]

Bleibt aber so, sehr strange... Wenn ichs sicher wüsste, würde ich verkaufen und Montag billig zurückkaufen!

Grüße
blb

[Frank888]

Antwort auf Beitrag Nr.: 25.592.804 von blb am 22.11.06 16:01:21

1. Kursziel 27 $, auf jeden Fall

[amorphis]

Antwort auf Beitrag Nr.: 25.625.217 von blb am 23.11.06 17:12:12

das ist relativ sicher...der kurs wurde mit gerade mal 600 und dann nochmal 500 stücken nach oben gelenkt...so sieht kein kursanstieg aus,welcher "news"verursacht ist!demnach...würde ich so handeln wie du es dargestellt hast!

[Frank888]

bei 19 $ haben wir ein Golden cross gesehen. Beim letzten Golden cross ist der Kurs von 19 bis 33 gelaufen.
Bin zwar zwischenzeitlich ausgestiegen, der Kurs lädt aber wieder zum Kaufen ein.

[metallix]

Frohes Fest...und steigende Kurse




wünscht allen,
Euer Metallix

[Fruehrentner]

Neuer Angriff auf die 18 EUR-Marke.

Ob der Durchbruch diesmal klappt?

[blb]

Ich bleib dabei, Kursziel 27$...

[Fruehrentner]

heute gehts aber satt hoch!


Meldung von neulich:

Trellis and PDL Biopharm to work on
discovery of MAbs

The US biotech firm, Trellis Bioscience, and PDL Biopharma
are to collaborate on a project to discover monoclonal
antibodies against a proprietary antigen from PDL. Under the
agreement, the companies will use Trellis’s CellSpot
technology to screen large populations of antibodyproducing
cells using a range of immunisation strategies.
Trellis will select and deliver hybridomas to PDL, which will
conduct further R&D on the antibodies. PDL will be
responsible for development and commercialisation of any
products discovered, while Trellis will receive an up-front
fee, milestone payments and royalties. CellSpot greatly
enhances the odds of finding and retrieving cells that make
desired antibodies but which escape detection by
conventional discovery techniques because of their rarity,
Trellis said.

[diwi0815]

Na dann halte ich mal den Thread am Leben und stell dies rein:

AP
PDL Biopharma Expects 2007 Revenue Jump
Wednesday February 21, 6:56 pm ET
PDL Biopharma Sees Higher 2007 Revenue on a Mix of Product Sales and Royalties

FREMONT, Calif. (AP) -- Biopharmaceutical company PDL Biopharma Inc. said late Wednesday it expects 2007 revenue to rise on increases in both product sales and royalty payments.

The company forecast revenue between $450 million and $500 million. Between $200 million and $220 million of that is expected from product sales and between $220 million and $240 million is expected from royalties.


Profit, excluding charges, is expected to range from $45 million to $65 million, or between 38 cents per share and 54 cents per share.

Analysts polled by Thomson Financial, who typically exclude one-time items, are looking for a profit of 50 cents per share on sales of $495.7 million.

In 2006, PDL Biopharma lost $130 million, or $1.14 per share, compared with a loss of $167.6 million, or $1.60 per share, in 2005. Revenue rose to $414.8 million from $250.6 million.

The stock plunged 74 cents, or 3.9 percent, to $18.40 in after-hours trading after adding 16 cents to close at $19.14

Gruß
DIWI

[diwi0815]

PDL BioPharma upgraded to "overweight"

Monday, March 26, 2007 10:28:33 AM ET
Prudential Financial

NEW YORK, March 26 (newratings.com) - Analysts at Prudential Financial upgrade PDL BioPharma Inc (ticker: PDLI) from "neutral weight" to "overweight." The target price has been raised from $23 to $28.


blb arbeitet du bei prudential als Analyst?

[blb]

Prudential hat erst letztes Jahr abgewertet, also die Analystenmeinungen kann man getrost vergessn.

Fantasie gibt es durch den Einstieg eines Hedgefonds, der Druck machen wird. Beispielsweise hat der gleiche Fonds bei Ligand Pharma (LGND) eine Sonderdividende von 2,5$ sowie ein Aktienrückkaufprogramm von 100 Millionen $ bewirkt. Bin gespannt wie es bei PDLI weitergeht.

Cramer pusht auch zur Zeit wieder...

[blb]

Der Hedgefond macht Druck:

Third Point Demands that PDLI CEO Mark McDade be Terminated or Resign; Insists that Company Pursue Cost Cutting Measures and Consider Alternatives to Maximize Shareholder Value

NEW YORK, April 11, 2007 /PRNewswire via COMTEX/ -- Third Point LLC sent to the PDL BioPharma Inc. Board of Directors today the following letter:

April 11, 2007

Mr. Mark McDade
PDL BioPharma Inc.
34801 Campus Drive
Fremont, CA 94555

CC:
Jon S. Saxe
L. Patrick Gage
Laurence Jay Korn
Karen A. Dawes
Bradford S. Goodwin
George M. Gould
Samuel Broder

Dear Mr. McDade and PDL BioPharma Board Members:


In our initial letter to you dated March 5, 2007, we expressed a sincere and strong interest, as PDL BioPharma's ("PDLI" or the "Company") largest shareholder, to work constructively and discreetly with management and the Board of Directors to implement the cost-cutting and other measures necessary to fully enhance the extraordinary value inherent within PDLI that is currently being obscured by the Company's equally extraordinary current levels of spending. Indeed, we are certain that you are aware that our initial overtures have been greeted by overwhelming shareholder support and positive Wall Street research reports. The Company's shares have also reacted positively, rising 15%, or increasing in value by over $300mm, as a result of our involvement - to the benefit of all shareholders. After our first telephone calls with management in March, we were hopeful that matters were moving in the right direction, as they agreed to retain either the leading consulting firm that we proposed, or one of similar stature, to analyze your excessive R&D and SG&A spending, and to seriously consider our highly- qualified nominees to the PDLI Board of Directors.
Unfortunately, our initial optimism that we could work constructively with management quickly faded through a series of subsequent telephone calls with Mr. McDade, culminating in a "slap-in-the face" on Friday, April 6th, in which it became abundantly clear that Mr. McDade has no intention of pursuing a constructive dialogue. It became apparent that the earlier dialogue was a charade intended to stall for time, a tactic we have seen employed many times before by underperforming CEOs. Mr. McDade's inexplicable insouciance towards us, along with numerous negative findings that emerged over the course of our ongoing investigation (the "Investigation") into Mr. McDade's managerial abilities, judgment and ethics (discussed below), led us to determine that it is in our best interests, and those of all shareholders, to terminate discussions with Mr. McDade.
Many fund managers who have been similarly rebuffed, and who have detected such a deficit in talent, probity and judgment as we have come to find in Mr. McDade, might come to the logical conclusion to "cut and run" and decrease their positions as one major mutual fund has done according to recent filings. Instead, we have come to a different view: we concluded that the Board of Directors has no choice but to immediately terminate Mr. McDade. We believe that a PDLI unencumbered by Mr. McDade's management blunders and wasteful spending will appreciate in value considerably, and thus we have increased our position by 1,100,000 shares and now beneficially own 9.7% of the Company's outstanding stock.
In support of our demands for Mr. McDade's immediate termination, we review below the content of our discussions and negotiations over the past month and elaborate on the specific significant mismanagement and waste for which Mr. McDade is directly culpable.
McDade's Insincerity and Disorganization
During the past month we had four separate calls with Mr. McDade in which we repeatedly expressed our concerns regarding spending levels and other planned strategic initiatives by the Company. In each call, we reiterated our interest in working with him and with the Board in order to better understand and rationalize the cost structure at PDLI and to help realize the many valuable, currently poorly-recognized assets embedded within the Company. From the very first conversation, we made it clear that, as PDLI's largest shareholder by a wide margin, Board representation would be essential, and we submitted to Mr. McDade the names of four highly-qualified candidates for consideration. On March 30th, Mr. McDade informed us that none of our four candidates fits the profile of what PDLI is looking for in a Board member, but that the Board would (reluctantly) consider one of our candidates. We replied that this was not acceptable, and demanded that two of the other three candidates be named to the Board. At our suggestion, and in response to his now obviously feigned interest, we provided to Mr. McDade that very afternoon the contact information for TWELVE references for our Board candidates - all of them senior management or Board members of public companies with whom we've worked (and, in most cases, served on boards with). Mr. McDade and his assistant sent follow-up emails with questions regarding the references list. However, when we spoke with Mr. McDade again this past Friday, he informed us that none of our candidates is "qualified" to serve on PDLI's board. Although Mr. McDade is dead wrong about this, what is truly galling, and what speaks directly to Mr. McDade's lack of character, professionalism, and competence, is that our references reported to us that Mr. McDade did not call a single one of them to hear first-hand about the tremendous value that our candidates have brought to shareholders by working on other public boards, both within and outside of the biotechnology arena.
Moreover, one of our director candidates, Mr. Jason Aryeh, emailed to Mr. McDade contact information for his references, followed up with a confirmatory call to Mr. McDade's assistant Diana, and sent a second email to ensure its receipt. Nonetheless, Mr. McDade claimed days later never to have seen this important correspondence so essential to evaluating our candidates' qualifications to join the PDLI board, and even then he did nothing with the information it contained (despite assurances to the contrary). How can Mr. McDade purport to effectively run a public biotechnology company with a market capitalization of over $2 billion when he cannot even manage his own Microsoft Outlook inbox?
It is now clear to us that we've wasted the last month attempting to engage in a productive dialogue with Mr. McDade, while his only objective was to buy himself more time. We've been engaged in discussions with the Company for over a year about our concerns, and have heard management's explanations and excuses countless times over that entire period. The unfortunate truth is that so long as Mr. McDade remains CEO, which we expect will not be much longer, the Company will have no intention of doing the "right thing" by scaling back SG&A and R&D spending to economically justifiable levels.
We also want to emphasize that during the course of our discussions over the past month it became clear that Mr. McDade does not see the benefits of adding representatives of the major owners of the Company to the Board. In fact, he told us that the Board's ideal next candidate(s) would be a late- stage development expert. We have explained to Mr. McDade why adding shareholder representatives is vital at this point, as management is demonstrably not effectively telling the PDLI story to the world - as evidenced by the major disconnect between the current stock price of PDLI and the much higher inherent asset value of the Company. Additionally, it is obvious that PDLI needs to understand the investment community's perspective regarding the Company's economically unjustifiable spending. On this point, as noted earlier, we are pleased that the Company has agreed to hire a major consulting firm immediately to undertake the critical analysis of all of the Company's current and planned SG&A and R&D spending, with the goal of materially cutting back on both if they are deemed to be economically imprudent.
McDade's Taj Mahal - Massive Waste, a Shorter Commute for McDade and a Slip for his Yacht, but a Longer Commute for Employees
There is no better example of McDade's "empire building" philosophy, pathological selfishness and poor business judgment than his decision to build out PDLI's absurdly large and unnecessary new corporate headquarters (the "Taj Mahal"). It is appalling that Mr. McDade is spending nearly $100 million of our money to build out 450,000 square feet of leased space, much of which is completely unnecessary. But what is most troubling is what this says about his overall business judgment and qualification to continue to run the Company. As examples:

* Mr. McDade decided to lease, and build out, the Taj Mahal (reportedly
the largest corporate lease deal, as measured in square footage, signed
in the Bay Area in 2006) despite the fact that members of PDLI's
financial team reportedly advised him that the expenditures were both
unnecessary and imprudent;

* Mr. McDade has, from the beginning of this project, apparently been
fixated on when his boat slip in the marina adjacent to the new
corporate headquarters will be ready (one would think that the CEO of a
Company, the stock price of which was down 40% last year - and the
second worst performer in the entire biotechnology index - would have
more important priorities), and

* Mr. McDade has made it clear in private that one of the key drivers
behind his decision to relocate the Company from Fremont to Redwood City
is that the new headquarters location will lead to a far shorter commute
to work for him from his home in Woodside (not only less than one-half
the mileage, but he will not have to cross any heavily-trafficked Bay
bridges to get to the new headquarters). For those unfamiliar with the
geography, below is a map detailing the pertinent locations:

(Photo: http://www.newscom.com/cgi-bin/prnh/20070411/NYW097)



Although the propinquity of the Taj Mahal to McDade's home is convenient for PDLI's imperial CEO, scores of current dedicated PDLI employees are to be significantly inconvenienced by the move. This issue was so significant that the Company's attorneys felt that it was an issue that merited disclosure in the risk section of PDLI's 2006 10-K:

We believe that the move of our corporate headquarters from Fremont,
California to Redwood City, California, in the second half of 2007, may
before and for a period after the move cause employee turnover to increase
and make retaining key employees more difficult because our new
headquarters is 12 miles away from our current headquarters and on the
other side of the San Francisco Bay, which will increase the commute time
of the many employees that reside in and around Fremont, California and
the greater East Bay Area of the San Francisco Bay area.




Premium Offer Rebuffed? ... Strategic Alternatives Should be Reviewed Immediately
We also learned from sources we deem to be reliable that PDLI received a takeover bid from a large pharmaceutical company for more than $30 per share (approximately 50% above the current stock price), which Mr. McDade effectively dismissed out of hand as being grossly insufficient. While we share the view that PDLI is significantly undervalued, we believe that due care requires management to present all such expressions of interest to the Board. We are not necessarily advocating a sale of the Company at this time (although it should be carefully considered), but we believe that if such bidding interest exists, it should be carefully weighed against the present value of the Company in a scenario where it executes its long term operating plan under new, better-qualified management.
In addition, we believe that the Company should examine splitting into two publicly traded entities - one a commercial operation, and the other an R&D company. We believe that material incremental value could be created through such a separation and have raised this concept with Mr. McDade (not surprisingly, given his empire-building mindset, he had not given this structure a thought previously, and laughed dismissively - or perhaps defensively - when we suggested it). We would be happy to share with the Board our analysis as to why we believe that separating PDLI into two public companies would create significant shareholder value. Finally, we firmly believe that any deals currently being contemplated to encumber Ularitide, or to commit the Company to further R&D spending on this product, should be suspended while the above analyses are ongoing.
In Monday's press release announcing Max Link's resignation from the Board, Mr. McDade again referred to "continuing to build stockholder value by leveraging our antibody platform ...." Perhaps Mr. McDade uses a different, more favorable, group of stock charts than we do, but ours show that PDLI was down 40% last year; was flat in the three years from 2004 to 2006 while the biotech index gained 50% (and the stocks of PDLI's partners flourished); and, by the way, is only up this year because the market has reacted favorably to Third Point's involvement.
We are confident that we have the support of a majority of PDLI's shareholders, and clearly have the support of a large number of sell-side research analysts. Indeed, Prudential upgraded PDLI from a hold to a buy on March 25th in a report headlined "Calls for Strategic Changes Increasing; Could Spark Stock Rally if Implemented." Prudential's report then went on to say:

The public pressure being applied by Third Point could lead to positive
dramatic changes in the company. The primary reason for our change of
heart is that we believe some drastic measures would have to be taken to
transform this company from a slow moving, yet costly specialty/biotech
company to a more focused biotech company that can deliver returns that
match investors' expectations.



On that same day Merrill Lynch wrote a positive report entitled "Does Third Point have a point?" - with the answer being a resounding "yes."
Lastly we would note that we have spoken with many business development directors from major and mid-sized pharmaceutical and biotechnology companies, and the consistent feedback is that Third Point is correct in its analysis of PDLI - that it is a poorly-managed company with substantial assets. A few comments we heard from this well-respected and knowledgeable group include:

McDade acts and spends like he runs a big pharma company, but he has none
of the infrastructure, assets or managerial ability.

PDLI has enviable assets, but they will never get the benefit of them with
McDade running the Company. He needs to be thrown out immediately.

He has consistently disappointed the Street by missing revenue and
earnings projections and development timelines. Why will it be any
different going forward?

He is an empire builder. The Company is being treated like McDade's
personal science experiment.

What PDLI needs is financial discipline and new management.



Needless to say, we agree wholeheartedly with these opinions. We are confident that some members of PDLI's Board share our negative sentiment towards Mr. McDade. We urge these members to speak up and take action to dismiss him immediately. Indeed, we believe that there are several Board members who are far more capable that Mr. McDade of managing PDLI properly and would ask that they volunteer to serve as interim-CEO at a minimum, while the Company reassess its spending plans and analyzes all options to maximize value for PDLI's shareholders.
When Mr. McDade became CEO in 2002, he made a pledge to create shareholder value. Nearly five years later he has not lived up to his pledge. It is now time to put the valuable assets of this Company into more capable hands, either by bringing in a high-quality CEO or selling the assets to a larger, better-run company, before the Company's asset values are further diminished by uncontrolled and wasteful spending under his ineffective stewardship. Mr. McDade has said repeatedly that he serves at the will of shareholders, and would immediately step down if shareholders do not want him running the Company anymore. It is clear to us that a majority of PDLI's shareholders share our views, so we therefore demand that Mr. McDade stop hiding behind the Company's corporate defenses and newly-instituted poison pill and live up to his word by resigning. (We believe that we can deliver consents from a majority of the Company's shareholders calling for Mr. McDade's resignation to prove our point.) Also, we have high regard for the professional scientific personnel at PDLI, and the scientific accomplishments of many PDLI Board members, and believe that the languishing share price deprives them of opportunities to be appropriately rewarded for their efforts.
We would be pleased to speak directly with the Board, once Mr. McDade is terminated, to work together constructively to achieve our goal, and your fiduciary duty, to run the Company properly in order to create maximum value at PDLI for all stakeholders.

Sincerely,

Daniel S. Loeb
Chief Executive Officer

About Third Point LLC


Third Point LLC, founded by Daniel S. Loeb in 1995, is a registered investment adviser based in New York with over $4.5 billion of assets under management.

Media contact:
Steve Bruce / Shawn Pattison / Ann Taylor Reed
The Abernathy MacGregor Group
[phone]



SOURCE Third Point LLC
Steve Bruce, Shawn Pattison, or Ann Taylor Reed, all of The Abernathy MacGregor Group, [phone] for Third Point LLC http://www.prnewswire.com Copyright (C) 2007 PR Newswire. All rights reserved End of Story

[blb]

Mein Kursziel von 27$ und der Gapclose sind mittlerweile erreicht. Da gute Studienergebnisse vermeldet wurden und zudem der Hedgefonds weiterhin Druck macht seh ich jedoch noch weiteres Aufwärtspotenzial!

Grüße
blb

[blb]

Super am 200er Durchschnitt nach oben gedreht, aber keine News zu finden... Seltsam!

Naja ich bin gespannt!

Viele Grüße
blb

[blb]

Sehr gute Zahlen heute, nachbörslich schön im Plus!

[diwi0815]

Nach dem Kursverfall der letzten Zeit hier mal ein positives Statement vom Finanzen-newsletter:

Wie üblich ein Rückblick auf vergangene Empfehlungen. Vor einem Jahr stellten wir Ihnen die Aktie PDL Biopharma vor. Das Unternehmen hat Bausteine für Krebsmedikamente geliefert und kassiert dafür hohe Lizenzeinnahmen, die stetig wachsen. Daneben hat die Firma versucht, eine eigene Medikamentenpipeline aufzubauen. Dabei war PDL weniger erfolgreich. Letztlich musste der Vorstandschef auf Druck der Investoren seinen Hut nehmen.
Die Kursentwicklung des Wertes war bis Ende Mai 2007 erfreulich. Unter starken Schwankungen stieg der Wert auf 20,50 Euro an, ein Plus von 36 Prozent im Vergleich zum Besprechungskurs. Doch die Probleme in der Pipeline und beim Management gingen nicht spurlos am Kurs vorbei. Der Wert büßte seit Ende Mai den kompletten Gewinn ein und notiert nun leicht im Minus. Wir glauben, dass die Firma nun vor dem Ausverkauf steht. Lizenznehmer wie Genentech werden versuchen, PDL zu übernehmen und PDL hat eine Investmentbank engagiert, um Alternativen auszuloten. Im Fall eines Verkaufs könnte die Aktie auf 30 Dollar steigen. Beim aktuellen Wechselkurs errechnet sich ein Potenzial von 50 Prozent. Wir würden die Aktie deshalb nicht verkaufen. Die aktuellen Kurse bieten eher eine Einstiegschance, da der Wert durch die Lizenzzahlungen gut abgesichert ist.

Gruss diwi